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Abstract
There are three theories of cancer development analyzed in this review. The first theory is the immunological theory, which states
that cancer is a result of the immune system failing to detect a cancerous cell in which results in uncontrolled cell growth.The second
theory is the somatic mutation theory, which states that genetic mutations are a direct cause cancer. The third theory is the stem
cell theory which states that cancer results from an uncontrolled stem cell. The difference in each theory helps guide a clinician’s
judgment in how to treat cancer. If a clinician believes in the immunological theory, he/she will view the best route of treatment as
being by targeting the patient’s immune system. One who believes somatic mutation theory would say that the patient’s genetic
makeup of the patient is the ideal target for treatment. One who believes in the stem cell theory would say that the only method of
treatment is to remove the cancer entirely as any residual cancer will return. Based on all the evidence it appears that there is not
one individual factor that causes cancer development, rather it is a combination of several factors that result in cancer.
Introduction
In 2013 cancer was reported to affect over 1.6 million
people (Siegel, et al., 2013). Despite cancer being such a
highly discussed and researched disease there are many
things that remain unknown. One of the major debates is
how cancer develops; there are three major schools of
thought: the immunological theory, the somatic mutation
theory, and the stem cell theory.
The immunological theory postulates that cancer develops as a result of the immune system failing to detect
the cancerous cell. As a result of an undetected cell the
cancer grows at an uncontrolled and dangerous rate,
thereby damaging the host. If this is the sole etiology of
cancer, the immune system could be harnessed to treat
a person who had developed cancer. For example, a new
cancer vaccine has been developed for prostate cancer
patients. This vaccine was developed for two reasons.
Firstly, prostate cancer cells have several tumor-associated antigens. Secondly, because the prostate is a nonessential organ, annihilation of any normal prostate tissue that
comes about because of the immune response has no
clinical consequence (Singh & Gulley, 2014). While not all
cancers have these qualifications that make them susceptible to a vaccine, other forms of immunotherapies are in
development to try and take advantage of the specifics of
each cancer to attack it immunologically.
The somatic mutation theory postulates cancer develops due to a genetic mutation leading to uncontrolled
growth. A study showed that there are specific gene mutations involved in breast and ovarian cancer. These are
mutations of either the BRCA1 or BRCA2 gene (Miki,
et al., 1994). More specifically, it has been shown that
women with BRCA1 mutation by age 80 have a 72 percent chance of developing breast cancer. While women
who have the BRCA 2 mutation have a 69 percent chance
of developing breast cancer (Kuchenbaecker, et al., 2017).
Treatments based on this theory focuses more on the
genetics of a person and using that field as a method to
control or treat the cancer.
The stem cell theory of cancer assumes that cancer develops because there is an uncontrolled stem cell in the

body. All humans develop from stem cells that multiply
repeatedly. However, during human development stem
cells become specialized and eventually stop multiplying.
This theory of cancer development says that cancer results from a stem cell that has not “turned off”, resulting
in uncontrolled growth to the point of being detrimental
to the host. This theory has many implications. Some clinicians evaluate a cancer treatment based on how much
it causes the tumor to shrink, but without removing the
source the tumor will come back very quickly because
the stem cells are still there. Physicians and Oncologists
who subscribe to the stem cell theory may treat cancers
differently than those who believe in the immunological
theory or the somatic mutation theory.
The significance of each theory is that the information
regarding how the disease develops can help determine
the best course of treatment. Evidence seems to point to
all three of these theories, hence there is no conclusive
explanation. This review will examine all the evidence in
order to determine which hypothesis best explains the
development of cancer.
Methods
The articles and journals used in this review were found
on PubMed, Ebsco, and Google Scholar. These articles
were carefully reviewed in order to determine their relevance to the thesis.
Discussion
Immunological Theory of Cancer
This theory has been associated with three general steps
the body constantly goes through: elimination, equilibrium
and escape. The elimination step consists of the immune
system surveying for all cancerous cells and destroying
them. However, there are times when tumorous cells remain undetected while remaining dormant. This period is
defined as equilibrium because there are cancerous cells
in the body, but they are not doing any harm. The final
step is escape in which the tumor gains dominance over
the immune system and starts spreading (Lopez, et al.,
2016). This implies that the immune system’s activity and
5
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ability to detect cancerous cells is important before the
cancer gets out of hand.
To try to determine how immune activity affects cancer,
residents of Japan, mostly above 40, were given a questionnaire that covered 90 lifestyle factors. People who
participated in the study gave a peripheral blood sample after fasting for over 12 hours. A follow-up was performed 11 years later where cancer incidence and death
totals were gathered. Based on the questionnaire, each
patient was assessed for cancer risk at one of three levels,
low, medium, or high. Of the 8552 individuals who took
the survey, 211 of the 3625 whose blood was sampled
were identified as cancer cases. A number of the cases
had to be excluded based on age, blood samples being
inaccessible, etc.The total number of cases remaining was
154, 92 men and 62 women. Accounting for age, it was
found that patients with lower cytotoxicity activity, were
at a significantly higher risk for developing cancer when
compared to those with medium or high activity (Imai,
et al., 2000). This study points to the fact that cytotoxic
activity can help a person fight cancer, further illustrating
that the immune system plays a role in cancer treatment.
A specific type of immunotherapy is currently being
developed in which some of the patient’s T-cells are
extracted and modified to become chimeric antigen receptor t-Cells (CAR-T cells). These T-cells are then given
artificial receptors that are from monoclonal antibodies
which allow the CAR-T cell to bind to the cancer cells.
The patient is then treated with chemotherapy to eliminate any immunosuppressant activity in the body. The
CAR-T cells are then injected and are free to attack the
cancer cells. This treatment sounds perfect but there are
some complications that arise. Cytokine release syndrome (CRS) is a life-threatening complication in which
the immune system goes into a state of being overly active and releases an excessive number of cytokines which
results in organ toxicity. CRS is manageable but one has
to be conscious of it when treating a patient with CAR-T.
Another complication that can arise is CAR-T cell related
encephalopathy syndrome. This syndrome can result in
some patients feeling slightly disoriented while others can
have seizures (Graham, et al., 2018). This methodology of
cancer treatment is new but is showing great promise. It
shows that the immune system, under careful monitoring,
can be harnessed to fight cancers.
A person’s immune system doesn’t allow cancer cells
to grow because the natural killer cells, or NK cells detect the cancers and kill them. These cells can identify a
cancerous cell because they identify which cells are “not
self” cells by searching for specific receptors that only
one’s own cells have. Therefore, they find the cancer cell
6

and kill it before it starts growing. Although some cancer
cells go undetected, there are researchers who believe
that the NK cells can be used to kill an active cancer.
A new treatment is being studied in which NK cells are
being combined with the concept of CAR-T cells creating CAR-NK cells. These cells have several advantages
over CAR-T cells. Firstly, because NK cells have natural
receptors for tumors, they have an easier time identifying cancer cells even if the CAR portion of the cell is
downregulated by the cancer. Secondly, CAR-NK cells do
not undergo clonal expansion or immune rejection thus
eliminating the issue of cytokine release syndrome that
is present with CAR-T cells. Lastly, HLA matching is not
necessary for CAR-NK cells, which means the graph-versus-host disease is not an issue when it comes to CARNK cell treatment. Currently there is not enough clinical
data to fully implement the treatment, however, there are
studies being performed to help investigate new treatment options. For example, CAR-NK cells are being researched to help determine their ability to fight hematological and solid tumors, including glioblastoma, prostate
cancer, and ovarian cancer (Hu, et al., 2019). While this
treatment is in very early stages it has had great results
thus far. If this treatment can prove to be effective it can
have massive implications in the successful treatment of
cancers because there are few side-effects.
Dendritic cells are another one of the immune cells
being used to fight cancer. Dendritic cells function as an
antigen presenting cell meaning, when it recognizes an
antigen it alerts the body to produce antibodies. There
are vaccines that have been proven to work that are prepared by removing a patient’s dendritic cells and “teaching” them to recognize cancer cells, then reinjecting them
into the patient. Once these dendritic cells are in the
bloodstream, they can identify the cancer cells and initiate
a T-Cell response to them. However, there were several
issues when the dendritic cells were taken from ex vivo
and put inside patients. Firstly, some patients experienced
a T-cell response from the injection, but it did not result
in significant improvement. This alteration in functionality could be a result of the cells being transferred from
an in vivo environment to an ex vivo environment, then
returned to in vivo. Another issue with the vaccine is
that the process is very time-consuming and expensive.
Lastly, the dendritic cell vaccine is reliant on the patient’s
immune system and its function. Because of this, in vivo
preparation of the dendritic cell is still being perfected
(Le Gall, et al., 2018).This technique can be very helpful to
cancer patients as often the cancer proliferates because
the immune system fails to recognize the cancer cells.
With this treatment the incidents of cancer cells going
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undetected can be virtually eliminated resulting in the
body halting the cancer cells growth.
Another form of immunotherapy using dendritic cells
is called dendritic-cell cytokine induced killer cells (DCCIK). In the study, there were several criteria that had to
be met when determining who was an appropriate candidate. The first requirement was that the patients had to
have advanced cancer (stages 3-5). Secondly, prior to this
study, patients had to have received first-line treatment,
including surgery, adjuvant chemotherapy and/or radiotherapy. The study examined a total of 142 patients with
histologically confirmed colorectal carcinoma, 71 were
treated with DC-CIK and 71 were not. Patients were examined at three separate times, after 1, 3 and 5 years.The
retrospective study found that patients who were treated
with DC-CIK had 1,3 and 5-year prolonged progression
free survival and overall survival versus those who were
not treated. Minor side-effects were experienced by the
patients treated with DC-CIK such as mild fever, chills,
fatigue, while three also developed a headache and one
developed chest tightness and hypotension. While these
symptoms cannot be ignored, in the grand scheme of cancer treatment these side-effects are very mild. This study
shows the effectiveness of DC-CIK and its ability to combat colorectal cancer in patients who were treated with
first-line treatments (Xie, et al., 2017). While this study
has its limitations because it required first line treatment
such as surgery, it does provide a powerful tool for patients who have already gone through or may require first
line treatments.
The examples listed above all seem to point to the accuracy of the immunological theory of cancer. Perhaps the
most indicative proof that cancer prevention is a function
of the immune system is from a study performed several
years ago which analyzed 12 patients with glioblastoma
who received regular course of immunotherapy (a dendritic cell vaccine). However, a few patients were also
given a tetanus vaccine. The patients who were given the
immunotherapy and the tetanus vaccine lived between
four to eight years after their treatment.The patients who
received the immunotherapy with another placebo drug
lived only 11 months following their treatment (Mitchell,
et al., 2015).The reason the tetanus shot impacts the cancer defense is because once given, the body begins to
create t-cells as a typical reaction to a vaccine. Due to this
additional t-cell production the body was more prepared
to fight the cancer as well (Haelle, 2015).While this study
was performed on a small sample size the results point to
the same conclusion as the previous studies; it illustrates
the role the immune system plays when fighting cancer.
These are just some of the treatments in development,

all working under the assumption of the immunological
theory of cancer being correct. As it stands, the treatments appear promising and with further research they
can hopefully be perfected and cancer patients can be
cured with minimal side effects. All the studies cited point
to the immunological theory of cancer as a very real and
likely explanation for cancer development.
Somatic Mutation Theory of Cancer
The somatic mutation theory analyzes the development
of cancer by looking at genetic factors. The specific genetic variances in squamous cell carcinoma (SCC), adenocarcinoma (AC), and adenosquamous carcinoma (ASC), 3
types of cervical cancers, were analyzed. Three hundred
and one patients with SCC, AC, or ASC who were all
treated with radical hysterectomy with lymphadenectomy as their primary treatment were analyzed. All follow-up data was obtained 5 years after primary treatment. One hundred and sixty-six (55%) of the patients
had SCC, fifty-five (18%) had AC and eighty (27%) had
ASC. In 103 of the tumors there were 123 somatic mutations detected as roughly 4% of the tumors had multiple
mutations.The specific mutations were identified for each
cancer. The PIK3CA was most common in SCC and ASC
while KRAS was most common in AC. However, in each
type of cervical cancer there was not only one mutation
rather there were several mutations found across multiple genes such as, PTEN, PPP2R1A, CTNNB1, CDKN2A,
FBXW7, FGFR3, NRAS, and HRAS. The KRAS mutation
is not exclusive to cervical cancers as it has also been
linked to colorectal, lung and pancreatic cancers. KRAS
and PIK3CA mutations were both not associated with
survival; however a clear trend of lower survival rate was
in patients carrying a PIK3CA mutation (Spaans, et al.,
2015). This study points to a connection between specific
cancers and mutations that result in them. If an unknown
cancer’s genetic sequence could be inspected it could give
a clinician a clear idea of what cancer he/she is dealing
with and how to properly treat that patient.
Cervical cancers are not the only cancers to have a
gene associated with them as prostate cancers were also
found to have specific genes connected to them. These
genes were identified by looking at a prostate specific
antigen (PSA) a protease produced in the prostate, as
well as prostatic acid phosphatase (PAP). By looking at
these two markers the researchers used the technique of
guilt-by-association which works based on combinatoric
measure of association. Forty-thousand different genes
were analyzed, and each gene was determined to be
present in prostate cancers if the cDNA corresponding
to that gene is detected in the library. Upon analysis of all
7

Ariel M. Mayer

40,000 genes most of them were determined to not be
related to prostate cancer. However, eight of the genes
were identified as being associated with it (Walker, et al.,
1999). The extent of their association is difficult to prove
because correlation is more provable than causality, but
the association is significant none the less.
Certain genes have been identified as being related to
breast cancer that is metastatic to bone. One hundred
and seven breast cancer patients who had developed
metastasis had their negative-lymph nodes biopsied.
Sixty-nine of the relapses were categorized as bone
while 38 were labeled as not bone. Upon analysis, 69 significantly unique gene sets were discovered across bone
and non-bone samples. The five most common genes in
bone cancer were TFF1, TFF3, AGR2, NAT1, and CRIP1.
TFF1 was studied in 122 independent breast tumors in
node-negative patients which indicates it is the most
prevalent mutation. The researches then attempted to
predict a correlation between a cancer’s gene sets and
that cancer spreading to the bone. The samples were divided into a test set and a training set. Five hundred and
eighty-eight genes were selected and subjected to PAM
analysis. A 31-gene predictor was selected after 10-fold
cross validation that could identify relapse to the bone
at 100% sensitivity and 50% specificity. The predictor
showed 79.3% positive predictive value and TIFF1 was
present in the gene list. Two random gene sets of 50
and 100 genes were analyzed to test the validity of this
method. Twenty-nine of the 50 random genes showed
100% sensitivity and of these 29, the average specificity
is 13.2% which indicates that the 50% specificity found
by the earlier gene list is significantly higher than a random gene set. Based on SAM sets the researchers determined that the most common genes associated with
the cancer metastases were TFF1 and TFF3. TFF3 was
also found as overexpressed in some metastatic prostate cancers, while TFF1 was found to induce cellular
invasion of kidney and colon cancer (Smid, et al., 2006).
This further proves that there is a strong tie between
cancer and genetics.
In high-grade serous ovarian cancers, triple-negative breast cancers, esophageal cancers, small-cell lung
cancers, and squamous cell lung cancers, the p53 gene
is mutated in at least 80% of patients’ tissue samples
(Duffy, et al., 2017). P53 has two major functions in the
cell cycle thereby linking it to cancer. P53 serves as a
cell cycle regulator, so if the cell no longer needs to go
through the cell cycle p53 will stop the cycle. Another
function is that a normal p53 protein stops a cell that
has already grown too much and is technically cancerous by initiating apoptosis for that cell (Zilfou & Lowe,
8

2009). When p53 is mutated the cells experience uncontrolled growth either because its cell cycle is not
arrested or because a cell that is already out of control
is not sent to apoptosis.
Because of the prevalence of mutant p53 in cancer
patient’s researchers have looked into a way to stabilize
these mutant forms of p53. They analyzed mice whose
p53 proteins were removed by one of several methods.
One method was that the mice were injected with an
anti-p53 antibody in which the p53 proteins in the mice
underwent ubiquitination. Another method was by using
an adenovirus, either Ad/GFP (green fluorescent protein) or Ad/His. They found that when these mice were
exposed to a drug called CP-31398, not only was the
DNA binding activity of mutant p53 restored thus allowing cell cycle arrest and induction of apoptosis, but it
can also increase the steady-state levels of wild type p53
(Takimoto, et al., 2002). Another study showed that CP31398 also inhibited the ubiquitination of p53 proteins.
A non-small-cell lung carcinoma cell, H460, was exposed
to CP-31398 for an hour, it was then exposed to ALLN,
a proteasome inhibitor, for four hours. Another group
of cells was exposed to ALLN alone and both were
analyzed. The results showed that the cells that had
just been exposed to ALLN showed a typical pattern
of ubiquitinated p53 ladders. However, the cells treated
with a mixture of CP-31398 and ALLN or just CP-31398
alone showed no ubiquitinated p53 ladders (Wang, et al.,
2003).These two applications of CP-31398 demonstrate
how useful it can be in preventing cancer because of the
prevalence of p53 mutations in cancer patients.
Another protein that has been a target for treatment
is p21, a cell cycle inhibitor, cell proliferation effector,
and apoptosis regulator. As with p53, many cancer
patients have been shown to have their p21 proteins
mutated. Gene editing techniques such as CRISPR,
TALEN’s, ZFN’s and rAAV have all been used to change
p21 expression and have been shown to suppress tumorigenesis phenotypes and reduce drug resistance.
Several chemical treatments target p21 as well. Histone
deacetylase inhibitors help increase the expression of
p21. Trichostatin A, PAC-320, and HDAC inhibitor combined with bortezomib or doxorubicin, have shown to
enhance p21 expression in pancreatic cancer, prostate
cancer and ovarian cancer respectively (Shamloo &
Usluer, 2019). All these treatments targeting p21 can
have massive ramifications because of p21’s effect on
cell cycle arrest.
Specific genetic mutations are directly linked to specific cancers which seemingly indicates that certain
genetic mutations are linked to specific cancers, thus
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legitimizing the claim that cancers have genetic components to them.
Stem Cell Theory of Cancer
This theory assumes that cancer is a result of a stem cell
that is unregulated and grows uncontrollably. Because of
several unique characteristics of prostate cancer such as
histological heterogeneity, metastatic growth, drug resistance, and distant relapse after effective primary treatment, the stem cell theory was proposed as a possible
explanation for prostate cancer. It was tested by searching for stem cell markers in the cancerous tissue. While
there is not one marker specific for prostate cancer stem
cells, there are a few methods used to help identify the
stem cells such as: β1 integrins, CD133, CD44, stem cell
antigen 1 and the ABCG2-associated drug-resistance
proteins. β1 is a marker for “stemness” because it is essential for sustaining a functional stem cell population and
establishing asymmetric division. β1 is also important to
stem cell maintenance. CD133 is a marker because it is
generally found in progenitor stem cells, linking it to a
stem cell. CD133+ prostate cells use their stem cell like
features developing prostatic-like acini in immunocompromised male mice. CD44 is a cell surface protein involved in cell-to-cell interaction, migration and adhesion.
Stem cell antigen 1 is expressed in the tissue of several
stem and progenitor stem cells including, cardiac mammary, hematopoietic, testicular, integumentary and muscular. These markers have been found in prostate cancers
thus giving credence to this theory (Tu & Lin, 2012). It was
also found that cancers that had CD44 were much more
tumorigenic and metastatic than cancers without CD44.
This further proves that these markers have relevance
when it comes to identifying cancers (Patrawala, et al.,
2007). These two studies indicate these classic stem cell
markers are present in cancers and furthermore they
enhance the growth and metastasis of the cancer when
they’re present.
Breast cancer was also examined for these markers.
The researchers analyzed surgically removed breast cancer tissue in 47 cases of only invasive duct carcinoma
(IDC), 135 cases of IDC with ductal carcinoma in situ
(DCIS), 35 cases of DCIS with microinvasion, 58 cases
of pure DCIS and 73 cases of IDCs with adjacent DCIS.
Four major subtypes of breast cancer were looked for in
this analysis: luminal A, luminal B, HER2+, and basal-like.
Each subtype was defined based on certain characters,
luminal A (ER+ and/or PR+, HER2−), luminal B (ER+ and/
or PR+, HER2+), HER2+ (ER−, PR−, HER2+), basal-like
(ER−, PR−, HER2−, basal cytokeratin+, and EGFR+/−).
CD44+/CD24− and CD44−/CD24+ cells were found by

way of double immunohistochemistry. It was found that
luminal A tumors were least common in DCIS with microinvasion, luminal B tumors were least common in IDC
alone, and basal-like tumors were least common in pure
DCIS groups. CD44, CD24 and ALDH-1 markers were
analyzed in normal breast tissue they were then compared to cancerous breast tissue. In normal breast tissue
CD44 was localized to the basal, myoepithelial, and a subset of luminal epithelial cells. CD24 was found on the
apical membranes of luminal cells while ALDH1 was heterogeneously expressed in luminal and basal cells. CD44
was expressed in 57% of IDC only samples, 59% IDCs
with DCIS samples, 62% of DCIS with microinvasion samples, and 85% of DCIS samples. CD24 was not nearly as
prevalent as it was present in 24% IDC only tumors, 38%
of IDC with DCIS tumors, 59% of DCIS with microinvasion tumors and 62% of DICS tumors. While ALDH1
was not commonlyf ound in any of the four subtypes, it
was far more common in IDC alone and IDC with DCIS
than the other two subtypes of DCIS with microinvasion
and DCIS alone, 9%, 6%, 3%, 3%, respectively (Park, et al.,
2010). These figures point to the fact that there is an association between stem cell markers and breast cancer,
further legitimizing the stem cell cancer theory.
Head and neck squamous cell carcinoma (HNSCC)
such as cancers of the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity, salivary glands, or head and
neck lymph nodes were studied to aid in further proving
stem cell theory. Multi-modality therapy including surgery,
has been emphasized as the method of treatment, yet
the five-year survival rate for HNSCC is 0-40%, with no
significant improvements in the past 30 years. A study
was done using tissue specimens of cervical lymph nodes,
primary tumors, and normal mucosa of patients undergoing surgical treatment of squamous cell carcinomas of
multiple sites in the upper aerodigestive tract. A total of
82 primary tumors and 24 metastatic lymph nodes from
82 patients were analyzed. Several variants of CD44 were
tested for: CD44s, CD44 v3, CD44 v6, and CD44 v10. It
was found that a majority of the cells from both the primary tumors and lymph nodes presented strong expression
of all 4 variants. CD44v3, v6 and v10 had a higher proportion of being strongly expressed in lymph nodes than they
did in primary tumors. Strong expression of CD44 v3 in
primary tumors was also proven to have association with
lymph node metastasis. Strong expression of CD44 v10
in primary tumors showed association with radiation failure and with distant metastasis. The expression of CD44
v6 was significantly associated with perineural invasion.
Next, an analysis was performed with regard to disease
free survival and overall survival. Overall tumor stage was
9
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found to be correlated with shorter disease-free interval.
Non-oropharyngeal primary site, positive cervical lymph
nodes, distant metastasis, CD44 v6 and CD44 v10 expression, in primary tumors, were all significantly associated with worse disease-free survival. Prior radiation
therapy, expression of CD44s and, both the standard and
variant form of CD44, in metastatic lymph nodes, were
all not significantly associated with disease free interval
or overall survival. Expression of CD44s, v3, v6, v10 were
all associated with advanced primary tumor stage, treatment failure, reduced disease-free interval, and metastasis
(Wang, et al., 2009). These stem cell markers are all indicative of very poor prognosis in HNCSS patients.
Researchers analyzed two cell groups of one patient
who suffered from colon cancer, the primary tumor cell
(SW480) and the metastatic lymph node (SW620). These
cells were analyzed by phase contrast microscopy and
were revealed as having two separate morphologies.
SW480 was shown to have 80% of its fully adhered cells
to be irregularly shaped, while 20% were spindle-like.
SW620 displayed a more mixed morphology amongst
its cells with 53% of its adhered cells as elongated spindle-shaped and the remaining 47% were either more
rounded spindles or irregularly shaped. The two cell lines
displayed similar measures of cell growth normal to their
respective cell line’s. When measuring migratory potential, SW480 cells were found to have a significantly higher
migratory potential than SW620 cells. Several stem cell
markers were analyzed in each cell line including, CD338,
CD44, CD133, CD24 and CD49f. SW620 revealed a
50.6% proportion of CD44+/CD133+ cells and SW480
displayed 28.6%. But the proportion of CD44+/CD133cells favored SW480 over SW620 with 54.3% and 20.7%
respectively. CD44+/CD24- cells were abundant in both
cell lines with SW480 having 62.7% and SW620 having
75.3%. The presence of CD49f+/CD338- was the highest
with SW480 and SW620 expressing it at 98 and 99%.
Because of the prevalence in both groups of cell lines,
it was deemed that these stem cell markers were not
significant enough to differentiate between SW480 and
SW620 in vitro cells (Slater, et al., 2018). While utilizing
stem cells did not prove to be a method to differentiate
between colon and metastatic tumors, it does prove the
presence of these stem cell markers in cancers.
Utilizing the stem cell theory, researchers have developed a new treatment for leukemic stem cells (LSCs)
that reside mainly in the bone marrow. Chronic myeloid
leukemia (CML) and acute myeloid leukemia (AML)
were analyzed. CML is categorized as a clonal hematopoietic stem cell that is caused by a translocation of a
fusion of two parts of two separate chromosomes, ALB1
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(chromosome 9) and BCR (chromosome 22). AML is the
most common form of adult leukemia and is categorized
by infiltration of leukemic cells into the bone marrow
and blood. The current therapies have an overall survival of roughly 40% in patients under 60 and decline by
5-15% in older patients. AML is very difficult to treat because of how drug resistant the disease is. While CML
and AML are both considered to have leukemia stem
cells, the environment of the bone marrow that contains
many growth factors only expedites the growth process.
The markers used to indicate CML LSCs are CD25 IL-1
and CD26 have been suggested as markers that are
specific to this disease as opposed to other stem cells.
CML LSCs vary from ALM LSC in that CML LSCs are
defined as CD34+/CD38- fraction whereas AML LSCs
are composed of heterogenous populations and aside
from CD34+/CD38- they also are in CD34+/CD38+ and
CD34-. The treatment method for these cancers is to
disconnect the cancer from the growth promoting bone
marrow environment thus making them more sensitive
to conventional therapy. There are several compounds
being studied as possible ways to disconnect the AML or
CML from the bone marrow such as: BL-8040, CAR-LMC,
Ruxolitinib, AMD3100, TH-302, Aflibercept, AS101, AMG
386, SRF231, TTI-621, CC90002 Hu5F9-G4, LY3039478.
These compounds all have different target cites but are
all designed to disconnect the cancer from the growth
advances provided by the bone marrow. IL-1RAP has also
been shown as a good marker to target CML LSCs in a
more selective manor because of its specific expression
in CML LSCs. Inducing apoptosis is a common approach
to AML treatment (Houshmand, et al., 2019).
Antibodies targeting IL-1RAP were thought as a possible way to treat CML LSCs without harming normal
stem cells. The antibodies mAb81.2 and mAb3F8 were
used and generated by the hybridoma technique. The cell
cultures were bone marrow and peripheral blood from
healthy volunteers and CML patients.The CML cells were
stimulated with IL-1B, IL-33, IL-36 or SCF. IL-1B and SCF
resulted in a slight expansion of CD34- CML progenitor cells. The stimulation as a result IL-1B on CD34+/
CD38- cells resulted in a 30-fold increase in cell numbers
as opposed to normal cells that responded weakly. In vivo
samples were studied to show the therapeutic effects of
IL-1RAP antibodies. Mice who expressed IL-1RAP were
treated with mAb81.2 which resulted in prolonged survival. The treatment proved to be very effective to the
point where the treatment was stopped after 45 days, yet
the mice survived an additional 12 days with 2 mice living
until day 101. Several of these mice displayed significantly
lower bone marrow leukemic cell levels compared with
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control mice. These antibodies are effective because they
block the signals of IL-1 as well as initiating effector cells
to kill tumor cells. This treatment does not affect normal
human stem cells because normal stem cells do not express IL1RAP (Agerstam, et al., 2016). This study shows
tremendous promise of utilizing the stem cell theory’s
principles as a route of treatment.
Conclusion
While there is a lot of data supporting each understanding of cancer development, there seems to be one correct
approach to cancer; it appears that the correct answer is
not one of these three theories rather a combination
of the immunological theory and the somatic mutation
theory. The immunological theory seems almost entirely
correct based on the utilization of CAR-T and CAR-NK,
DC-CIK as successful methods of treatment as well as the
case-report of a tetanus shot proving to increase cancer
prognosis. The issue with solely using the immunological
theory is that it better explains the treatment of cancer
and what should happen to prevent cancers from developing (NK cells) but it does not address why a cancer
cell forms. Rather it only states once a cancer forms the
immune system should prevent it from developing. The
somatic mutation theory explains why a cancer starts
to develop but the immunological theory explains how
to prevent it from continual growth. These theories, in
tandem, are the best explanation of cancer development.
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Abstract
Dentistry is a continuously evolving field with new materials and technologies constantly innovated. The oral cavity presents a
harsh environment in which restorative and implant materials must be able to withstand. Aside for meeting the appropriate physical and chemical standards, it is important that dental materials be biocompatible. Biocompatibility relates to the material’s ability
to function in the body without causing harm to living tissue. It is necessary to analyze the materials being used and determine
whether they interact with the body in a detrimental manner. This will enable dental professionals to choose the most beneficial
material to utilize for patient safety and overall health.
Introduction
Tooth decay is a prevalent health issue faced by the general population. In fact, according to the National Institute
of Dental and Craniofacial Research, 92% of adults between the ages of 20 to 64 have had dental caries in their
permanent teeth. Our teeth are comprised of four tissue
layers. Enamel, dentin, and cementum, are the three outer
layers of hard tissue, which surround the soft pulp tissue
layer containing nerves, blood vessels, and connective
tissue. Cavities form when bacteria and food debris combine with saliva to create a layer of plaque which sticks to
the teeth. Plaque contains acid which begins to dissolve
the enamel of our teeth and cause dental caries when the
plaque layer is not removed. Tooth decay is an active process that will continue to progress through the multiple
layers of tooth structure if left untreated.
There are various restorative treatment options that
exist to treat damaged teeth. Choosing the right material
is important considering that our teeth are exposed
to constant wear and tear. At times, teeth can regress
beyond the ability to be repaired. Fortunately, implant
replacement has become a viable option, with the use of
various metals and synthetic materials. Materials must be
durable as well as viable in an aqueous environment.
Amalgam and composite resin fillings are the two most
common materials used to fill cavities. Amalgam is composed of liquid mercury combined with an alloy made of
silver, tin, and copper solid particles. Dental amalgam is inexpensive and easy to work with, making it a convenient
option for dental restorations. Composite resin material
is made of a ceramic and plastic compound which makes
it a good tooth colored alternative. At present, titanium is
the gold standard in implant dentistry. On the other hand,
there are other materials being explored in cases where
titanium may present issues of biocompatibility.
However, when introducing any foreign substances
into the human body there is always the risk of detrimental side effects. Some of the components in these filling
materials can be cause for concern. For example, the use
of dental amalgam gives rise to mercury vapor exposure.
In contrast, composite resin fillings may release bisphenol
A (BPA) and other monomers into the blood stream.
Both of these restorative materials contain components

that can have toxic effects on the human organ systems
and may be hazardous to our health.
This review will explore the biocompatibility of these
restorative and replacement materials and analyze the
possible long-term side effects that they may have on
one’s overall health.
Material and Methods
Research was done by studying original research articles
and scientific papers found on the Touro College online
library. Specific scientific databases such as ProQuest and
EBSCO were utilized, and additional information was obtained by analyzing articles found.
Discussion: Amalgam
Amalgam fillings, also known as silver fillings because of
their appearance, are one of the oldest used materials in
restoring decayed teeth. The low cost, ease of placement,
and durability make amalgam a great option for dental
fillings. The material is composed of a powdered alloy of
silver, tin, copper, zinc, and elemental mercury. Directly
prior to placement, the components are mixed together
to activate the filling, which makes it soft and pliable for
easy placement. It is not necessary for the area receiving
the amalgam to be completely dry, which makes it a good
choice in locations that are difficult to isolate from saliva.
With a composition of about 50% elemental mercury
by weight, there is a concern regarding the toxicity of
this material. Interestingly, although it has been in use
for over one hundred years, dental amalgam has not
undergone the regulatory proof of safety testing required
of materials intended to be implanted into the human
body. Therefore, the question remains as to whether the
components of this material interact with the body in a
harmful way.
Inhaled mercury vapor can cause damage to the brain,
kidneys, and other major organs. After being inhaled into
the lungs, it is transported through the blood to the
brain. Liquid mercury is dangerous because it vaporizes
at room temperature and can easily be inhaled. Although
amalgam fillings harden rapidly and remain in the solid
metallic form once placed in the tooth, studies have
shown elevated levels of mercury in the blood and urine
13
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following restorative procedures utilizing amalgam as the
material of choice (Nicolae, et. al., 2013). This indicates
that there is some inhalation of mercury vapor prior to
the material hardening.
Aside for the inhalation upon initial placement of
amalgam fillings, low levels of elemental mercury vapor
are released when amalgam filled teeth are subject to
stress due to chewing, brushing, bruxism, and ingesting
hot foods. Measuring urinary mercury concentration is
a good method of analyzing the long-term influence due
to the presence of such fillings. A comprehensive study
utilizing this method of analysis was conducted within
the Canadian population (Nicolae et. al., 2013). Factors
considered included age, gender, and the number of filled
surfaces. Of all groups, 95.42 – 98.23 % of participants
had mean urinary mercury levels below 5 ug Hg/L. When
compared to a normal range of up to 20 ug Hg/L, these
concentrations do not seem to be cause for concern.
Overall, less than 5% of participants had mean urinary
mercury levels that qualified for possible reevaluation.
Although amalgam seems safe to use in the mouth,
there is a potential concern for dental professionals who
experience daily exposure (Jamil et. al., 2016). A recent
study demonstrated that people working in the dental
environment who handle amalgam do have increased
levels of mercury concentrations in their blood. Mean
concentrations in both dentists and dental assistants
were above the normal range of 20 ug/ L, with dentists
at a mean concentration if 29.835 ug/L and assistants at
22.798 ug/L. Also, the study demonstrated a correlation
between dentists who had more years of experience
with greater increases in mercury levels in the blood.This
seems to indicate that there is somewhat of a cumulative
effect. In addition, working longer shifts was associated
with higher concentration of mercury in the blood (Jamil
et. al., 2016).
With the phase down of amalgam fillings, this should
be less of a concern. Although dental professionals are
still utilizing amalgam fillings sporadically, other fillings
have become more popular. This would suggest that the
occasional use of amalgam for a filling would not contribute significantly to an increase in mercury concentration
in the blood. A possible method of preventing increased
mercury concentration in the blood of dentists would
be to implement appropriate regulatory safety measures,
such as wearing protective masks and gloves.
The New Zealand children’s amalgam trial (CAT) was
a study that explored the impact of exposure to mercury
from amalgam fillings on neuropsychological and renal
function, focusing specifically on children as the population (Bellinger et. al., 2007). The randomized sample size
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was 534 participants, and at baseline there were no amalgam restorations present. Over a five year period, there
was an average of 15 tooth surfaces restored per patient.
When measured, the group with amalgam as the dental
material of choice for restorations had significantly higher
mercury levels in the blood. However, this did not translate into impaired neuropsychological and renal function.
A possible explanation can be that this was a study
conducted with children as the participants. Increased
mercury levels may have a cumulative effect. Perhaps
adverse health effects would not appear until later in life.
For this reason, it would be appropriate to take precautions with pregnant women and children who are still
developing. In fact, studies have shown that mercury easily
crosses the placenta as well as the blood brain barrier
(Magos, Clarkson, 2006).
Furthermore, with the increase of exposure to electromagnetic fields due to common sources such as Wi Fi
routers, laptops, mobile devices, and MRI, there is a new
aspect to consider regarding the safety of amalgam fillings.
Although fillings have been shown to release mercury
vapor even after being placed, countless studies have
demonstrated that the release is generally at extremely
low dosages which is not a cause for concern. However,
the presence of electromagnetic fields increases the release of toxic mercury from amalgam fillings (Mortazavi
et. al., 2015). This creates an extra concern specifically
for pregnant women who have amalgam fillings. Mercury
circulating in the blood easily crosses the blood brain
barrier, as well as the placenta (Magos, Clarkson, 2006).
An in vitro study was conducted to examine this new
concern regarding amalgam toxicity. The goal was to test
the effect of electromagnetic fields on the release of
mercury from amalgam fillings.The study included twenty
healthy premolar teeth that had been removed for orthodontic treatment. The teeth were all prepared to be filled
in an identical way, by the same dentist. They were then
restored using amalgam and placed into artificial saliva.
The control group was stored in an environment away
from any exposure to electromagnetic fields. The experimental group was placed in the vicinity of a Wi-Fi router
that was actively exchanging data with a nearby laptop.
Following electromagnetic exposure, the mean concentration of mercury in the artificial saliva was tested.
The concentration in the saliva containing teeth that
had been exposed was .056 mg/L, in contrast to the
unexposed control group that had a mean concentration
of .026 mg/L.The results clearly indicate that the radiofrequency radiation given off via Wi-Fi devices can increase
mercury release from amalgam fillings (Paknahad et. al.,
2016). Being that it is one of the first studies exploring
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this concern, it would be necessary to conduct further
studies before stating that it is a concern.
There are people who remain concerned with the
presence of amalgam fillings, and even desire to have such
fillings removed. However, removing such filling for no
other dental related reason may cause more harm than
benefit.This is because drilling old fillings would cause the
release of additional mercury vapor and would cause the
patient to unnecessarily inhale additional mercury vapor.
A study was conducted to determine whether the
removal of amalgam fillings alleviated symptoms of health
issues attributed to the presence of mercury. The presence of these symptoms had no other medical or psychological explanation. The study consisted of 90 patients
between the ages of 20 -50 who reported 10 symptoms
of health problems that were suspected to be due to
amalgam. There were three groups; a group whose fillings
were removed, another group that underwent biological
detoxification therapy in addition to filling removal, and a
final group that did not remove fillings but participated in
a lifestyle improvement regimen.
To begin, baseline mercury levels were taken to be
compared to the end results. In addition, all participants
were given a 50 item symptom list to complete, ranking
each item 0-3, and combining the scores for a weighted
sum score. The amalgam fillings were removed and replaced by other materials over a period of time, in the
two groups chosen to have fillings removed. The fillings
were removed one quadrant at a time with a wait period
of one week between treatments. The group undergoing
biological detoxification therapy, took vitamin supplements in addition to filling removal.
Mercury levels measured in the blood and urine were
significantly lower in the two groups to have their fillings
removed as compared to the group that did not have any
fillings removed.The 50 item symptom list was completed
by all participants at 6, 12, and 18 months following initial
treatment. All groups showed a decrease in the main
complaint sum score, with a slightly larger decrease for
the two groups to have the amalgam removed (Melchart
et. al., 2008).
It is difficult to demonstrate a correlation between
the amalgam fillings and attributed symptoms of health
issues. The results of this study indicate that although the
presence of amalgam fillings increase levels of mercury in
the blood, they are not the source of any known adverse
health effects. Therefore, it would be unwise to have such
fillings removed if not deemed necessary for improved
oral health.
Amalgam continues to be used as a great option in
restorative dentistry. Research thus far has demonstrated

that amalgam remains a biocompatible material that does
not cause harm to the human body. Although it does
increase mercury levels, the concentration is too slight to
be considered significant. Specifically in the case of posterior teeth where aesthetics are not as much of a concern,
it may actually be a preferable option. This is because it
can withstand stronger chewing forces.
On the other hand, being that it is not the only source
of environmental exposure to mercury, there is a movement to utilize other available materials in cases where
it will not compromise treatment outcomes. In addition,
appropriate protective safety measures should be taken
to protect dental personnel who are more frequently
exposed.Thus far the use of amalgam has not been linked
with adverse health effects. Further studies are necessary
to determine the association between electromagnetic
fields and the release of mercury from amalgam fillings.
Resin-Based Composite
Resin-based composites (RBC) are a more recent innovation in restorative dentistry. These fillings are made
up of a mixture of ceramics and plastics. RBC are often
preferred, as they match the color of teeth and have a
nicer esthetic appearance. However, these fillings may
contain Bisphenol A (BPA), and other components that
are toxic when released as monomers. BPA is used to
synthesize various monomers that make up RBC, such as
BPA–glycidyl methacrylate (BisGMA). Often, residues of
BPA remain in the process of synthesizing RBC material
(Luo, et. al., 2016).
BPA is in the class of xenoestrogens. Xenoestrogens
are chemicals that are known to be endocrine disrupters,
and they inhibit normal hormone function (ZimmermanDowns, et. al., 2010). BPA is thought to be related to
various diseases including diabetes, heart disease, obesity, as well as immune and reproductive disorders. The
European Food Safety Authority has established a tolerable daily intake of no more than 4 ug/ kg of body weight
per day.
Most of the BPA that humans are exposed to comes
from people’s diet. Upon entering the body and passing
through the digestive tract, BPA passes through the liver
and is detoxified. The liver converts most of the BPA
from its free unconjugated form to a non-estrogenic
conjugated form. This prevents it from interacting with
the body in a harmful way. However, research has shown
that even after fasting, the concentration of unconjugated
BPA is higher than predicted (Stalhut, et. al., 2009). This
demonstrates that it is not metabolized immediately, but
remains in the body for some time.
In addition, BPA entering the body via the skin, as well
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as oral or respiratory mucosa, bypasses initial liver metabolism and circulates in the blood for a longer period
of time in its unconjugated form. This presents a concern
specifically when dealing with dental treatment. Materials
that contain BPA or precursor molecules may leech these
harmful chemicals into saliva and enter the blood stream.
Various studies have been conducted both in vitro and
clinically to determine if the use of these materials in
dental fillings negatively impacts overall health.
A study was done to test whether the presence of
composite fillings was related to increased levels of BPA
in saliva. The study consisted of 40 volunteer participants
between the ages of 20 -35 who were patients of dental
clinics in Bergen, Norway. All of the participants underwent a comprehensive dental evaluation and were given a
score between 1 and 3 based on the number of existing
composite restorations. The experimental group consisted of twenty individuals with at least 6 tooth surfaces
restored with RBC. The control group was made up of
twenty people without any composite fillings. Five ml. of
saliva was collected from all participants and stored in
BPA free test tubes.
The collected saliva samples were then tested using a
liquid chromatography technique. Both the unconjugated,
as well as total BPA concentrations were measured. In the
experimental group, eight out of the twenty were found
to have saliva BPA concentrations above the detectable
limit of .1 ng/mL. Within the control group there were
3 participants with concentrations above the detectable
limit. However, in both cases the concentration was still
very low (Berge et.al. 2017). This study seems to indicate
that the presence of RBC alone is not the cause of BPA
related health concerns. However, there are factors that
limit this study (i.e. sample size), and further studies are
necessary to explore this issue.
An in vitro study was done to test cytotoxicity of resin
based composite fillings. The harmful effects of these materials are decreased once placed in dentin, but not completely eliminated. The release of toxic materials from
composite materials was previously thought to be a concern only within the first 24 hours following placement.
Therefore, many studies were designed focusing on the
potential harm caused only following initial placement.
This study aimed to test whether or not there is a longterm release of toxic materials into our body systems.
Various common composite materials used were prepared in lab dishes and light cured. The specimens were
then split into three groups; a control group stored as is,
a second group aged in lab simulated artificial saliva for
seven days, and a final group also in saliva for 14 days.
High- pressure liquid chromatography was used to test
16

the components of the artificial saliva for presence of
harmful substances. The results indicated that although
the release of these substances decreased after 24 hours,
a cytotoxic effect on cell activity remained even after a
two week wait period. This study suggests that further
clinical testing should be designed with a focus over more
than a 24 hour release period (Al-Hiyasat, et. al., 2005).
Composite fillings require a bonding agent, which assists the material in adhering to a prepared tooth structure. 2-hydroxyethyl methacrylate (HEMA) and BPA are
components contained in bonding agents that can be
cytotoxic to human gingival fibroblast (HGF). In a recent
study, cell cultures were grown using healthy human gingival tissue to test various bonding agents. It demonstrated
that both HEMA and BPA negatively impact cell viability
of HGF although they exhibit different patterns of cytotoxicity. Although the cytotoxic effect was reduced after
24 hours, this is a matter of concern that requires further
study being that all of the bonding agents displayed some
level of cytotoxic activity on HGF (Reddy, 2017). The
study was important as it displayed that different bonding
systems had varying effects, with some being more harmful to HGF cells than others. Until an improved method
is developed it is necessary to evaluate and choose a low
risk bonding agent.
When using RBC, the technique for placing them varies. Composite fillings are soft and pliable for placement,
and then cured with a blue light to harden the material
into a strong durable filling. These fillings are available in
flowable, paste like, and bulk consistencies. Interestingly,
studies have demonstrated that the method used for
placement is related to the degree of release of toxic
monomers and BPA into circulation (Pongprueksa et.
al, 2015). They are generally placed in 2 mm increments
to ensure adequate polymerization and reduce polymerization shrinkage stress. For deep fillings, a bulk fill
composite has been developed that can be cured in 4
mm increments. Fillings that are not cured completely
can result in monomers leeching into the oral cavity and
reaching pulp tissue.
The efficiency of polymerization is important, as composites with low degree of polymerization release more
monomers. The degree of conversion (DC) can be measured by means of spectroscopy. A study was conducted
with the objective of determining how the DC varied
based on the consistency of RBC used, and how it related to monomer elution. It also analyzed the change in
release of monomers over time. Cylindrical samples were
prepared using three types of RBC. They were filled in
two 2 mm thick layers or one 4 mm bulk layer, and light
cured to polymerize.
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For all of the composites, there was a mean DC between 60 and 70%. There was a significant difference in
total monomer release depending on the composite type.
The paste-like composite showed the lowest monomer
elution. This can be attributed to the fact that it has a
lower resin content to begin with. In addition, it is administered in layers allowing for better curing. Four mm bulk
placement resulted in a lower DC and higher monomer
release. Evidently, curing through a thicker layer of composite material is not as effective in complete polymerization of the material.This results in greater release of toxic
monomers. In addition, fillings that are not fully cured can
lead to gaps forming between the filling and the tooth
structure. This can lead to secondary caries.
The study demonstrated that monomer release is dependent on both the composite type and the method of
application. Therefore, the usage of paste-like composite
and a layered placement technique seem to be the preferable method of treatment.This would limit the unnecessary
release of monomers and BPA. In addition, it was found
that rinsing and scrubbing fillings following placement further reduces the escape of harmful monomers. This extra
step should be implemented for a safer procedure.
During the placement of RBC, composite dust particles are released into the surrounding environment.
These nano sized particles become airborne and upon
inhalation can travel deep into the lungs.This may present
a concern for patients, and for dental personnel who perform multiple such procedures daily. RBC are composed
of methacrylate monomers, which have been shown to
provoke allergic reactions. It is important to investigate
whether the composite dust that escapes into the atmosphere releases methacrylate monomers.
A recent study analyzed the dust particles released
from four common composites used in dentistry. Samples
of composite were light cured and polished in an enclosed
chamber using a diamond bur. The dust was collected by
means of a cyclone vacuum for analysis. The particles
collected underwent various examinations by means of
microscopy and spectroscopy. They were shown to release unpolymerized methacrylate monomers (Cokic, et.
al., 2017). This poses a respiratory risk to those in the
surrounding environment. Interestingly, dental workers
are prone to developing asthma and other respiratory issues, although the cause has not been verified. Composite
dust particles released in the air may be the culprit of
this observed phenomenon. Further measures should be
taken to reduce the inhalation of composite dust. Perhaps
better safety masks should be implemented to reduce the
inhalation of unhealthy composite dust.

Amalgam vs. Composite: Which to Choose?
The biocompatibility of materials used in restorative dentistry relates to how well it can interact with living tissue.
According to the above data both amalgam and composite fillings contain components that can create issues of
biocompatibility. However, although studies indicate the
presence of toxic materials circulating in the body following dental procedures, the concentrations generally remain
below levels that are harmful. Therefore, the question remains as to which material is preferred for treatment.
With the increased focus on esthetics, many patients
opt for composite fillings. Particularly when dealing with
anterior teeth, it definitely seems to be a better option.
However, when considering which material to use for
posterior teeth, amalgam does have some advantages.
This is because the back molars bear a lot of stress from
chewing forces. Amalgam has been shown to withstand
more strain and is less prone to cracking or needing
to be replaced. In addition, composite fillings are sensitive to temperature, and shrink upon exposure to heat,
which can cause increased tooth sensitivity. Furthermore,
shrinkage of composite material creates a gap between
the tooth and the filling. This is known as leakage, and is
a big cause of secondary caries formation. However, with
proper oral hygiene much of this can be avoided.
Implants
Prosthetic implant devices are an evolving field in dentistry, and choosing the right materials are key to a successful procedure. Implants provide an excellent replacement
option for teeth that are no longer restorable and need
to be removed. Titanium is often the material of choice,
as its osteophilic nature makes it highly biocompatible.
Titanium is very reactive, and will rapidly form a layer
of titanium oxide when exposed to an aqueous environment (such as the mouth) or air.This forms a boundary at
the interface between the implant material and biological
environment, which protects the material from corrosion.
Therefore, the metal ion release into the body is limited
and generally unreactive (Kumar et. al, 2016).
Although less prevalent than other metal allergies,
titanium allergies do exist (Lahori et. al., 2015). An allergic
reaction can create a rift in this oxide layer formation and
may impair the biocompatible function. Allergic reaction
to titanium is caused by the release of ions interacting
with native proteins in the nearby environment. This may
cause a hypersensitive reaction and rejection of the implant. Determining the presence of titanium allergies and
working with alternative materials is an area of continued
research. Titanium allergies may be the culprit to otherwise unexplainable implant failures.
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Another potential issue of this otherwise successful
material is its elasticity. Young’s modulus is a mechanical
property which measures the stiffness of a solid material. It is a measurement determined by the slope of the
stress-strain curve of a material. At 113.8 GPa, the elastic
modulus of titanium is significantly higher than bone (18.6
GPa).This makes it less flexible than bone and can result in
strain upon implant insertion and subsequent implant failure (El Hajje et. al., 2014). The implant material will act to
shield the bone from stress, which eventually can lead to it
loosening and losing contact with the surrounding tissue.
Zirconium has been introduced as a possible alternative implant material. Clinically, it has demonstrated
success similar to traditional titanium implants. Studies
have shown little difference in osseo-integration between
the two materials. In addition, zirconium implants actually
display reduced microbial growth as compared to titanium. This decreases plaque formation on the implant and
surrounding tissue, which is important for the long-term
success of an implant.
Peri-implantitis is the inflammation of the gum and
bone structure in the area of a dental implant. It is caused
by the buildup of trapped bacteria and can lead to bone
loss. An in-vitro study was conducted to explore the adhesion of oral bacteria to different implant materials. It
included both titanium and zirconium, as well as a combination of both.The results displayed that oral bacteria have
less of an affinity for zirconia (Al- Radha et. al., 2012). This
suggests that zirconia implants can lead to better implant
results and more successfully prevent the development of
peri-implantitis.
Over time, recession of soft tissue surrounding implants can occur. This can lead to exposure of implant
parts and is a particular concern when dealing with anterior teeth. Also, titanium implants can result in discoloration
of gingival tissue. In patients with a thin gingival biotype
or high smile line, such discoloration is readily apparent.
Zirconium implants may provide a solution to this issue
as they result in a more esthetic appearance (Bhasin, et.
al., 2015).
Polyetheretherketone, or PEEK, is a new material being
explored as a possible alternative implant material. This
may be an effective way to circumvent the titanium allergy,
as well as provide a more esthetic option. In addition, with
a low elastic modulus it can prevent issues of stress-strain
distribution. This is in contrast to both titanium and zirconium, which possess higher elastic modulus (El Hajje et. al.,
2014). However, being that its elastic modulus is actually
lower than that of bone it is necessary to reinforce the material in order to use it successfully (Schwitalla et. al., 2015.
A finite element analysis technique, which is commonly
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used to test dental materials in vitro, was used to study
the stress distribution on the jaw following implant placement. It focused on titanium vs PEEK as the materials to
be analyzed. A 3D model of the left mandibular jawbone
was produced and an implant screw and abutment was
inserted. Three different implant materials were used in
the study to be compared, including titanium, and two
different forms of commercial PEEK.
Circular contact areas were used for the purpose
of testing the degree of stress caused to the different
implant materials. Force was applied to the occlusion
areas of the simulated implant via a specialized device,
and the stress, deformations, and contact pressure were
measured. The results of the study indicated that PEEK
reinforced with 60% vertical carbon fibers was similar in
stress distribution as titanium. Pure PEEK displayed higher stress damage. Perhaps this can be attributed to the
fact that the elastic modulus of pure peek is lower than
that of cortical bone. Reinforcing it with vertical carbon
fibers makes it strong enough to withstand more stress,
yet still maintain a lower elastic modulus than titanium
(Schwitalla et. al., 2015).
The characteristics of PEEK suggests that it possesses the potential to be a good alternative to titanium.
However, long term studies regarding clinical success are
lacking. Further research is necessary before implementing the use of this synthetic material as a final abutment
for implants.
For the most part, titanium implants have a track record of success and continue to be used as an excellent
replacement option. It is a highly biocompatible material
that generally integrates into the bone well. In the case
of allergies or hypersensitivity, there are other options
being explored. Zirconia is a good alternative as it has
shown similar clinical success and may even have higher
antimicrobial properties. In addition, it seems to be a
preferred option in the case of anterior teeth and thin
gingival biotypes.
Conclusion
The above studies indicate that the field of biomaterial
compatibility requires further attention. It is necessary
take a closer look, even though they are already being
utilized in the dental field. Amalgam as an older material
is less of a concern. However, in regard to composites,
future studies focusing on the long term and cumulative
effect should be designed. This information is important
in being able to further improve the biocompatibility of
dental materials. On the other hand, with both of these
materials, the release of toxic components is shown to
be below baseline levels of what is harmful to the body.
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Therefore, in terms of clinical applications the decision
of which material to utilize can be made by practicing
dentists. The choice can be made based on the individual
needs of each patient and situation.
When dealing with implants, titanium remains an excellent option. Although it is a small percentage, there are
some people who experience hypersensitivity or allergies
to this material.There are other materials being explored
with similar success rates. Some of these materials have
shown good potential experimentally, yet clinical case
studies are lacking. Further studies are necessary before
implementing the widespread use of such materials.
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Abstract
The management of Venous Thromboembolism in terms of treatments and prevention has been well researched for patients
who have been discovered as positive for Factor V Leiden genetic clotting disorder, in either the homozygous or the heterozygous genotype. In fact, the research and development of new agents called Direct oral anticoagulants aim to treat and prevent
clotting events while minimizing the risks of bleeding. Although several risk factors have been identified in relation to VTE, Factor
V Leiden mutation presents a seemingly higher risk due to its unpredictable incidences of clotting events, even in patients with
optimal health characteristics. Yet, we haven’t transitioned to routine testing of the common population for the Factor V Leiden
as a preventative measure, rather the focus has been on those at risk due to family history of VTE or if clinical decisions might
depend on it, such as the proper choice of contraception for female patients. Additionally, the increased risk of thrombophilia
during pregnancy raises concern for proper medical management that would benefit the mother, without harming the baby, at
any point of the pregnancy.
Introduction
For many people, the thought of having a blood clot is
terrifying and rightfully so because it is potentially fatal
and essentially invisible. A blood clot can appear in the leg,
in the lungs or even in the brain. Also called a thrombus, a
clot represents an accumulation of blood in a solid state,
essentially caused by coagulation processes. Although
coagulation is an important and vital function of homeostasis, the resultant clot formation may obstruct blood
vessels enough to limit perfusion of their field of supply.
Medicine has shown that many risk factors for developing
thrombi are acquired and depend on a patient’s physical or medical conditions such as obesity, hypertension,
atherosclerosis, or even pregnancy. However, different
genetic mutations appear to be linked to increased risk
of thrombosis, such as Factor V Leiden, named after the
city of Leiden in the Netherlands, where it was first identified while researching links between oral contraceptives
and increased cases of thrombosis (Vandenbroucke et
al., 1994). Factor V Leiden is the most common genetic
mutation causing increased risk of thrombophilia, or abnormal coagulation, therefore treatment options should
be carefully considered for patients with clotting history, as well as preventative measures for those who have
not presented with thrombi. In view of the association of
blood clots with family planning measures, this review will
focus on women with Factor V Leiden, considering female
individuals with or without a history of thrombophilia.
Background:
Pathophysiology of Factor V Leiden
The factor V Leiden thrombophilia, also called Activated
Protein C resistance, stems from a genetic mutation that
affects parts of the clotting cascade, a physiological process necessary for proper regulation of coagulation (Van
Cott et. al, 2016). More specifically, Activated Protein C
(APC), along with a cofactor Protein S, normally inactivates some coagulation factors, hence acting as an anticoagulant system. The mutation results in a decline in

that inactivation, which has the potential to increase the
coagulation activity. As for all genetic mutations, they can
be present as heterozygous with one abnormal copy of
the gene, or homozygous, for which both copies of the
gene are mutated, the latter increasing the risk for thrombophilia by 80-fold. Regarding the population distribution
of the Factor V Leiden mutation, it appears to be more
prevalent in Europe, followed by Africa, and less prevalent
in America (Rees, Cox, 1995).
Methods
To complete this review, multiple scientific scholar databases and peer-reviewed articles mainly found on the
Touro College online library were used. The Proquest,
Browzine, Google scholar, and Dynamed databases were
utilized with specific associations of key words in order
to optimize the research and the results necessary to
complete this study.
Discussion
When exploring the Factor V Leiden mutation and its
relation to increased risk of venous thrombosis, it is first
essential to make the distinction between individuals who
have had a previous clotting event such as a deep vein
thrombosis or a pulmonary embolism and those who
have not. In fact, treatment options, preventative measures
and family planning possibilities may be affected by a positive history of thrombophilia, regardless of the presence
of any physiological risk factors, not to be dismissed, but
to be utilized in conjunction with factor Factor V Leiden
mutation at the time of medical management (Anderson,
2003).Those risk factors should be touched upon for reference and comparison throughout this review.
Non-genetic Risk Factors of Venous Thrombosis
The risk factors for VTE (venous thromboembolism)
mainly consist of obesity, long periods of immobility,
surgery, smoking, age, pregnancy and use of oral contraceptive pills, according to the NYU VTEC center and the
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Figure 1: Most common risk factors of Venous Thromboembolism

Cornell center for blood disorders, both specializing in
venous thrombosis. Although common knowledge supports their statement, others might argue about the true
character of “risk factor” for some of the elements above
mentioned. For instance, obesity appears as a weak link
to increased VTE, based on multiple studies, therefore it
should be carefully analyzed when considering treatment
or even prophylaxis (Anderson, 2003). Similarly, although
age seems to count as a risk factor for many diseases or
medical complications, its direct connection to increased
VTE is questionable, especially due to the variety of ethnicities throughout the world and their life standards, as
described by an epidemiology review with respect to
China presenting an impressively low rate of DVT per
year (Cushman, 2007). Therefore, we should denote the
importance of evaluating an association of physiological
and potentially genetic risk factors when treating or preventing venous thrombosis.
Treatments and Preventions of Venous
Thromboembolism
It is essential to distinguish between patients who have
had a VTE event and those who haven’t, as it may affect
their treatment approach, even if they are positive for factor V Leiden. Additionally, this section will analyze whether treatments and preventions will be influenced by the
homozygous vs heterozygous factor V Leiden status.
When discussing treatment options, we refer to patients who have actually had a DVT or a pulmonary embolism and require treatment with anticoagulant. Although
the review focuses on patients with Factor V Leiden, it is
important to make the comparison with patients who do
not have any genetic mutation that would favor VTE, in
order to better understand the rationale for treatment
and prophylaxis.
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Duration of Treatment
A minimum of 3-6 months of anticoagulation therapy is
recommended for all patients who suffered a VTE, regardless of physiological or genetic risk factors (Kearon, Akl,
2014). However, if a VTE is unprovoked, meaning without
obvious risk factor, it is highly recommended to pursue
anticoagulation for at least 12 months, or perhaps indefinitely to avoid recurrence, as highlighted by multiple
studies compiled in one of the articles on UPTODATE,
an online medical reference, that strongly emphasized the
reduction in rates of VTE recurrences in patients who
had been on anticoagulation long term (Lip, Russell, 2019).
Moreover, it is debatable whether a genetic mutation
causes unprovoked VTE or if it is provoked by the mutation. Even if provoked, opinions about the duration of
treatment vary widely, especially if the patient’s genotype
is heterozygous for factor V Leiden; in fact, many providers will not treat indefinitely for a VTE provoked by a
genetic factor, (Lip, Russell, 2019). More surprisingly, the
actual difference in VTE incidence between both Factor
V Leiden genotypes seems questionable. Indeed, when
analyzing the number of actual cases and the percentage
of recurrence after a first event, only a slim difference
between homozygous and heterozygous percentages in
VTE events (Perez Botero, Ormsby, 2016). Therefore, we
can argue that the Factor V Leiden genotype shouldn’t be
used alone to distinguish between lengths of treatment.
On a separate note, it is essential to take into consideration the bleeding risk associated with taking anticoagulant agents, commonly named “blood thinners”. As
a matter of fact, all anticoagulants increase the bleeding
risk to some extent and require vital risk versus benefit
assessment when initiating treatment for VTE and determining duration of treatment. Bleeding associated with
anticoagulation can range from a simple hematoma or
easy bruising, to life threatening gastrointestinal or intracranial hemorrhage (Garcia, Crowther, 2019). Evidently,
the longer a patient is on anticoagulation treatment, the
higher chances he/she has of developing internal bleeding
events, and those shouldn’t be taken lightly, therefore
must be investigated even with minimal symptoms, such
as coughing up a little blood. In fact, the Mayo clinic recommends precaution when prescribing blood thinners
especially to older patients (>75 years old) who present
higher chances of GI bleed (Harringa, 2019). On a similar
note, when treating a patient with factor V Leiden with
anticoagulation on a long-term basis, one ought to carefully monitor the bleeding effect of the prescribed agent.
Indeed, we can also include female patients with factor V
Leiden, for which continuous anticoagulation therapy will
result in heavier menstruations. Although, we previously
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argued that the factor V Leiden genotype alone doesn’t
determine the length of treatment, those patients will
need long term treatment since the factor V Leiden is a
genetic component, and by definition cannot just disappear, as opposed to obesity. Therefore, if it is a constant
risk factor, it will most likely represent a constant threat.
The next section will present various anticoagulants that
have been discovered and manufactured.
Different Anticoagulants on the Market

Table 1: Oral Anticoagulant comparative table

Based on the table above, multiple factors are to be considered when initiating a patient on oral therapy following
an acute VTE event, especially when the patient is positive
for factor V Leiden, and will most likely require long term
anticoagulation therapy The drug class can be taken into
account . In this case, both warfarin and the rest of the
agents called Direct Oral anticoagulants (DOACs) are
acceptable for treatment of VTE (Milling, Frontera, 2017).
Furthermore, the daily dosage varies among all AC agents,
from once a day with Warfarin or Xarelto, to twice a day
with Eliquis or Pradaxa. Therefore, it raises an obvious
question of medication compliance. Surely patients would
be more likely to comply with their medications if only
they needed to be taken once a day instead of twice a
day. In that respect, Warfarin or Xarelto seem to be optimal options. However, as indicated on the table above,
the daily dose of warfarin is dependent on a standardized

international blood test called INR. In fact, patients on
warfarin need to check their INR blood test quite often
as their dose of warfarin will be adjusted based upon the
results. Therefore, the frequent change of coumadin dosage undoubtedly will result in patients confused with dosage, that is without considering frequent venipunctures
to test the INR. In addition, warfarin is a vitamin K antagonist, which means all foods high in vitamin K will counteract the effect of coumadin; hence, those foods should
be avoided or eaten in small portions all throughout the
duration of the treatment with
warfarin; a factor to consider
greatly since a lot of greens or
even garlic can interact with warfarin (Mayo Clinic, 2018).
The next component of the
table includes the creatinine
clearance, representing a potential risk of certain DOAC agents
such as Xarelto, on the renal
function. Although it doesn’t directly concern a DVT or a PE,
certain patients who present
with blood clots events, may also
suffer from other medical conditions such as renal disease, which
in this case can render the choice
of AC more challenging.
The last component of the
table indicates the possibility
to reverse AC agents due to
overuse or excess bleeding for
example as a result of hypovolemic shock or major trauma.
Warfarin’s reversal agent is Vitamin K. Moreover, a reversal agent became approved by the FDA for both Eliquis
and Xarelto this year, by the name of Andexanet Alfa
(Cuker et. al., 2019).
Besides for the factors indicated on the table above, it
is essential to also mention the potential risks of bleeding
and consequent serious medical conditions such as GI
bleed and intracranial hemorrhage. According to multiple trials, it appears that DOACs have a lower risk of
intracranial hemorrhage or even GI hemorrhage than
warfarin and therefore should be used as a first choice,
if all contraindications have been carefully considered
(Garcia, Crowther 2019).
Additionally, considerations must be made for female
patients who are pregnant, because all the above-mentioned agents, whether Warfarin or DOACs are not indicated during any of the stages of pregnancy. Alternatives
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will need to be used as needed for treatment of a VTE
during pregnancy or even as a prophylactic agent; those
will be contemplated in the family planning section.
The duration of anticoagulation treatment varies with
the unprovoked versus provoked status of a VTE, in patients with either Factor V Leiden genotype, heterozygous
or homozygous. A blood thinner treatment is designed to
treat the current thrombosis, and even more importantly
to prevent recurrence. The nature of the AC agent will
depend on the availability of a reversible agent, the patient’s current renal status and the level of compliance a
provider attempts to achieve, apparently more in favor of
DOACs due to decreased risk of internal bleeding, compared to warfarin. Recent tendency has it to get tested
for genetic conditions such as Factor V Leiden, generally
due to family history of clotting.Therefore, if a patient has
a Factor V Leiden mutation, there may be some preventative measures to consider in certain cases, even if that
individual has never experienced a VTE.
Prevention of Venous Thromboembolism for
Patients with Factor V Leiden
There are several non-genetic risk factors to venous
thromboembolism (VTE), such as obesity, age, recent surgery or long immobilization states. If we also consider
the positive Factor V Leiden mutation genotypes, we can
understand that certain patients are at serious risk for
developing thrombi, whether from a physiological or genetic standpoint, or both. Moreover, patients who have
had a VTE can certainly develop another one, hence the
necessity for treatment, and preventative measures. Let’s
explore some risk factors and analyze the preventative
measures that would best benefit those at risk.
First of all, we can raise the question regarding testing
for genetic mutations such a factor V Leiden for patients
who have had a VTE or are family members of Factor V
Leiden. As a matter of fact, knowing that condition exists
can be part the prevention process. It seems that newborn or infant screening for Factor V Leiden or testing
of the population is not recommended, however the recommendations seem strong for female patients of child
bearing age with personal or family history of VTE, as well
as those under 50 years of age with a personal history
of Thromboembolism (Grody, et. al, 2001). While testing
family members of Factor V Leiden genotypes carriers is
important in certain cases, it appears it doesn’t necessarily
prevent the occurrence of VTE, unless those patients are
being educated on the mutation. It is especially important
to educate about VTE risks and implications in different
aspects of healthcare such as after a surgery, while on oral
contraceptive or even during pregnancy (Segal et. al, 2009).
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Regarding the prophylactic interventions using medications, patients undergoing surgery or long-term immobilization following a surgery such as a knee or hip
replacement, will be offered anticoagulation prevention
via a low molecular weight heparin (LMWH). The most
common of those agents is called enoxaparin, with brand
name “Lovenox”, available as an injectable product, that
can be self-administered by the patient, but requires several calculations to determine proper dosage based on
weight and monitoring with a blood test called the “Anti
Xa activity” that calculates its efficacy (Busti, 2015). More
precisely, the LMWH acts as an inhibitor of a factor Xa,
one of several proteins involved in the coagulation cascade, which results in clotting formation, either in a normal ratio or abnormal, with consequences such as VTE. .
Another commonly used agent for prophylaxis, especially following a surgery, is warfarin, previously mentioned. In fact, it may seem undesirable for a lot of patients to go through daily injections. Although the use of
prophylaxis Warfarin has been associated with more than
50 % reduction of VTE post orthopedic surgery, LMWH
was concluded as a superior alternative for protection
against thromboembolism post-surgery (Paj, Douketis,
2019). Moreover, the use of low dose Aspirin has been
contemplated as well for prevention of VTE but is most
commonly used for cardiovascular prevention such as
protection from strokes or myocardial infarctions.
Although the goal of anticoagulant agents is for preventing VTE, the bleeding consequences are not to be
ignored. Therefore, hospital settings also offer non-pharmacological options such as an IPC device, intermittent
pneumatic compression device, that improves venous
circulations in upper and lower extremities to prevent
edema, as well as venous thromboembolism. However,
since data hasn’t shown the IPC device as a complete
alternative to medicated options, according to “uptodate”
latest research(Paj, Douketis, 2019), it is becoming common practice to start off with IPC devices for patients
with a high risk of bleeding, and then transition to a blood
thinner medication agent, as presented by the AHRQ, a
government agency in charge of research and quality in
healthcare systems (Maynard, 2016).
Testing for Factor V Leiden is not commonly done with
the general population but focuses on family members of
those with the genetic mutation. In regard to prophylaxis
agents for long term immobility, such as post-surgery,
different agents are available and will depend on the patient’s abilities to self-administer daily injections, as well as
the risk of bleeding, yet it is always important to measure
the levels of risk, especially for those patients with a
genetic component such as factor V Leiden mutation. The
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factor V Leiden genetic mutation was discovered in relation with increased risks of VTE for female patients on
oral contraception. Indeed, it appears that an important
amount of the research regarding Factor V Leiden thrombophilia is associated with female individuals and attend
to pregnancy or contraception related matters.
Female Patients with FactorV Leiden-Family Planning
Female patients of child-bearing age who are positive for
factor V Leiden need to be aware that their genotype can
affect their choices when dealing with contraception and
family planning.
Contraception
It is believed that oral contraceptives, especially estrogen
containing agents have the potential to increase the risk
of VTE; indeed, the estrogen will increase the plasma concentration of certain clotting factors and fibrinogen, all of
which are favorable to clotting formation (Busti, 2015).
Although several sources have pushed for testing
patients for Factor V Leiden prior to prescribing oral
contraceptives, it represents a large population of female
patients being tested and consequent precautions to be
taken for life with constant awareness of the genotype,
when there is no guarantee one of those women will
ever experience a thrombosis event. Rather, a review
suggests recording a comprehensive personal and familial
medical history or VTE when prescribing oral contraceptives (OCP) (Rosendaal, Koster, et. al, 1995), which seems
more appropriate and targeted.
It is important to understand that the association of
factor V Leiden and use of oral contraceptives cause great
thrombosis risk, and has been long studied and concluded
as such (Choe, Suh, 2019), therefore a female patient
should always mention it to her doctor before being
prescribed any oral contraceptives. Luckily, several contraceptive options have become available on the market
to satisfy all preferences and medical conditions, which
becomes handy for those with a history of VTE or known
Factor V Leiden. For example, the oral contraceptives
containing only progesterone have been categorized as
little to non-affecting coagulation. Therefore, these can
become an ideal option for those women at higher risk
of developing VTE, such as those with factor V Leiden
genotypes. Similarly, Intrauterine devices (IUD) containing only progestin, such as the Mirena, are an excellent
alternative to oral contraceptives for those who can’t
seem to comply to the daily regimen of birth control,
especially when indicated to be taken at the same time
every day. It is however essential to bring to light the fact
that fewer studies were conducted on progesterone-only

agents, therefore more data may be necessary to fully
draw the conclusion of its higher grade of safety in terms
of VTE prevention (Tchaikovski, Rosing, 2010). In addition,
The Journal of Community Hospital Internal Medicine
published an article this year warning about the progestin-only IUD, when a female patient in her early 30’s with
Factor V Leiden suffered a pulmonary embolism while on
that intrauterine device (Jean, 2019). Therefore, although
it appeared at first that only estrogen containing oral or
intrauterine agents were associated with increased risk
of VTE incidences, we find it questionable whether the
progestin only agents are truely safe alternative for those
patients at risk such as the Factor V Leiden genotypes,
or even those without the genotype but with a history
of clotting. Luckily for those individuals, there is now
a non-hormonal intrauterine device available such as
the Paragard IUD, releasing copper as a contraception
method, therefore seemingly the ideal option for those of
at VTE risk. In its mechanism, the copper acts as a toxic
environment for sperm, which significantly reduces the
chance for fertilization of the egg (Higginbotham, 2018).
Though it seems like the ideal option, it is interesting
to present the reported increase of menstrual bleeding
associated with the Copper Intrauterine device, as well as
cramping (Galan, 2016). Furthermore, the idea of having
an internal device can be disturbing for a lot of patients
and has shown serious medical consequences such as
ectopic pregnancies or infections, although only shown in
low percentages.
To sum it up, it appears that although ample options
are available on the market for contraception, the choices become limited for patients with Factor V Leiden or
patients with personal or even a family history of VTE.
Although intrauterine devices optimize compliance with
the regimen, they aren’t always the preferred options
for contraception due to their potential serious consequences. Ultimately, patients at risk of developing VTE
should resort to using the copper IUD, because it doesn’t
contain any hormones, despite its potential increase of
bleeding risk, which can be even more exacerbated for
those patients who already take daily anticoagulant.
Factor V Leiden plays an important role in a patient’s
choice for contraception, but also during pregnancy or
when planning to become pregnant.
Pregnancy
Pregnancy represents a risk factor on its own for Venous
Thromboembolism. During pregnancy, a patient will be
considered in a hypercoagulable state, or increased tendency to coagulate, due to higher levels of fibrinogen and
certain clotting factors, as well as a vascular damage or
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reshaping that the increase in weight and fluid can cause
(Gibson, Powrie, 2009). Following that thought process, a
risk factor should be avoided, or if cannot be, should be
carefully managed; in this case management of pregnancy
for patients at risk of VTE.
Patients with Factor V Leiden and/or those with a
history of VTE should carefully monitor their cycles as
to know when to get pregnant because of the high probability those individuals will need to modify the types of
AC they take. Multiple studies have examined the optimal
options for prophylaxis AC in patients who are at high
risk of developing VTE or those who have a history of
VTE. It appears that the current recommendations suggest the use of heparin injections throughout pregnancy
and up to 6 weeks after delivery, because heparin does
not cross the placenta and is not transmitted via breast
milk. Therefore, it is considered a relatively safe option
for both the mother and baby (Gibson, Powrie, 2009).
However, while Heparin is safe for pregnancy, it is important to distinguish between unfractionated heparin,
which has been linked to osteoporosis and thrombocytopenia when used long term, and low molecular weight
heparin (LMWH), with less incidence of the above mentioned (De Santis, et., al, 2006). An example of LMWH
is Lovenox, with the generic name enoxaparin, and has
demonstrated success as a prophylactic agent against
VTE in several instances world-wide, one of which was
reported regarding a young pregnant patient in Nigeria
with factor V Leiden homozygous who was treated with
LMWH during her pregnancy due to a DVT (Dogara, et,
al, 2018). Since pregnancy might occur while on an anticoagulant, it is essential for those individuals to be aware
of their cycles in order to start the appropriate AC agent
as soon as soon they become pregnant. The use of direct
oral anticoagulants (DOACs) are still contraindicated
during pregnancy. In fact, it is due to the lack of data proving them safe, the few results demonstrating a high rate
of miscarriage, as well as relatively significant amount of
fetal abnormalities for patients on DOACs, concluded to
be directly related to the DOACs, but poorly investigated
(Lameijer, et, al, 2018).
Female patients who are aware of a risk factor for
VTE, usually genetic such as factor V Leiden mutation, can
evidently be more prepared and educated on the precautions to take regarding anticoagulation management
during pregnancy. However, many patients in fact find out
about their Factor V Leiden mutation during pregnancy, as they experience a DVT or pulmonary embolism,
requiring emergency treatment with LMWH, or after
suffering multiple spontaneous miscarriages. Interestingly,
some studies have compared the rate of first trimester
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miscarriages in patients with known factor V Leiden and
those with known regular genotype, and the incidence of
early pregnancy miscarriage doesn’t seem to have a close
relationship with Factor V Leiden. Rather it does when
comparing later term miscarriage, possibly caused by
clotting within the uterine vasculature (Jivraj, et., al, 2009).
Furthermore, while Factor V Leiden had been thought
more risky, it doesn’t appear to affect the management
of pregnant patients for VTE prevention, since several
studies have yet to discover significant differences in
clinical pictures between homozygous and heterozygous,
(Gat, et, al, 2014).
Other forms of prevention for VTE during pregnancy
include compression stockings however these have received a low grade of compliance among those women
due to discomfort. Moreover, it usually can improve
blood circulation in lower extremities but are limited to
lower extremities.
As with all patients, pregnant patients with factor V
Leiden should in addition keep a healthy lifestyle, combining a balanced diet and regular exercise, to keep proper
perfusion, for theirs and their babies’ sake.
Conclusion
The high incidences of VTE has stimulated much research
to find optimal forms of treatment and preventative
agents in the forms of Anticoagulants, whether oral or
injectable, for patients at higher risk of developing Venous
thromboembolism, such as those individuals with the
Factor V Leiden genetic mutation. Although the newer
DOACs have become more popular due to decreased
necessity for close monitoring, decreased bleeding risk,
and statistical efficiency in the prevention of thrombosis,
it appears they still cause issues for pregnant patients,
and require more extensive research to prove their safety. Fortunately, low molecular weight heparin injections
have been used for management of pregnant patients
since they don’t cross the placenta, and they have been
utilized often as a post-surgery prophylaxis on a shortterm basis. Regarding the management of patients who
wish to utilize contraception measures, careful attention
is to be applied due to the elevated clinical relationship
between the use of estrogen and episodes of VTE, but
unfortunately most of the contraceptive options do not
seem adequate for those high-risk female individuals,
therefore requiring further research and development.
Although Factor V Leiden appears to be the most popular genotype associated with VTE, multiple other genetic
mutations have close relationships with increased risk
of thrombosis. Since the pregnancy represents a high
risk factor on its own, perhaps the thought of prenatal
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testing with a thrombophilia panel doesn’t seem inadequate, although the question remains about a reasonable
response to the screenings in terms of prophylaxis, that
would be beneficial to patients’ physical health without
being detrimental to their mental health, once aware that
an important genetic mutation is present, especially at
sensitive times such as during pregnancy.
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Abstract
Anemia of chronic disease (ACD) is the result of altered iron metabolism, blunted erythropoiesis, and shortened red blood cell
survival caused by inflammatory cytokines. Hepcidin plays a key role in anemia of chronic disease by inducing endocytosis of
the iron exporter ferroportin. Iron is trapped in enterocytes, hepatocytes, and macrophages, and is unavailable for hemoglobin
synthesis. When treating the underlying disease is not an option, or anemia is severe, ACD should be treated. While oral iron
supplementation is not suitable for ACD, intravenous iron may be effective. Erythropoiesis stimulating agents are a common approach to treating ACD, but a large percentage of ACD patients are refractory to ESAs. Additionally, there are many safety issues
associated with ESA therapy. Concomitant IV iron supplementation increases patient response to ESAs and may reduce safety
concerns as well. Several new, more targeted approaches to ACD treatment are being studied. Isocitrate supplements have been
shown to improve ACD by minimizing the iron restriction response to increase erythropoiesis. Antibodies such as infliximab and
tocilizumab, which neutralize the inflammatory cytokines TNF-α and IL-6, respectively, decrease hepcidin expression and improve
hemoglobin levels. Finally, antibodies and speigelmers that target hepcidin directly are being developed.These new therapies, alone
or in combination with IV iron or ESAs, show promise in alleviating anemia of chronic disease.
Introduction
Iron is an essential element for life. From the smallest
microbes to the most complex of organisms, all require
this vital nutrient to survive. As such, one of our bodies’
many host defense mechanisms is to limit the amount of
iron available to pathogens. Inflammatory cytokines cause
an increase in the expression of hepcidin, a liver protein
that is a key regulator of iron metabolism. Hepcidin binds
to ferroportin, the only known exporter of cellular iron,
and causes it to be internalized and degraded (Nameth
et al., 2004a). Thus, iron is trapped inside the cells, out of
reach of bacteria, cancer cells, or other pathogens.
When inflammation becomes chronic, however, this
innate defense mechanism becomes counterproductive.
Too much of the iron from senescent red blood cells is
sequestered within macrophages, rather than recycled
for erythropoiesis. Patients with chronic inflammation
often develop a unique form of anemia, known as the anemia of chronic disease (ACD). ACD is the second most
common type of anemia, caused by some cancers, chronic
infections such as HIV, autoinflammatory diseases such
as rheumatoid arthritis, and other diseases that feature
chronic inflammation such as inflammatory bowel disease
or heart disease.While treatment for these patients must
focus primarily on curing the underlying disease, treating the anemia may greatly improve the patients’ quality
of life. Because of the unique mechanism by which the
anemia develops, treatment of ACD can be complicated.
Treatments often used to treat other forms of anemia,
such as iron deficiency anemia, may be ineffective, or
even detrimental. This paper examines several possible
approaches for treating anemia of chronic disease, given
its unique pathogenesis.
Methods
The information in this article was compiled by review
and analysis of articles located using PubMed, ProQuest,

and Google Scholar. Access was provided by the Touro
College Library system. Emphasis was placed on original studies, although review articles were also used.
References cited in the articles provided further reading. Articles discussing anemia of chronic kidney disease
(ACKD), a related but different disorder were not included in this review.
Discussion:
Pathogenesis of Anemia of Chronic Disease
Hepcidin is a small peptide containing multiple disulfide
bonds that is secreted by the liver. It was first isolated
from human urine (Park et al., 2001). Initially recognized
for its anti-microbial properties, it soon became clear
that hepcidin is a key regulator of iron metabolism. Ironoverloaded mice overexpress mRNA coding for a peptide
closely homologous to human hepcidin. Additionally, iron
depletion results in a decrease in hepcidin expression
(Pigeon et al., 2001). Genetically modified mice overexpressing hepcidin were born with pale skin and died soon
after birth. Those that survived had severe microcytic
iron deficiency anemia (Nicolas et al., 2002a).
A 2004 study by Nameth et al. provided a breakthrough toward understanding the role of hepcidin in
iron homeostasis. Using in vitro cells expressing ferroportin (Fpn) labeled with green fluorescent protein
(Fpn-GFP), they demonstrated the effect of hepcidin on
ferroportin. Hepcidin binds directly to Fpn, inducing its
endocytosis. Upon addition of hepcidin, Fpn-GFP disappears from the cell surface, and is localized in intracellular
vesicles. (Nameth et al., 2004a). Hepcidin binds directly
to ferroportin and induces rapid ubiquitination of several
lysine residues of ferroportin. This tags ferroportin for
internalization (Qiao et al., 2012). Ferroportin is subsequently degraded by lysozymes.
Ferroportin (also called MTP-1) is an iron transporter
located at the surface of cells involved in iron metabolism,
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including duodenal enterocytes, hepatocytes, macrophages,
and placental cells. It is structurally similar to the DMT1
class of metal transporters (Abboud and Haile, 2000).
Ferroportin acts as an iron exporter, releasing iron into
the bloodstream. Fpn null/null mice are not embryonically
viable. Inactivation of ferroportin at birth results in severely
anemic mice with accumulation of non-heme bound iron
in enterocytes, macrophages, and hepatocytes (Donovan
2005). In vitro, cells expressing ferroportin only in the presence of an inducer, accumulate ferritin when ferroportin is
inactive. Induction of ferroportin results in a clearance of
ferritin from the cell (Nameth et al., 2004a).
There are no known cellular iron exporters other
than ferroportin. The removal of ferroportin from the
cell surface inhibits transport of iron to the serum. Iron
is trapped within the cell and stored as ferritin. Hepcidin
levels, and thus ferroportin levels, are modulated by
serum iron levels. Iron overload activates a BMP (Bone
Morphogenetic Protein)/ SMAD signaling pathway which
causes increased hepcidin expression. Hemojuvelin, a protein that is mutated in juvenile hemochromatosis patients,
plays an important role in this pathway as a coreceptor of
BMP (Babbit et al., 2006). Hepcidin expression is downregulated in response to anemia and hypoxia, allowing the
iron necessary for erythropoiesis to be released into the
plasma (Nicolas et al., 2002b).
Hepcidin also increases as part of the acute phase
response to inflammation. The inflammatory cytokine
Interleukin-6 (IL6) is the primary inducer of inflammatory
upregulation of hepcidin mRNA expression. In vitro, the
increase of hepcidin stimulated by inflammation is inhibited by the addition of anti-IL6 antibodies. IL-6 infusion
in humans causes an increase in urinary hepcidin, along
with a decrease in serum iron and transferrin saturation
(Nameth et al., 2004b). IL-6 activates a JAK/STAT signal
transduction pathway. The immediate -165 base pairs
of the hepcidin promoter are necessary for hepcidin
induction by IL-6. Deletion of the STAT binding motif
within this promoter fragment inhibits IL-6 activation.
In particular, the transcription factor STAT3 is required
(Falzacappa et al, 2007). Chronic inflammation results in
increased hepcidin and anemia in WT mice, but not in
STAT3 knockout mice (Sakamori et al., 2010).
In patients with chronically elevated IL-6, hepcidin is
persistently elevated. The resulting lack of ferroportin
causes iron to be retained within the cells. Dietary iron is
not absorbed into the plasma. Iron stored in hepatocytes
of the liver is not released. Most significantly, iron from
senescent erythrocytes is sequestered in macrophages
in the spleen. Rats with ACD had higher levels of ferritin
in the spleen than healthy controls, with less iron being
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released from macrophages (Theurl et al., 2010). The resulting hypoferremia limits the amount of iron available for
erythropoiesis.
In addition to the functional iron deficiency induced by
hepcidin-mediated iron sequestering, inflammatory cytokines have been shown to have other effects which contribute to anemia of chronic disease. Specifically, Interferon-γ
(IFN-γ) has been shown to suppress erythropoiesis.
Inflammation inhibits the wave of reticulocytosis normally
seen in cells treated with erythropoietin (Epo) in vitro.
Neutralization of IFN-γ reverses this effect. Treatment of
mice with anti-INF-γ antibodies prevents inflammatory
suppression of erythropoiesis (Thawani et al., 2006). This
blunting of erythropoiesis may explain why ACD is often
normocytic and normochromic. Other anemias caused by
inappropriately high hepcidin levels, such as iron refractory
iron deficiency anemia, are severely microcytic and hypochromic. IFN-γ suppression of erythropoiesis seems to
compensate for the lack of bioavailable iron by producing
fewer normal RBCs, rather than many abnormal ones
(Nameth & Ganz, 2014).
Further contributing to anemia, erythrocytes have a
moderately shortened life span in inflammatory conditions.
Biotin labeling of erythrocytes in mice showed a complete
RBC turnover by day 15 in mice with inflammation, compared to day 36 in control mice (Thawani et al., 2006). In
humans, erythrocyte life span in patients with rheumatoid
arthritis (RA), often used as a model for ACD, is significantly shorter than in healthy controls. Red blood cells from
these patients transfused into healthy individuals showed
normal survival. This indicates that the shortened survival
was not caused by defects in the red blood cells. Rather,
inflammation causes a decrease in erythrocyte life span
by some extrinsic mechanism (Freireich et al., 1957). The
premature destruction of erythrocytes is likely the result
of increased macrophage activity in the spleen in response
to various cytokines (Nameth & Ganz, 2014).
Tumor Necrosis Factor (TNF-α) and Interleukin-1
(IL-1) were among the earliest inflammatory cytokines
to be implicated in anemia of chronic disease. However,
the mechanisms involved are still unclear. Both TNF-α
and IL-1 reduce hepcidin expression in vitro (Song et
al., 2013). It seems that their role in ACD is indirect, via
regulation of other cytokines. Cytokine-cytokine interactions are complex, and researchers still have a lot to learn
before the pathogenesis of ACD can be fully understood.
Treating Anemia of Chronic Disease
Anemia of chronic disease is a secondary effect of an underlying illness. ACD is usually mild. As such, the major
focus of treatment protocols for ACD patients must be on
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curing the primary disease.As the inflammation caused by
the disease subsides, inflammatory cytokine levels return
to baseline. Consequentially, the anemia will be resolved
without the need for anemia-related treatment. However,
often the underlying disease is not curable. Anemia may
also have a profound negative impact on the patient’s
quality of life. The most common complaint of patients
with ACD is fatigue, which can be debilitating. In such
cases, direct treatment of the anemia of chronic disease
is recommended. As with any medical intervention, the
benefits of treatment must be weighed carefully against
any possible risks. It is important to note that anemia in
chronically ill patients is often multifactorial. Anemia of
chronic disease may occur in conjunction with true iron
deficiency anemia, or anemia of another cause. It is necessary to correctly diagnose the cause of anemia before
deciding on a treatment option. Finally, certain treatments
may not be suitable for certain patients, depending on
which underlying disease is causing the inflammation.
Oral iron supplementation, the obvious solution for
iron deficiency anemia, is not appropriate for anemia
of chronic disease. The removal of ferroportin from the
basolateral surface of duodenal enterocytes prevents
oral iron from being adequately absorbed into the plasma. Much of the minimal iron that is absorbed will be
diverted into hepatocytes (Weiss & Goodnough, 2005).
Intravenous iron therapy may be effective in treating anemia of chronic disease, because parenteral administration
allows it to bypass the “mucosal block” in the duodenum.
Indeed, several trials have shown that IV iron therapy is
beneficial for anemia of chronic disease in cancer patients.
A pilot study showed a significant increase in hemoglobin
levels in cancer patients with non-iron deficiency anemia
in response to weekly doses of ferric hydroxide sucrose
(Abdel-Rezeq et al, 2013). A single dose of ferric carboxymaltose improved hemoglobin levels in chemotherapy patients with ACD. This improvement was maintained for a
minimum of 8 weeks. (Hedenus et al., 2014). A large study
comparing the efficacy of IV iron and oral iron supplementation in cancer patients found that both treatment
options induce a similar increase in hemoglobin levels,
although the response time was faster for IV iron. IV iron
also caused less side effects than oral iron. The efficacy
of oral iron seen in this study is surprising, as it conflicts
with many other studies. However, this study included patients with iron deficiency anemia (Birgegard et al, 2016).
Trials that were specific to patients with functional iron
deficiency showed IV iron to be superior.
Several concerns have been raised regarding the safety
of iron supplementation. Iron overload is associated with
oxidative stress and cardiovascular events. Additionally,

iron sequestering is an innate host defense mechanism.
Iron supplementation may increase the risk of infections
and tumor growth. (Weiss & Goodnough, 2005). Although
the trials reported here have indicated that intravenous
iron is safe for cancer patients, these trials only followed
patients for short periods of time. Long-term studies
are necessary to establish whether IV iron is truly safe
for patients with anemia of chronic disease (Rodgers &
Gilreath, 2019). Most of the research regarding efficacy
of IV iron monotherapy for anemia of chronic disease has
been in chemotherapy patients. Further experimentation
is necessary to assess whether parenteral iron is useful in
cases of ACD caused by illnesses other than cancer.
Among the earliest treatment options available for
anemia of chronic disease are Erythropoiesis Stimulating
Agents (ESAs).This category includes recombinant human
erythropoietin (rHuEpo) and its derivatives, Epoetin-α
and Darbepoetin-α. ESAs target the blunted erythropoiesis characteristic of ACD and should minimize the iron-sequestering effect of hepcidin as well. Pharmacological levels of erythropoietin cause a dose-dependent decrease
in hepcidin expression in vitro (Pinto et al., 2008). In
another study, pretreatment with erythropoietin partially
prevented the increase in hepcidin normally induced by
inflammation in mice. This effect was dose dependent.
Pharmacological doses of Epo were effective, but the
endogenous increase in erythropoietin in response to
hypoxia was insufficient to reduce hepcidin expression.
IL-6 levels were similar in Epo-treated and control mice.
However, STAT3 phosphorylation decreased significantly.
Suppression of STAT3 is likely the mechanism by which
erythropoietin decreases IL-6 induced hepcidin expression (Huang et al., 2009). Erythropoiesis stimulating agents
have been proven effective for ameliorating anemia of
chronic disease in humans. In a placebo controlled double
blind trial, normal hemoglobin levels were achieved in
94% of rheumatoid arthritis patients with ACD treated
with rHuEpo. Interestingly, rHuEpo also reduced disease
activity in RA patients (Peeters et al., 1996). ESAs are
likewise used to treat anemia of chronic disease in cancer
patients.
Unfortunately, there are serious safety concerns regarding ESAs. Although few side effects were reported
in early trials of ESAs for rheumatoid arthritis patients
(Peeters et al., 1996, Nordström et al., 1997), ESA treatment is associated with numerous adverse effects, especially in cancer patients. In a meta-analysis of 53 trials
including close to 4,000 patients, mortality increased by
17% in cancer patients with anemia treated with ESAs
compared to controls (Bohlius et al., 2009). In 2007,
the FDA issued a black box warning stating that “ESAs
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increase the risk of death, myocardial infarction, stroke,
venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence [in cancer
patients]”. Venous thromboembolism is one of the most
prevalent adverse effects of ESAs. This may be because
ESAs induce iron-deficient erythropoiesis (IDE), by increasing erythropoiesis despite the lack of bio-available
iron caused by ACD. This results in elevated platelet
counts, which increases the risk for thrombolytic events
(Henry et al., 2011).
Aside from increased safety concerns, the functional
iron deficiency of ACD limits the efficacy of ESAs. Many
patients do not respond to ESA treatment. Response
rates vary from trial to trial. One study, in RA patients,
reported that only 14.6% of patients achieved target
hemoglobin levels. Decreased iron levels and more severe
inflammation were predictive of a poor response. In an
extension to the study, four out of five initial non-responders who were now given iron supplementation
in addition rHuEpo treatment did show significant improvement in hemoglobin levels (Nordström et al., 1997).
Hemoglobin does not increase significantly in response to
ESAs in mice overexpressing hepcidin (Sasu et al., 2010).
In another study, rats with higher pre-treatment levels of
hepcidin, which correlates to lower iron availability, were
shown to respond poorly to ESA treatment. Although
ESAs decrease hepcidin expression somewhat, and thus
decrease splenic iron retention, this effect is inadequate.
Serum iron remains low, and ESA treatment does not
effect an increase in hemoglobin in rats with very high
hepcidin levels (Theurl et al., 2014).
The limitations of iron-deficient erythropoiesis to ESA
treatment has led researchers to investigate whether
concomitant iron supplementation could improve the
safety and efficacy of ESAs. Indeed, many studies have
shown positive results when erythropoiesis stimulating
agents are combined with intravenous iron. Parenteral
iron administration is preferable to oral supplements, as
oral iron is not well absorbed by patients with ACD. IV
iron could correct ESA-induced iron-deficient erythropoiesis and improve response to rHuEpo in rheumatoid
arthritis patients with anemia of chronic disease (Arndt
et al., 2005). Encouraging results were seen in cancer
patients with ACD as well. Patients receiving supplemental iron intravenously achieved higher hemoglobin
levels in response to epoetin-α than patients receiving
epoetin-α with oral iron or epoetin-α alone. Response
rates were significantly improved in the IV iron group
as well. In the IV iron group, 73% of patients responded
to the ESA treatment, compared to only 45% and 41%
in the oral and no iron groups, respectively (Henry et
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al., 2007). Auerbach et al. similarly reported that cancer
patients who received combination of darbepoetin-α
and IV iron were more likely to reach target hemoglobin levels, with more rapid and significant improvement
than patients who did not receive IV iron. Interestingly,
the incidence of adverse effects, including thrombolytic
events, was similar in both groups (Auerbach et al., 2010).
By contrast, post-hoc analysis of data from the first study
showed that IV iron decreased the likelihood of elevated
platelet counts and venous thromboembolism (Henry et
al., 2011). One trial failed to show a significant difference
between chemotherapy patients receiving darbepoetin
and intravenous ferric gluconate versus oral iron or oral
iron placebos. Additionally, many adverse events were
reported among those patients receiving parenteral iron
(Steensma et al., 2010). However, this study had several
limitations. The overall iron dose was lower than in other
studies, potentially limiting the benefit of IV iron. By contrast, the individual doses of iron administered were 50%
above the recommended dosage, which may explain the
excessive number of adverse events. Finally, the study was
terminated early, with few patients completing the study
(Steensma et al., 2010 & Aapro et al., 2011). Nevertheless,
the high incidence of adverse events in this study highlights the need for additional studies as to the safety of
parenteral iron.
Experimental Treatment Options
Another option for targeting the blunted erythropoiesis
of ACD which is currently being studied is isocitrate supplements. Aconitase is a Krebs’s cycle enzyme responsible
for converting citrate into isocitrate. Insufficient iron levels result in decreased aconitase activity, to produce less
isocitrate.Aconitase activity is used by the body as an “iron
sensor”. Decreased isocitrate results in downstream inhibition of erythropoiesis by sensitizing erythroid progenitor cells to the inhibitory effects of IFN-γ (Richardson, et
al., 2013). This is known as the iron restriction response.
Supplementation of exogenous isocitrate inhibits the iron
restriction response via a PKC mechanism (Bullock et al.,
2010). Isocitrate does not change serum or stored iron
levels, nor does it alter erythropoietin levels (Kim et al.,
2016). Rather, it seems to “fool the system” into increasing erythropoiesis despite hypoferremia.
Low doses of isocitrate supplementation reversed
anemia of inflammation in a model of rat arthritis by
preventing the iron restriction response (Richardson et
al., 2013). However, later studies found that much higher
doses were necessary to achieve even transient results
in mice. Administration of high doses of isocitrate caused
increased inflammation in these mice (Kim et al., 2016).
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The necessity of such high doses to improve anemia of
chronic disease may limit the efficacy of isocitrate as
a treatment for ACD in humans. Recent research has
shown that treatment with a combination of isocitrate
and fumarate is effective in curing anemia of chronic
disease in a murine model, even at low doses (Goldfarb
et al., 2019). Further research, including human trials, is
necessary to determine whether isocitrate may be a clinically appropriate treatment for ACD. It seems reasonable
to assume, however, that isocitrate treatment may have
limitations similar to those seen with ESAs, as bypassing
the iron restriction response would lead to iron deficient
erythropoiesis. As with ESAs, supplementation with IV
iron may be beneficial.
ACD is caused by the result of the interaction of
various cytokines. Recent research has focused on inhibition of these inflammatory signals using humanized
antibodies as a target for treating anemia of chronic disease. Inhibition of Tumor Necrosis Factor-α (TNF-α) is
a common treatment option for the auto-inflammatory
disease Rheumatoid Arthritis. Treatment with infliximab,
an anti-TNF-α antibody, reduces hepcidin levels and improves blood parameters in RA patients. TNF-α alone
actually decreases hepcidin mRNA expression in vitro.
Paradoxically, TNF-α also upregulates IL-6 production,
resulting in the downstream upregulation of hepcidin.
Inhibition of TNF-α reduces IL-6, thereby indirectly reducing serum hepcidin levels, albeit not as effectively as
direct inhibition of IL-6 (Song et al., 2013).
Tocilizumab, an IL-6 inhibitor used to treat multicentric Castleman’s disease (MCD) and rheumatoid arthritis, effectively reduces anemia of chronic disease in
these patients. Tocilizumab is a humanized anti-IL6 receptor antibody. It binds to the IL-6 receptor and prevents
IL-6 binding (Mihara et al., 2011). Tocilizumab completely
inhibits IL-6 induction of hepcidin expression in vitro.
Short-term treatment of MCD patients with tocilizumab
results in decreased hepcidin and amelioration of anemia.
These results continue when Tocilizumab was given over
a longer period of time. Hepcidin expression keeps decreasing until normal serum hepcidin levels are reached
and hemoglobin increases. Other iron-related parameters
improve as well (Song et al., 2010). Tocilizumab decreases
serum hepcidin and improves iron related blood parameters including hemoglobin, serum iron, ferritin, and MCV
in rheumatoid arthritis patients as well (Song et al., 2013).
In monkeys with anemia of chronic disease, IL-6 blockade
with tocilizumab caused a rapid decrease of serum hepcidin. Hemoglobin levels and RBC improvement was drastic at first, then slowed and gradually continued until they
returned to pre-inflammation levels (Hashizume 2010).

The amelioration of anemia by tocilizumab seems to be
due to inhibition of IL-6 induction of hepcidin. However,
as IL-6 plays a role in the pathogenesis of MCD and RA,
and tocilizumab reduces disease symptoms, it may be that
the improvement of the underlying disease plays a role in
decreasing anemia as well.
A major concern with tocilizumab treatment is its
immunosuppressive effect and increased risk of infection.
Additionally, since tocilizumab suppresses biomarkers
of infection, it is necessary to observe patients closely
for symptoms that may indicate infection (Mihara et al.,
2011). The STREAM study, which followed RA patients
receiving tocilizumab monotherapy over a period of five
years showed the drug to have a good safety profile. The
majority of the adverse events reported were mild, and
the benefits of the drug on patient quality of life outweighed these events (Nishimoto et al., 2009). It remains
to be seen whether tocilizumab and other anti-cytokine
antibodies are safe and effective for treating ACD caused
by other diseases.
Perhaps the most targeted approach to treating ACD
is direct inhibition of hepcidin activity. Monoclonal antibodies (mAbs) and speigelmers which bind to hepcidin
and prevent its interaction with ferroportin are promising
developments. A Phase-1 study of the anti-hepcidin mAb
LY2787106 in humans showed that the antibody was safe
and well-tolerated in cancer patients with few serious
adverse effects reported. However, the drug elicited only
a transient increase in serum iron, which did not translate
into improved hepcidin, serum ferritin, and TSAT levels
(Vadhan-Raj et al., 2017). While ineffective alone, this
antibody may be useful in treating ACD in combination
with other drugs.
As an alternative to antibodies, Noxxon Pharma of
Germany has developed an anti-hepcidin speigelmer
called Lexaptepid Pegol (Nox-H94). Speigelmers are oligoribonucleotides with L-stereochemistry which bind to
the target protein and inactivate it in a manner similar to
antibodies.The advantage of a speigelmer over antibodies
is that it does not elicit an immunological response in
patients. Its L-stereochemistry prevents the development
of anti-drug antibodies (ADAs) and also makes it nuclease
resistant (Schwoebel et al., 2013). Indeed, patients receiving lexaptepid did not form antibodies specific to the
drug (Boyce et al., 2016), while some patients receiving
the mAb LY2787106 did develop ADAs (Vadhan-Raj et
al., 2017). In vitro, lexaptepid inhibits the hepcidin-induced decrease in ferroportin expression. In monkeys
with ACD caused by IL-6 injection, lexaptepid pegol partially improved reticulocyte hemoglobin levels, hematocrit, and erythrocyte counts (Schwoebel et al., 2013). A
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placebo controlled double blind study of lexaptepid pegol
in healthy humans showed a dose-dependent increase
in serum iron, transferrin saturation, and serum ferritin.
Reticulocyte hemoglobin did not increase in healthy volunteers but would be expected to increase in patients
with ACD (Boyce et al., 2016). Lexaptepid temporarily
prevents the inflammation-induced hypoferremia caused
by endotoxin injection in heathy individuals (van Eijk et
al., 2014). While the results have been promising in trials
involving healthy individuals, further trials in ACD patients
are necessary in order to know whether Lexaptepid can
be clinically useful.
One aspect which may limit the effectiveness of both
anti-hepcidin antibodies and speigelmers is the relatively
high production rate of hepcidin. High doses of these hepcidin-binding ligands are necessary to keep up with production of new hepcidin (Fung & Nameth, 2013). Further
experimentation, particularly in patients with anemia of
chronic disease, will show whether this indeed limits the
clinical value of such treatments. Even if these drugs are
ineffective alone, they may be useful in combination with
other treatments. Low dose antibody neutralization of
hepcidin was shown to increase responsiveness to ESAs
in mice with ACD. The combination of the antibody and
darbepoetin-α completely corrected anemia in these
mice (Sasu et al., 2010). If this is shown to be the case
in humans as well, these drugs could take the place of
parenteral iron, thereby eliminating the potential safety
hazards associated with IV iron.
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Abstract
Scientific and pharmaceutical advancements have revolutionized medicine. Many once- debilitating or fatal diseases can now be
managed with medication. However, the search for a cure for the inevitable aging diseased state remained futile until recently.
Rapamycin has been studied for its possible longevity effects, providing promising results for the development of anti-aging therapies.
This paper evaluates the benefits and risks of rapamycin use. While rapamycin cannot be supported as a safe anti-aging drug,
rapamycin studies have elucidated parts of the aging pathway, providing a breakthrough for anti-aging research.
Abbreviations
FKBP - FK506 Binding Protein
AKT – protein kinase B
Introduction
Hutchinson-Gilford Progeria Syndrome (progeria) is a
rare genetic disease caused by a mutation on the LMNA
gene which encodes for the Lamin-A protein. This causes
a modified form of Lamin-A, known as progerin, which has
an internal deletion of fifty amino acids (Graziotto et al.
2012). Wild-type Lamin A is the scaffolding of a cell, which
holds the nucleus together. Researchers believe the variant
Lamin-A leads to an unstable nucleus that causes the symptoms of progeria (The Progeria Research Foundation).
Children with progeria show early signs of aging, which
include loss of body fat and hair, growth failure, stiffness of
joints, aged looking skin, hip dislocation, cardiovascular disease, stroke, and generalized atherosclerosis. The lifespan
of children with HGPS is fourteen years, with the common
cause of death atherosclerosis (The Progeria Research
Foundation).
The Progeria Research Foundation is currently conducting a clinical research trial to test a possible cure for
Progeria.The trial is testing the combined use of Lonafarnib
and Everolimus on HGPS patients. Lonafarnib is a farnesyltransferase inhibitor. By inhibiting the attachment of a
farsenyl group to progerin, the progerin is unable to inhibit the cell function (The Progeria Research Foundation).
Everolimus, a derivative of rapamycin, promotes the autophagy of the progerin (Graziotto et al. 2012).
Increased levels of progerin have been found in the
skin and arteries of normal, aged individuals (McClintock
et al. 2007, Olive et al. 2010). The correlation between
increased progerin and the physiology of aging is seen in
the rapid aging of HGPS patients with high levels of progerin and the decrease in age-associated symptoms upon
autophagic degeneration of progerin. Thus, the correlation between HGPS and normal aging suggest rapamycin
as a possible drug to promote longevity in the general
population (Graziotto et al. 2012).
In 2009, a study showing that rapamycin extends the
lifespan of mice was published. This was the first study to
realize the anti-aging properties of rapamycin on mammals (Harrison et al. 2009). Since then, rapamycin has
been explored as a possible anti-aging drug for humans.

Method
Articles sourced in this paper were obtained by searching
Touro’s database and Google Scholar. Some articles were
referenced in review articles and the original articles
were retrieved. Additionally, data was obtained from the
Progeria Research Foundation and the lecture of Michael
Hall who discovered and studies TOR.
Discussion
The Mechanism of Rapamycin
Rapamycin is a macrocyclic lactone secreted by the bacterium streptomyces hygroscopicus which was discovered
on the Easter Island (Tee 2018). Is was originally intended
for use as an antifungal. However, its immunosuppressive
and anti- proliferative properties rendered it unsuitable
as a safe antifungal treatment. Instead, these properties of
rapamycin led to its development for other purposes, and
rapamycin along with its derivatives are FDA approved
for use as immunosuppressants and an anticancer agent
(Lamming 2016).
Rapamycin combines with FKBP to inhibit the activity of
the mechanistic target of rapamycin (mTOR), which is part
of the phosphatidylinositol 3-kinase-related kinases family
(Hall 2016). The mTOR protein forms two protein kinase
complexes - mTORC1 and mTORC2, both balancing cell
growth and metabolism with degradation. The mTOR
pathways responds to favorable growth conditions, such
as adequate nutrition, resources, and growth factors by
stimulating anabolic processes (Kennedy, Lamming 2016,
Laplante, Sabatini 2009). Conversely, stressful conditions
in the cell inhibit the mTOR pathway, thereby inducing
catabolic processes (Laplante, Sabatini 2009).
The two mTOR complexes have some shared components. They both contain the mTOR core, the regulatory
protein Deptor, and mLST8/GβL to ensure complex assembly and stability (Kennedy, Lamming 2016).
In mTORC1, the mTOR protein kinase interacts
with the scaffold protein Raptor, and the AKT substrate
PRAS40 (Kennedy, Lamming 2016). As shown in in Figure
1, MTORC1 controls many processes, including protein
synthesis, lipid synthesis, autophagy, mitochondrial metabolism, and biogenesis (Laplante, Sabatini 2009). Many of
the functions of mTORC1 are inhibited by acute exposure
to rapamycin which causes a decrease in biosynthesis and
an increase in biodegradation (Tee 2018, Hall 2017).
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survival, metabolism, proliferation, and
cytoskeleton organization (Laplante,
Sabatini 2009). The pathways involving
mTORC2 are outlined in Figure 2.
What Anti-Aging Effects does
Rapamycin have on the Body?
MTORC1 controls many processes linked
to aging. Therefore, the inhibition of these
processes by rapamycin contribute to
the drug’s anti-aging effects (Johnson et
al. 2013). The suggested mechanisms of
reduced aging by mTORC1 inhibition are
discussed in this section.
MTORC1 inhibition promotes autophagy,
which is the recycling of amino acids and
degradation of damaged macromolecules
Figure 1. Diagram of the pathways involving mTORC1 (Kennedy, Lamming 2016)
and organelles. Autophagy in the cells
declines with age, and it is proposed that
the accumulation of damaged particles
contribute to cellular dysfunction of aged
individuals (Cuervo 2008). MTROC1 inhibition promotes autophagic mediated
longevity, as supported by studies on yeast
and invertebrate (Johnson et al 2013).
Regulation of mRNA translation is another process that may contribute to the
anti-aging benefits of rapamycin. Under
favorable growth conditions, mTROC1
promotes mRNA translation and protein
synthesis. Inhibition of mTORC1 reduces
translation, and studies on yeast, nematodes, fruit flies, and mice provide evidence
Figure 2. Diagram of the pathways involving mTORC2 (Kennedy, Lamming 2016)
that regulation of mRNA translation inMTORC2 contains the scaffold protein Rictor, the
creases lifespan (Kaeberlein, Kennedy 2011). A main reaprotein subunits mSIN1 and Protor-1/2 (Laplante 2009).
son for the increased lifespan accompanying global mRNA
Prolonged rapamycin use inhibits mTORC2 by binding to
translation reduction is the differential protein translation
free mTOR and preventing it from forming the mTORC2
of specific mRNA. Molecular evidence is seen in yeast;
complex (Johnson et al. 2013, Sarbassov et al. 2006, Tee
when mTORC1 is inhibited Gcn4 is preferentially trans2018). MTORC2 is stimulated by IGF-1, insulin, and leptin
lated and increased translation of Gcn4 increases lifespan.
(Kennedy, Lamming 2016). MTORC2 regulates mTORC1
Similar mechanisms are seen in studies of nematodes and
via the phosphorylation of AKT. AKT phosphorylates
fruit flies (Johnson et al 2013).
TSC2, which is part of the TSC complex. TSC2 promotes
Another function possibly contributing to the anti-agthe conversion of Rheb-GTP, which activates mTORC1
ing benefit of rapamycin is reduced inflammation through
to Rheb- GDP. Therefore, the phosphorylation of TSC2
mTORC1 inhibition. Hyperactivation of mTORC1 causes
inhibits this conversion process, allowing the Rhebinflammation which is present in many age-related disGTP complex to remain in its active form and activate
eases such as kidney disease, vascular inflammation after
mTORC1 (Manning, Toker 2017). AKT also phosphoryangioplasty, atherosclerotic plaques, and lung infection.
lates PRAS40It, which is an inhibitor of mTORC1 in its
Therefore, rapamycin use reduces inflammation associated
unphosphorylated form (Sancak et al., 2007). The other
with these diseases. (Johnson et al 2013).
regulatory functions of mTORC2 include regulating cell
Additionally, studies on yeast link mTORC1 inhibition to
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the activation of a stress response pathway. The increased
stress resistance promotes lifespan extension. Also, regulation of mitochondrial function and enhanced stem cell
function seem to contribute to the longevity effects of
rapamycin (Johnson et al 2013).
Rapamycin Studies on Mammals
The 2009 study conducted by Harrison et al. on 1,901 mice
provides evidence for the longevity effects of rapamycin on
mammals. In comparison to the control group, rapamycinfed female mice had a 13% lifespan extension, and male
mice had a 9% lifespan extension. The average age of the
mice was 600 days, which is the equivalence of 60 years in
humans. Thus, the study demonstrates rapamycin’s effectiveness when started late in the lifespan.
In 2019 Sills et al. studied the safety of rapamycin on 23
middle-aged marmosets who were fed rapamycin for nine
months. The marmoset showed no significant side effects
and only minor effects on hematological markers. Since
marmosets are biologically similar to humans, the study
suggest similar outcomes would occur in humans.
Rapamycin Side Effects in Humans
Although rapamycin has been found to increase the lifespan of flies, mice, and marmosets, few studies have tested
its anti-aging effect on humans (Graziotto et al. 2012). This
section will review negative side effects of rapamycin treatment and the evidence to support the drug as an anti-aging
therapy for humans.
Many studies on rapamycin have been conducted on immunocompromised patients. Side effects of renal and heart
transplant patients taking rapamycin for its immunosuppressive property include delayed wound healing, interstitial pneumonitis, anemia, high cholesterol and triglyceride
levels, infection, edema, and gastrointestinal symptoms.
(Baur et al. 2011, Ekberg et al. 2010, Graziotto et al. 2012).
Long term side effects of rapamycin include glucose intolerance, decreased insulin sensitivity, and increased risk of
new onset diabetes (Johnston et al. 2008, Lamming 2016).
While these reported side effects may seem to outweigh
the potential benefits of rapamycin, it is important to consider that the adverse effects may be influenced by the
patients’ underlying condition or drug interactions (Kraig
et al. 2018).
A small-scale study found that short term everolimus
treatment boosted the immune response of normal, elderly
individuals to the flu vaccine. This suggests that rapamycin
improves immunosenescence, one characteristic of aging.
Since rapamycin is also known for its immunosuppressive
properties, its effects on the immune system seem to be dependent on disease, age, and/or antigen (Mannick et al. 2014).

Another small-scale study of a similar population found
rapamycin use safe for elderly individuals with stabilized
medical conditions. This population did not show a significant change in plasma glucose, insulin, and insulin sensitivity,
which contrasts with the increased risk of diabetes seen
with transplant patients.Additionally, there was no significant
elevation in triglyceride levels, which was also a concerning
side effect seen in previous studies. The side-effects reported in the study group were limited to a facial rash and GI
symptoms. However, the study did not reveal any change
in cognitive functioning, physical performance, or immune
parameters.While these results do not support the anti-aging benefits of rapamycin, the limited side-effects on normal
individuals support the safety of rapamycin use for further
clinical testing (Kraig et al. 2018).
Despite the promising results of life extension seen in
mammals, only a limited number of clinical trials with small
sample sizes were conducted on humans. Therefore, rapamycin must undergo further studies to determine its efficacy.
Conclusion/Further Research
The substantial side-effects associated with rapamycin
use in transplant patients makes it difficult for it to be
approved as a preventative aging treatment. However,
the discovery of life extension by inhibiting mTOR provides a basis for the search of other anti-aging treatments
that work by a similar mechanism. One suggestion is
MTORC1 specific- inhibition, which is sufficient to extend
lifespan and may have reduced side effects. Studies have
demonstrated the importance of mTORC2 in human
physiology and metabolism (Lamming et al. 2016). For
example, mTORC2 plays an important role in B-Cells,
T-cell and macrophages (Byles et al. 2013, Festuccia et al.
2014). Additionally, prolonged ex-vivo exposure to rapamycin inhibits lipogenesis in rat hepatocyte which can be
attributed to the disruption of mTORC2 (Brown et al.
2007, Kennedy, Lamming 2016).
Kennedy and Lamming found that while chronic exposure to FKBP12-rapamycin complex inhibits mTORC2,
chronic exposure to the rapamycin-FKBP51 complex
does not inhibit mTORC2. The binding affinity of rapamycin with FBPK51 has an inverse relationship with the
inhibition of mTROC2. Therefore, a rapamycin analog
with a strong affinity for FKPB51 should be studied as a
mTORC1 specific inhibitor (2016).
Another possibility, which is not well-studied, is to harness the benefits of rapamycin by eating a low-protein
diet. Amino acids are one of the stimuli for mTORC1,
but not mTROC2 (Lamming 2016). Studies show leucine
consumption affects mTORC1 activity in humans, and a
short-term protein-free diet reduces mTORC1 signaling
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(Moberg et al. 2014, Harputlugil et al. 2014). The branchchain amino acids - leucin, isoleucine and valine – enhance
the mTORC1 activity in skeletal muscle, liver, pancreas
and adipose tissue in rodents. Therefore, a diet with limited proteins or specific amino acids may provide a more
natural approach to reduce aging (Lamming 2016).
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Abstract
Immunotherapeutic agents have been researched for many decades as an alternative treatment for cancer. Current research
demonstrates that immunotherapy is safer than radiotherapy or chemotherapy.This is attributed to immunotherapy’s mechanism
of utilizing the body’s own defense system, as opposed to absorbing harmful chemicals. Two forms of immunotherapy that have
been effective in curing cancer without the added danger of chemical toxicity are PNC-27 and PNC-28.These peptides were created by a supercomputer at SUNY Downstate Medical Center in New York in 2000. PNC-27 and PNC-28 work with the MDM2
-P53 tumor suppressor complex. It acts as a competitive inhibitor for binding, increasing the half-life of P53 in the cell and assisting
with the elimination of cancer cells (Sarafraz-Yazdi E, Bowne WB, et al 2010).These immunotherapy agents also have the ability
to bind to the cell membrane and lyse the cell.The clinical trials for PNC-27 and 28 were successful, and the drug is currently in
use outside of the United States. Although this form of immunotherapy does come with some side effects, research illustrates that
this form of immunotherapy can be a successful strategy in eliminating the cancer and ensuring that a relapse does not occur.
Abbreviations
MDM2- Mouse Double Minute 2 Homolog P53- Tumor
protein, Tp53
HDM2- Human Double Minute Homolog 2
Introduction
Cancer is one of the three leading causes of death across the
globe.Although researchers have been discovering cures for
many diseases, the cure for cancer still eludes them. There
are over 240 different forms of tumors that currently exist,
and each type comes with a unique mechanism that can
help it evade treatment. Tumors are caused by the ongoing
replication of a cell that does not adhere to cell regulations
for replication (Vassilev A, DePamphilis, 2017). Due to the
fact that tumors arise from our own cells, in order to cure
cancer, researchers have to come up with a treatment that
exclusively destroys malignant cells, keeping the healthy cells
intact. While there are many cures being evaluated in current research that target all cells,PNC-27 and PNC-28 have
the ability to target cancer cells only.
There are millions of cells in the human body. In order for
cells to thrive, the cells need to be replicated to ensure continuity. New cells are constantly being created as old cells are
dying. Cells are converted to tumor cells when the checkpoints that are responsible for monitoring the division do not
proceed as expected. (Chao et al., 2017) When the cell metastasizes and travels to another region within the body, the
tumor is transformed into a potentially lethal cancer.
When a cell goes through the division process, it replicates all of its chromosomes and sends an identical copy
to the new version of the cell that was formed. The process by which this is done is called mitosis. The cell has
three phases that ensure that cell replication is proceeding
correctly. These three checkpoints that ensure the legitimacy of DNA are known as the M Phase (Mitosis), G1
Phase (Gap 1), and the G2 Phase (Gap 2). At the G1 phase,
the accuracy of the DNA is evaluated before proceeding.
At G2, the chromosome duplication is assessed. (Veron,
2017) After these checkpoints, the cell goes on to produce identical daughter cells. In a normal, healthy cell, if a
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cell does not pass these checkpoints successfully, the cell
is destroyed. These checkpoints are the main regulators of
replication and ensure a low rate of errors in the DNA.
The process of mitosis guarantees perpetuation of life,
but it can prove lethal if it proceeds unchecked. Genetic
mutation (regardless of whether it was caused by carcinogens or through random errors during DNA replication)
takes place in cells throughout the lifetime of an organism
(Ahluwalia, 2009). When one of these mutations results in
the breakdown of cell cycle regulation, it gives rise to an
“unregulated proliferating descendant clone of that particular cell’’ (Cooper, 2000). This clone of cells can form
a tumor. Tumors arise with significant frequency, but most
tumors pose slight risk to their host cell due to tumor
cell localization. These tumors are known to be benign tumors. It is generally evident when a tumor is benign since
the cells bear a close resemblance and role comparable to
normal cells. (Mims, et al. 2015).
One of the most significant stages in the diagnosis of
cancer patients is the series of events leading to the development of tumor cell invasion and metastasis. Cancer
metastasis is the dispersion of cancer cells to tissues and
organs outside the original site of the tumor. Once a tumor
has left its original source, it travels and forms additional
tumors in other organs. This process occurs in three main
developments: invasion, intravasation, and extravasation.
Metastasis occurs due to a loss of cell to cell adhesion. Initially, the malignant tumor cells isolate from the
main mass at the original source. Subsequently, the cells
proceed to invade the surrounding stroma. This development causes the secretion of substances to degrade
the basement membrane and extracellular matrix of the
organ it has invaded (Shields JA, Shields CL, 2016). The
secretion of substances helps express the proteins that
mediate the control of the tumor’s motility. In addition to
the tumor’s ability to migrate to other organs, there is a
process called angiogenesis. The process of angiogenesis
is necessary for the tumor to exist and keep itself satiated. Angiogenesis is the development of new blood vessels
that aid with local diffusion. This helps the cell sustain
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itself with nutrients, oxygen and transporting metabolic
wastes (Nowak-Sliwinska P, 2018).
After invading other organs, the tumor then goes
through the introversion stage. Introversion allows for
the tumor to make pathways throughout the blood so it
can travel through the body and settle in another location.
The tumor networks with the endothelial cells through
biochemical interactions. This process is regulated by a
carbohydrate-carbohydrate reaction.
Adhesion to the endothelial cells creates more solid
bonds to penetrate the endothelium and the basement
membrane (More SK, Vomhof-Dekrey EE, Basson MD., et
al 2019).Through this process, the new tumor reproduces.
As mentioned previously, the common driving force
behind cancer is a genetic mutation, but there are many
distinctions in how cancer can evolve. There are different
mutations that can alter the genes standard structure and
function. It is generally not possible to determine what
the underlying cause of the mutations. However, research
has linked different risk factors to an increased probability of cancer. Carcinogens and viral or genetic factors have
all been linked to cancer. For example, exposure to the
environment plays a role in how genes will be transcribed.
The atmosphere and our food contain many toxins that
can cause mutations. UV radiation that is induced by exposure to the sun without ensuring proper protection
causes thymine dimers, which researchers believe causes
skin cancer. Smoking is also a significant cause of cancer.
Chemicals in tobacco smoke harm the cleansing system
that the body employs to remove toxins. Thus, smokers are not as capable of handling toxic chemicals as
those with healthy lungs and blood (O’Keeffe LM 2017).
Moreover, smoking damages DNA, and generates potent
carcinogens which not only affect the trachea, bronchial
system and lungs, but also permeate the entire system.
Methods
Data was collected using ProQuest and PubMed databases, and the National Library of Medicine. The images,
graphs, and diagrams are in the research articles referenced. Additional materials were found in the SUNY (State
University of New York) Downstate research library.
Radiation Therapy Mechanism:
Treatment of cancer originally involved surgical removal
techniques alone. Over the previous centuries, radiation
therapy has been discovered as an alternate treatment.
Radiation therapy treats cancer by focusing beams of intense energy on a specific part of the body to eliminate
cancer cells. Some of these forms of energy typically includes X-rays, but can also use high-energy particles or

waves, such as gamma rays, electron beams, or protons.
The larger the amount of energy involved in the therapy,
the more penetration is accomplished by the ionizing ray
into the cancer tissue (Orth M, Lauber 2014). The ionizing ray kills the cells that are actively dividing. Although
radiation is effective for preventing division of rapidly dividing cells, it can cause only minimal breaks in the DNA.
Nevertheless, these breaks stop cancer cells from replicating and producing, activating their elimination. It can
be used to shrink early stage cancer, or treat advanced
symptoms of cancer.
Radiation therapy attempts to strike a balance by eliminating the harmful dividin cells and minimizing damage to
the normal cells around the tumor site. Normal cells can
often repair much of the damage caused by radiation.The
majority of people with cancer receive radiation therapy
as part of their treatment plan, along with a combination
with other treatments.
Physicians prescribe radiation therapy to treat all forms
of cancer, including benign tumors. Although radiation
therapy is effective, research shows that radiation therapy
has a large number of side effects. These include tooth
decay, third degree skin burns, and difficulty breathing
(Murphy, et al. 2019). Radiation therapy is rationed, and
there is a limit to the amount of radiation people can
safely receive. Depending on how much radiation an
organ has received during the first round of treatments,
the body may not have the ability to receive radiation a
second time.
The major lethal side effect of radiation therapy is the
relapse of the cancer. Because radiation therapy damages healthy cells, these damaged cells can metastasize to
other locations and cause a recurrence of the cancer.
Most types of leukemia cancer, including acute myelogenous leukemia (AML), chronic myelogenous leukemia
(CML), and acute lymphoblastic leukemia (ALL) are all
forms of cancer that originate from radiation exposure.
Myelodysplastic syndrome (MDS), a bone marrow cancer
that may evolve into leukemia, has also been associated
with previous radiation exposure” (Cidon,EU 2016). Not
all cancers may return immediately after radiation therapy. Research shows that solid tumors take much longer to
develop, and don’t come back quickly. Most of these cancers are not spotted for years after the radiation therapy
has caused the damage, and some are diagnosed more
than a decade later. We may be inevitably perpetuating
the disease itself by using radiation therapy as an option.
C Hemotherapy Mechanism:
A common form of treatment that is currently in use
is chemotherapy. Chemotherapy is a systemic treatment,
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and travels through the bloodstream. The treatment is
often given to the patient for a specific time, ranging from
6 months to a year. In cases where there is no possible
cure, chemotherapy may be given to extend the patient’s
life, or relieve painful symptoms. The drugs are usually
given by IV or orally. Chemotherapy has a lower probability of damaging cells that are at rest, such as most normal
cells. Physicians can prescribe the treatment after surgery
was performed to remove the original tumor, in order to
eliminate the individual cancer cells that may have metastasized before they are able to form a tumor.
The mechanism of chemotherapy is to eliminate cancer
cells by targeting different cells at different phases of the
cell cycle in order to halt the replication. The chemotherapy damages the genes inside the nucleus of cells, and
attack cells that are at the point of splitting. Some damage the cells while they are replicating their gene before
they split (Johnstone RW, 2016). Some chemotherapeutic
agents attack the DNA of the cell by adding a methyl
group, in order to prevent them from producing additional clones of the cancer cell. These are known as alkylating agents, and they attach to DNA, RNA, and proteins
through covalent bonding.
Alkylating agents will attack at any point in the cell
cycle. There are many types of alkylating groups, such as
nitrogen mustards, nitrosoureas, and aziridines. The molecules bind to the DNA and change the DNAs conformation. DNA is composed of a double strand, and the

to a form of programmed cell death called apoptosis.
Another chemotherapy drug that interferes with transcription and translation is a topoisomerase inhibitor.
When the DNA double-strand helix is unwound during
DNA replication or transcription, the adjoining DNA
(that has not been opened yet) is wound up extremely
tightly. The topoisomerase inhibitor produces single- or
double-strand breaks into DNA, reducing the tension in
the DNA strand ahead of the replication point (Figure
2) This allows the normal unwinding of DNA to happen during replication or transcription. Inhibition of topoisomerase does not allow either of these processes
to continue (Nitiss JL, 2007). Other chemotherapy drugs
interfere with cell metabolism. This blocks off nutrients
and oxygen supply, which causes growth arrest.
Research has shown that chemotherapy has many side
effects. Some of these side effects include fatigue, hair
loss, infection, fertility problems, weight loss, damage to

(Figure 2) Topoisomerase I and II Inhibitors (Huda W. 2016)

(Figure 1) The figure illustrates two DNA bases that are crosslinked by a nitrogen mustard (Siddik ZH 2005

molecules may either bind two times to one strand of
DNA (known as a “intrastrand crosslink”) or may bind
once to both strands (called a “interstrand crosslink”)”
(Figure 1). If the cell attempts to replicate or fix crosslinked DNA during cell division, the DNA strands break
(Cancer Chemotherapy and Biotherapy, 2005). This leads
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lung tissue, heart problems, kidney problems, and nerve
damage (Uzun, 2019).) Studies show that one of the primary drawbacks is that chemotherapy does not achieve
remission. One reason is that the original treatment is
not successful in eliminating all the cancer cells. The remaining cancer cells that are left in the organ grew into
a new tumor. Another reason that chemotherapy is not
successful in achieving remission is that some cancer cells
have metastasized to other parts of the body and started
forming a new tumor in the new location. Cancer cells
may also develop a mechanism that makes it become resistant to treatment when it relapses, thereby blocking a
possible cure (Stadlr, WM, 2014).
Immunotherapy
Researchers have discovered that one of the best methods
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for treating cancer is immunotherapy. Immunotherapy is a
biological therapy that utilizes substances made from living
organisms to treat cancer. Some immunotherapy treatments use genetic engineering to improve immune cells’
cancer-fighting capabilities and are commonly referred to
as gene therapies. Many immunotherapy treatments for
preventing, managing, or treating different cancers can
also be used in combination with surgery, chemotherapy,
radiation, or targeted therapies to aid their overall effectiveness (Yang, Wang, Wang, 2019).
Immunotherapy boosts the immune system’s ability to
identify, target, and remove cancer cells. While many cells
replicate naturally, this behavior is tightly regulated by an
assortment of factors, including the genes within cells.
When growth is not required at certain points, cells are
instructed to halt growth. Cancer cells acquire defects
that cause them to ignore these inhibitive signals, and
their replication proceeds in an unregulated and rapid
manner. Because cancer cells grow and behave through
abnormal methods, this can alert the immune system of
a potential threat, which can recognize and eliminate cancer cells through a process called immunosurveillance.
Immunosurveillance is an extremely effective method
for eliminating pathogens from the body, but the process
isn’t always successful when it pertains to cancer. Even
though the immune system can prevent or slow cancer
growth, cancer cells have ways to evade destruction by
the immune system. For instance, cancer cells may have
genetic changes that make them appear less discernible
to the immune system, have proteins on their surface that
turn off immune cells, or change the normal cells around
the tumor so they interfere with how the immune system
responds to the cancer cells (Pardoll D. 2015).
Cancer cells develop ways to evade and escape the immune system, which allows them to continue to thrive
and metastasize to other organs (Prendergast GC, Jaffee
EM, 2007).
Therefore, immunotherapies are designed to enhance
the cancer-fighting capabilities of immune cells and utilize
the body’s own protective measures to fight the tumors.
NC-27 and PNC-28 Peptides
PNC-27 and PNC-28 are synthetic peptides designed to
specifically target and destroy cancer cells. Therapeutic
peptides have the ability to treat an extensive range
of diseases and cancers and contain a large number of
advantages over proteins or antibodies. They are easily
synthesized in a lab and are not toxic to the human body.
They are manufactured to have a very specific affinity for
the targeted cell. PNC-27 and PNC-28 were created using
a super computer by Dr. Matthew Pincus and Dr. Joseph

Michl of SUNY Downstate Medical Center. The peptides
were created with a specific fold that only interacts with
a particular structure present on cancer cells. It can be
administered by nebulizer, vaginal or rectal suppository
or intravenously at the tumor site. Many patients travel
to foreign countries to receive this treatment. PNC-27
and PNC-28 have been used with exceptional results,
and over 500 patients have had a high success rate with
the drug since 2007. PNC-27 and PNC-28 peptides have
been shown to be highly effective in specifically targeting
a large variety of different cancers. These peptides have
had high success rates with breast cancer, leukemia, melanoma, and pancreatic cancer lines. It has proven to be the
most effective when taken simultaneously with immune
system boosters, proper hydration, and a diet that avoids
excess sugars and red meat.
P 53 Mechanism for PNC-27 AND PNC 28
TP53 or ‘’tumor protein 53’’ is a gene that is located on
the seventeenth chromosome of humans. It codes for a
protein that regulates the cell cycle and hence functions
as a tumor suppressor. P53 has been described as “the
guardian of the genome”, referring to its role in keeping
the cell stable by preventing genome mutation (Uehara
2018). TP53 has 4 domains that are responsible for activating transcription factors, tetramerization of proteins,
recognizing DNA sequences, and checking damaged
DNA (Sabapathy et al 2019).
The p53 tumor suppressor has a very significant role in
growth arrest, DNA repair, and apoptosis, and it causes a
response to different attacks on the cell. Rapid induction
of high p53 protein levels by various stress types prevents
inappropriate propagation of cells carrying potentially
mutagenic, damaged DNA (Zhang et al., 2014). In normal
cells, p53 is an extremely unstable protein that has a halflife ranging from 5-30 minutes.The p53 protein is present
at very low levels in the cell, due to continuous degradation. This continuous degradation is primarily regulated
by MDM2. Research over the past decade has assigned
MDM2 as the central controller of p53 by regulating the
p53 tumor suppressor function (Carotenuto, 2019).
A mutation of the p53-MDM2 complex during the induction of p53 can lead to the accumulation of active
p53 in the cell (Figure 3). Consequently, p53 half-life extends from minutes to hours. This can aid p53 in stopping
cancer. Both PNC-27 and PNC-28 were tested as agents
that would competitively block p53 from interacting with
HDM-2. By acting as a competitive inhibitor, the peptides
would prolong the half-life of p53 in cancer cells. This
eventually leads to more efficiency in inducing apoptosis
of cancer cells.
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Mechanism through Membrane and Affinity to HDM2
The PNC-27 and PNC-28 cancer peptides are substances that causes the death of cancer cells only. PNC-27
and PNC-28 accomplish this due to their affinity for
binding to a protein called HDM-2. Cancer cells have
high levels of HDM-2 present in their cell membranes.
(Ehsan Sarafraz-Yazdi, Wilbur B. Bowne, 2010). Dr. Ehsan
Sarafraz-Yazdi (Sarafraz-Yazdi E et al 2015) explains in detail how the PNC-27 and PNC- 28 cancer peptide manifests themselves, and what their mechanisms could mean
for progress in the field of cancer research. The study
points out that the peptide’s mechanism hinges on the
fact that there are formations of oligomeric pores in the
plasma membrane of tumor cells. (American Association
for Cancer, 2010) The oligomeric pores are present exclusively in cancer cells. Additionally, the observations illustrat-

signal, these cells then became inclined towards PNC-27
and PNC-28”. This research established that the PNC-27
peptide was able to exclusively mark HDM-2 in the membranes of cancer cells and destroy them through membranolysis, while at the same time leaving the healthy cells
alive (Sookraj, et al (2010). Additional research established
that PNC-27 and PNC-28 uses the entire peptide when
destroying cancer cells, as opposed to fragments. (Cancer
chemotherapy and pharmacology, 2010).
“The PNC-27 peptide has an HDM-2 binding domain
that has the same residues 12-26 of p53 and a transmembrane-penetrating domain (Sarafraz-Yazdi, et al, 2010).
PNC-28 is a p53 peptide from its HDM2-2-binding domain (residues 17-26), which contains the penetratin sequence enabling cell penetration on its carboxyl terminal
end. This domain is connected to a transmembrane-penetrating sequence, also referred to as the
membrane residency peptide (MRP). When
p53 binds to the HDM-2 protein through the
12–26 amino acid sequence, HDM-2 causes
ubiquitination of p53 that targets it for proteolysis in the proteasome. Both PNC-27 and
PNC-28 peptides , which contains a sequence
that is identical to that of PNC-27 but lacks
the first six amino acid residues of PNC-27
(i.e., p53 residues 17-26), are highly toxic to a
wide variety of cancer cells with IC50 values
that range from around 75 ug/ml (18.6 uM) to
200 ug/ml (50 uM).” “While PNC-27 and PNC28 are toxic to cancerous cell, neither peptide
affects normal cells that are in culture, even at
the highest doses (around 500 ug/ml) tested”.
This discovery illustrates that both peptides
would not be toxic to the human body, in contrast to the effects of many chemotherapeutic
agents (Davitt K, Babcock BD, 2014).
In a newer study that was analyzed in
(Figure 3) A chart of the disruption of mdm2 and the p53 complex (Hashimoto N,
2014 and published in Annals of Clinical &
Nagano H, 2010)
Laboratory Science, researchers concluded that PNC-27 and PNC-28 were capable of distinguishing
ed that “the anti-cancer peptide, PNC-27 and PNC-28,
between cancerous and non-cancerous cells.
induces tumor cell necrosis of a poorly differentiated
In a 2009 study, researchers discovered that the ’’
non-solid tissue mammalian leukemia cell line that dethree-dimensional structure of PNC-27’s and PNC-28’s
pends on expression of HDM-2 in the plasma membrane
p53 residues of its amino acids may be superimposable
of these cells.” (Davitt, et al (2014). Studies based on inonto the structure for the same residues bound to HDMformation discovered in earlier experiments illustrated
2.” This discovery alerted researchers to the fact that that
that the PNC-27 and PNC-28 peptides were able to dePNC-27 and PNC-28’s could target HDM-2 in cancer cells’
stroy solid tissue tumor cells through the mechanism of
membranes (Pincus, et al (2011)).
binding to HDM-2 proteins in their cell membranes, an
Upon further research, it was discovered that by “inserteffect which was an effect that was different from the p53
ing untransformed cells that are not prone to PNC-27 and
activity in those cells.
PNC-28 with HDM-2 containing a localized membrane
The scientists wanted to determine whether PNC-27
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peptide would also be effective against non-solid tissue
tumor cells (Davitt et al., 2014). Their study determined
whether the non-solid tissue tumor cells expressed
HDM-2 in their membranes in the first place (solid tissue cells were found to do so), and find if PNC-27 could
cause these cell’s death by the HDM-2 binding. The researchers observed that these non-solid tumor cells do
express HDM-2 in cell membranes.
They also noted that the PNC-27 peptide could cause
cell destruction through membranolysis through the
same HDM-2 binding mechanism as it did in the solid
tissue tumor cells, independent of the p53 pathway. The
research established that the peptides are successful for
both solid and non-solid tumors, making it a valuable drug
that could treat a variety of cancers.

(Figure 4) “Blots of whole cell lysates (Lower) and membrane
fractions (Upper) for H (M) DM-2 in different cell lines as follows:
Lane 1, MCF-10-2A; lane 2, BMRPA1; lane 3, AG13145 fibroblasts;
lane 4,TUC-3; lane 5, MIA-PaCa-2; lane 6, MCF-7; lane 7, A-2058.
The first three cell lines are untransformed; the remainders are
different cancer cell lines. Each bar graph shows the percentage
of HDM-2 in whole cell lysate that is present in the membrane
of each cell line listed above.The numbers on the X axis of the
bar graphs correspond to the lane numbers shown in the blots.”
(Safaraz-Yazdi E, Bownwe WB, 2010)

Studies and Trials on PNC-27 and PNC-28
Electron microscopy was utilized to observe the levels of
HDM2 in the cell membrane (Wang, et al 2010). Parts of
the membrane were isolated, and whole cell lysates from
several different cancer and untransformed cell lines are
shown in the figure below. The cells were blotted for

HDM-2 (Figure 4). “In the lower section in the table, it can
be seen that all whole cell lysates had positive results for
the blotting procedure for HDM-2. On the upper section
for the blots shown in the figure, the membrane fraction of
each cancer cell line (lanes 4–7) is seen to contain significant levels of HDM-2. In contrast, the three untransformed
cell lines (lanes 1–3) were discovered to contain low
levels of HDM-2 in the region22 of the membrane. The
percentage of whole cell lysate of HDM-2 present in the
membrane fractions of the cell lines is shown in the lower
section of the bar graph.” (Safaraz-Yazdi E, Bownwe WB,
2010) The graph illustrated that the fractions of HDM2
present in the membranes of the cancer cell lines have an
increased level of four-fold to nine-fold.
When the PNC-27 peptide was tested, researchers
noted pain levels drop in the average time of a week.
Three weeks following the administration of the peptide,
the subjects sometimes developed flu-like symptoms.
This is an indicator that the immune system had the ability to recognize and react to the death of cancer cells
(Sookraj, Ka, Bowne WB 2010). Additionally, when the
cancer killing peptide PNC-27 was administered after
tumor growth had occurred at a different site from the
original tumor, the tumor decreased in size, followed by
a gradual increase in tumor growth that was “significantly
slower than growth in the presence of control peptide.” If
the cancer killing peptide is immediately senttouro to the
tumor, researchers concluded that the peptide would be
successful in treating cancer. (Prendergast, Jaffee, 2007).
At six weeks, the researchers noted an increase in lactate
dehydrogenase and bilirubin levels.
At ten weeks, a large amount of tumor breakdown is
noticeable. At the same time, the tumors become softer
and pliable. In addition, some increase in the size of the
tumor itself occurred simultaneously. However, this can
often be attributed to inflammation because of immune
system response. At about three months, researchers
saw that the subjects of the study exhibited better energy levels and less cancer-related symptoms.
A study published in the International Journal of Cancer
(2006) writes that researchers discovered that PNC-28
was able to reduce the rate of cancer cell growth in an
organism at a quicker pace. Research tested PNC-28 to
analyze its function to halt the replication of cancer cells.
When PNC-28 was given over a two-week timeframe,
the PNC-28 caused complete destruction of these tumors. (Science Daily, 2006) When administered simultaneously with tumor implantation, PNC-28 blocked the
tumor growth entirely in the duration of the two-week
period of administration, as well as two weeks after treatment, followed by weak tumor growth that leveled off at
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low tumor size (Bowne WB, Sookraj KA, 2015).The trials
on both drugs supported the theory that immunotherapy
is able to eliminate cancer cells without causing damage
to the human system.
All methods and studies in this paper have been completed, and the drug is currently being sold out of the
United States. It is in trial stages to be sold in the United
States as well. PNC-27 and PNC-28 are novel drugs that
bring much promise to the field of cancer research, and
promises an alternative to the other harmful treatments
being used today. However, larger studies should be conducted to reduce the side effects that are experienced
by patients taking the drug. There were no attempts in
proving that PNC-27 is harmful for ingestion, unless
contaminated by an outside source. There are multiple
factors involved in creating immunotherapeutic peptides
as treatment to cancer. Other approaches to improving
the drug would be to further elucidate the mechanism
by studying various models of the disease. By examining
different models, this will hopefully give a deeper perspective and aid the efforts for a cure.
Conclusion
Cancer is a disease that has caused an upward trend in
mortality rates. Although some progress has been made in
cancer research for a cure, there are many drawbacks to
the current treatments available. The current treatments
are chemotherapy and radiation.While both of these treatments can successfully eradicate tumors and cancer cells,
they also tend to damage healthy cells.There is also potential for a relapse because not all cancer cells are targeted
during treatment, as some cancer cells may drift to other
organs and rebuild there. As a result, many cancer patients
succumb to the toxic effects of cancer treatments rather
than the cancer itself. With wealth of evidence in support
of immunotherapy, this alternative treatment shows great
promise because it does not adversely impact healthy cells.
This is because the underlying concept of immunotherapy
is to invest the body’s healthy cells with resources to be
able to naturally combat the cancer cells. This is done by
PNC-27 and PNC-28 peptides.Through research and study
on animal subjects, the PNC-27 and PNC-28 peptides have
been shown to be highly effective in selectively targeting
a wide variety of specific forms of cancer, including pancreatic cancer, breast cancer, leukemia, melanoma, and additional cancer lines. Since PNC-27 is non-toxic, patients
can get rid of the cancer in a healthy manner, while aiming
to follow a lifestyle based on holistic health and wellness.
When properly administered, PNC-27 and PNC-28 puts
cancer on the defensive, resulting in outcomes that include
significant pain reduction and, in many cases, lengthening of
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life. This research supports the evidence that PNC-27 and
PNC-28 are one of the most effective ways to treat cancer.
Resources
Ahluwalia KB. Genetics.Vol 2nd ed. New Delhi: New
Age International; 2009. http://search.ebscohost.com/
login.aspx?direct=true&AuthType=ip,sso&db=e000xna&AN=2815 25&site=ehost-live.
Bell S, Klein C, Müller L, Hansen S, Buchner J. p53
contains large unstructured regions in its native
state. Journal Of Molecular Biology. 2002;322(5):917927. http://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=cmedm&AN=12367
518&site=ehost-live.
Bowne WB, Sookraj KA,Vishnevetsky M, et al. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human
pancreatic cancer cells. Annals of Surgical Oncology.
2008;15(12):3588-3600. doi:10.1245/s10434-008-0147-0.
Campton J. Biology : Molecules and Cells. Banbury:
Hodder Education Group; 2016. http://search.ebscohost.
com/login.aspx?direct=true&AuthType=ip,sso&db=e000xna&AN=1237 456&site=ehost-live
Chao HX, Poovey CE, Privette AA, et al. Orchestration
of DNA Damage Checkpoint Dynamics across the
Human Cell Cycle. Cell Syst. 2017;5(5):445–459.e5.
doi:10.1016/j.cels.2017.09.015
Carolina Barrientos-Salcedo, Diego Arenas-Aranda, Fabio
Salamanca-Gómez, Rocío Ortiz-Muñiz, Catalina SorianoCorrea. Electronic Structure and Physicochemical
Properties Characterization of the Amino Acids
12−26 of TP53: A Theoretical Study. Journal of Physical
Chemistry A.2007;111(20):4362-4369. doi:10.1021/
jp067841y.
Cidon EU. The Easy Book of Cancer Pharmacology. New
York: Nova Science Publishers, Inc; 2016.http://search.
ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=e000xna&AN=1292 490&site=ehost-live.
Cooper GM. The Cell: A Molecular Approach. 2nd
edition. Sunderland (MA): Sinauer Associates; 2000. The
Development and Causes of Cancer. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK9963/
Davitt K, Babcock BD, Fenelus M, et al. The anti-cancer
peptide, PNC-27, induces tumor cell necrosis of a
poorly differentiated non-solid tissue human leukemia
cell line that depends on expression of HDM-2 in the
plasma membrane of these cells. Annals of Clinical and
Laboratory Science. 2014;44(3):241-248. http://search.

Is PNC-27 and PNC-28 the Best way to Cure Cancer?

ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=cmedm&AN=25117 093&site=ehost-live.
Dunn GP, Koebel CM, Schreiber RD (November 2006).
“Interferons, immunity and cancer immunoediting”.
Nature Reviews. Immunology. 6 (11):
836–48. Doi:10.1038/nri1961. PMID 17063185
Hall EJ, A.J. GiacciaRadiobiology for the radiologist (7th
ed.), Lippincott Williams & Wilkins, Philadelphia (2011)
Huda W. Review of Radiologic Physics.Vol 4th ed.
Philadelphia: Wolters Kluwer Health; 2016. http://search.
ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=nlebk&AN=201828 7&site=ehost-live.
Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link
between cancer genetics and chemotherapy. Cell.
2002;108(2):153-164. http://search.ebscohost.com/
login.aspx?direct=true&AuthType=ip,sso&db=cmedm&AN=11832 206&site=ehost-live.
Kurian AW. Mutations and the Importance of Genetic
Testing: Advancing towards personalized medicine in
breast and ovarian cancers. Oncology (08909091).
2019;33(10):406-409. http://search.ebscohost.com/
login.aspx?direct=true&AuthType=ip,sso&db=ccm&AN=1394816 01&site=ehost-live.
Marx V. Cell biology: tracking a cell’s cycle. Nature
Methods. 2017;14(3):233-236. doi:10.1038/nmeth.4186.
Mims MP, Worden FP, Hayes TG, Todd RF, Cooney KA.
Tumor Board Review, Second Edition : Guideline and
Case Reviews in Oncology.Vol Second edition. New
York: Demos Medical; 2015. http://search.ebscohost.
com/login.aspx?direct=true&AuthType=ip,sso&db=e000xna&AN=9596 07&site=ehost-live.
Mokhtarzadeh A, Parhiz H, Hashemi M, Abnous K,
Ramezani M. P53-Derived peptides conjugation to PEI:
an approach to producing versatile and highly efficient
targeted gene delivery carriers into cancer cells. Expert
Opinion On Drug Delivery. 2016;13(4):477-491. doi:10.1
517/17425247.2016.1126245.
More SK,Vomhof-Dekrey EE, Basson MD. ZINC4085554
inhibits cancer cell adhesion by interfering with
the interaction of Akt1 and FAK. Oncology Letters.
2019;17(6):5251-5260. http://search.ebscohost.
com/login.aspx?direct=true&AuthType=ip,sso&db=a9h&AN=13636874 7&site=ehost-live.
Murphy CC, Lee SJC, Gerber DE, Cox JV, Fullington
HM, Higashi RT. Patient and provider perspectives on
delivery of oral cancer therapies. Patient Education and
Counseling. 2019;102(11):2102-2109. doi:10.1016/j.

pec.2019.06.019.
Nitiss JL. Targeting DNA topoisomerase II in cancer
chemotherapy. Nature Reviews Cancer. 2009;9(5):338350. doi:10.1038/nrc2607
Niazi S, Purohit M, Niazi JH. Role of p53 circuitry in
tumorigenesis: A brief review. European Journal Of
Medicinal Chemistry. 2018;158:7-24. doi:10.1016/j.
ejmech.2018.08.099.
O’Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward
M, Peters SAE. Smoking as a risk factor for lung cancer
in women and men: a systematic review and meta-analysis. BMJ Open. 2018;8(10):e021611. Published 2018 Oct
3. doi:10.1136/bmjopen-2018-021611
Orth M, Lauber K, Niyazi M, et al. Current concepts
in clinical radiation oncology. Radiat Environ Biophys.
2014;53(1):1–29. doi:10.1007/s00411-013-0497-2
Pincus MR, Fenelus M, Sarafraz-Yazdi E, Adler V, Bowne W,
Michl J. Anti-cancer peptides from ras-p21 and p53 proteins. Current Pharmaceutical Design. 2011;17(25):26772698. http://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=cmedm&AN=21728
981&site=ehost-live.
Pardoll D. Cancer and the Immune System:
Basic Concepts and Targets for Intervention.
Semin Oncol. 2015;42(4):523–538. doi:10.1053/j.
seminoncol.2015.05.003
Prendergast GC, Jaffee EM. Cancer Immunotherapy :
Immune Suppression and Tumor Growth. Amsterdam:
Academic Press; 2007. http://search.ebscohost.com/
login.aspx?direct=true&AuthType=ip,sso&db=e000xna&AN=1964 70&site=ehost-live
Rahman M. Systems Biology in Cancer Immunotherapy.
Sharjah: Bentham Science Publishers Ltd; 2016. http://
search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=nlebk&AN=128004 4&site=ehost-live
Siddik ZH (2005). “Mechanisms of Action of Cancer
Chemotherapeutic Agents: DNA-Interactive Alkylating
Agents and Antitumour Platinum-Based Drugs”. The
Cancer Handbook
Sarafraz-Yazdi E, Gorelick C, Wagreich AR, et al. Ex vivo
Efficacy of Anti-Cancer Drug PNC-27 in the Treatment
of Patient-Derived Epithelial Ovarian Cancer. Annals Of
Clinical And Laboratory Science. 2015;45(6):650-658.
http://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=cmedm&AN=26663
795&site=ehost-live.
Sarafraz-Yazdi E, Bowne WB, Adler V, et al. Anticancer

49

Miriam Silberstein

peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2
in their membranes. Proceedings Of The National
Academy Of Sciences Of The United States Of America.
2010;107(5):1918-1923. doi:10.1073/pnas.0909364107.
Shields JA, Shields CL. Intraocular Tumors: An Atlas and
Textbook.Vol Third edition. Philadelphia, PA: Wolters
Kluwer Health; 2016. http://search.ebscohost.com/
login.aspx?direct=true&AuthType=ip,sso&db=e000xna&AN=1473 235&site=ehost-live.
Sookraj KA, Bowne WB, Adler V, Sarafraz-Yazdi E,
Michl J, Pincus MR. The anti-cancer peptide, PNC-27,
induces tumor cell lysis as the intact peptide. Cancer
Chemotherapy And Pharmacology. 2010;66(2):325-331.
Stadler WM. Cancer Biology Review : A Case-Based
Approach. New York: Demos Medical; 2014. http://
search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=e000xna&AN=6226 18&site=ehost-live.
Uehara I, Tanaka N. Role of p53 in the Regulation of
the Inflammatory Tumor Microenvironment and Tumor
Suppression. Cancers (Basel). 2018;10(7):219. Published
2018 Jun 27. doi:10.3390/cancers10070219
Uzun Z. Side effects of chemotherapy in children
with cancer: effects of nursing training administered to caregivers. Australian Journal of Advanced
Nursing. 2019;36(4):37-44. http://search.ebscohost.
com/login.aspx?direct=true&AuthType=ip,sso&db=ccm&AN=1369498 92&site=ehost-live.
Vassilev A, DePamphilis ML. Links between DNA
Replication, Stem Cells and Cancer. Genes (Basel).
2017;8(2):45. Published 2017 Jan 25. doi:10.3390/
genes8020045
Viani GA. Radiation Therapy : Clinical Evidence for
Decision-Making. New York: Nova Science Publishers,
Inc; 2013. http://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=e000xna&AN=5716
05&site=ehost-live.
Williams PA, Cao S,Yang D, Jennelle RL. Patient-reported
outcomes of the relative severity of side effects from
cancer radiotherapy. Supportive Care in Cancer.
2020;28(1):309-316. doi:10.1007/s00520-019-04820-2.
Wang H, Zhao D, Nguyen LX, et al. Targeting cell
membrane HDM2: A novel therapeutic approach for
acute myeloid leukemia. Leukemia. 2020;34(1):75-86.
doi:10.1038/s41375-019-0522-9.
Yang L, Wang Y, Wang H. Use of immunotherapy in
the treatment of gastric cancer. Oncology Letters.
2019;18(6):5681-5690. doi:10.3892/ol.2019.10935.
50

Nowak-Sliwinska P, Alitalo K, Allen E, et al. Consensus
guidelines for the use and interpretation of angiogenesis
assays. Angiogenesis. 2018;21(3):425–532. doi:10.1007/
s10456-018-9613-x
Zhang B, Mehrotra S, Ng WL, Calvi BR. Low levels of
p53 protein and chromatin silencing of p53 target genes
repress apoptosis in Drosophila endocycling cells. PLoS
Genet. 2014;10(9):e1004581. Published 2014 Sep 11.
doi:10.1371/journal.pgen.1004581

Intra-Ocular Vascular Endothelial Growth Factor Inhibiting
Agents: Indications, Efficacy, and Alternatives
Rena Shilian
Rena Shilian will graduate with a Bachelor of Science degree in Biology in January 2021

Abstract
One of the most revealing parts of the human body is the eye. In fact, systemic conditions and diseases are commonly manifested
in the eye and display pathology that reflect disorders. An example of a chorioretinal vascular condition that can present itself in
the eye is diabetes mellitus, which if left uncontrolled can damage the eyes and a person’s vision. Age related macular degeneration
is specific to the eye, potentially leading to irreversible loss of central vision. Intravitreal injections containing vascular endothelial
growth factor inhibiting agents appear to be the leading lines of defense against diabetic retinopathy and macular degeneration
progression, helping to reduce both the pathological and visual manifestations of these chorioretinal vascular diseases.
Background
Diabetes is the fourth leading cause of health complications, making many people susceptible to diabetic retinopathy. In fact, the prevalence of diabetes is expected
to increase by 7.7% by 2030, leaving many people at risk
(Abbas et al., 2017). Age related macular degeneration is
another neovascular condition of the eye which can reduce visual acuity to 20/800 in a patient’s better eye by
60%, resembling a patient who “is bedridden with a catastrophic stroke” (Folk & Stone, 2012). These diseases are
capable of impairing the daily functioning of a patient if
they are not treated and monitored. Most ocular diseases can be identified with a dilated eye exam. Treatments
with delivery of vascular endothelial growth factor inhibitors to the retina via intravitreal injection has gradually
become the first line of treatment for ocular conditions
such as diabetic retinopathy and macular degeneration.
Pan-retinal photocoagulation (PRP) is a laser treatment
that can also be used in controlling these conditions and
preventing the progression of vision loss. Research is currently being done on both of these methods in an effort
to determine their use in ocular disease.
Hypothesis
In most circumstances, vascular endothelial growth factor
inhibiting medications can be implemented in a treatment
plan to alleviate both the visual complaints and the pathological findings associated with chorioretinal vascular
conditions. In some cases, however, this treatment option
may not be appropriate due to potential risks and another treatment may be indicated.
Methods
Research for this paper was conducted with the use of ProQuest, EBSCO, and Pub-Med databases. Figures used throughout include corresponding sources from research articles.
Diagnostic Methods
Conditions such as age-related macular degeneration
and diabetic retinopathy can be diagnosed with a proper exam. Ophthalmic tropicamide, a mydriatic, is used in
order to give the clinician a proper view of the fundus.

Imaging methods such as optical coherence tomography
(OCT), fluorescein angiography, and wide field fundus
imaging may also be used for future comparison during
treatment. Diagnostic guidelines have been established to
aid in classifying the type and severity of ocular disease.
Findings, diagnostic methods, visual complaints, and prognosis of these conditions will be discussed in the following
sections. Popular treatment options will also be outlined.
Diabetic Retinopathy
Diabetic retinopathy (DMR) is a complication resulting
from diabetes mellitus Type 1 or 2. It appears to be one
of the leading causes of blindness in patients aged 20-65
(Stewart, 2012). Currently, 336 million people suffer from
diabetes and are therefore at risk of developing diabetic
retinopathy, otherwise known as DMR (Abbas et al., 2017).
Diabetic damage to the eye is a result of macular edema,
which in more advanced cases, can lead to intraocular
bleeding, detachments of the retina, macular ischemia, and
retinal neovascularization. Possible risk factors for DMR
include hyperglycemia, elevated blood pressure, and elevated serum levels (Buffolino & Park, 2019). Patients can
usually control risk factors with lifestyle modifications
including diet and exercise, yet it is important to note
that specific patient demographics can predispose people
to diabetic retinopathy.
Firstly, individuals diagnosed with diabetes at an earlier
age tend to be more vulnerable to developing the condition. DMR becomes more prevalent as the age of diabetes
onset is younger. “What is hitherto unknown is whether
the increased prevalence of complications associated with
early-onset disease is simply a consequence of the longer duration of disease, a consequence of a more severe
metabolic phenotype, or in fact something specific to the
diabetic milieu in younger patients that makes tissues more
inherently susceptible to hyperglycemic damage” (Wong
et al., 2008). Long-term exposure to elevated blood glucose levels seems to lead to oxidative stress on the eyes
(Stewart, 2012). By the same token, retinopathy is not
common in the first five years of a Type 1 diabetes onset,
and diabetic retinopathy tends to be present after 20 years
of having Type 2 diabetes (Cook et al., 2008).
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Secondly, in addition to patient age, ethnicity is also
associated with DMR. African Americans, Hispanics, and
South Asians are especially prone to diabetic retinopathy.
African Americans seemingly have reduced glycemic control, which can lead to retinal complications due to higher
A1C values. The internationally recognized mark differentiating safe and unsafe A1C values is 7% (Long et al.,
2017). A study showed that over a six-year period, 72%
of African Americans with Type 1 diabetes mellitus developed retinopathy (Buffolino & Park, 2019). Furthermore,
the combination of male sex, African American ethnicity,
duration of standing diagnosis, and value of hemoglobin
A1C, were “positively associated with retinopathy severity” (Long et al., 2017).
Before any signs of diabetic damage appear on the
retina, choroidal vessels may constrict due to hypoxia
and vascular changes can develop. Furthermore, it is important to note that in the early stages of damage to the
retina, the patient may not be able to discern changes
in visual acuity; the condition is usually diagnosed in a
later stage of diabetic retinopathy (Wang & Tao, 2019).
About 50% of patients with diabetes do not come for
yearly screening visits (Buffolino & Park, 2019). The first
markers of diabetic damage in the eye are the results of
swelling and leakage of blood vessels because of poorly
controlled blood sugar levels. The natural synthesis of
vascular endothelial growth factors (VEGF) results in
the disruption of the blood-retina barrier that leads to
the spread of serum proteins leading to edema (Stewart,
2012). Bleeding near the macula can noticeably blur the
patient’s vision. According to Mayo Clinic’s webpage on
diabetic retinopathy (n.d.), the patient may also complain
of fluctuating vision. This can occur because of uncontrolled blood sugar levels that cause the lens to swell and
alter the refraction of light in the eye.Two other common
visual complaints are impaired color vision and floaters
(Vien, n.d.). Over time, the body may begin to generate
new blood vessels in order to properly supply the eye
with oxygen, which severely impacts the patient’s vision
and everyday functioning. Other lesions associated with
diabetic retinopathy such as microaneurysms, hemorrhages, cotton wool spots, and hard exudates can be seen.
Diagnosis and Prognosis of Diabetic Retinopathy
Diabetic retinopathy is classified into either proliferative
or nonproliferative diabetic retinopathy (PDR/NPDR)
and then further broken down into mild, moderate, and
severe. This classification considers the degree of damage
present on the retina. The job of the clinician is not an
easy one to classify the stage of diabetic retinopathy.With
the help of wide field fundus imaging, the ophthalmologist
52

is able to document and compare any changes to the appearance of the retina. The wide field images below can
demonstrate the classifications of diabetic damage to the
retina based on any associated findings.
Additionally, optical coherence tomography (OCT) is
used to provide cross-sectional scans of the retina which
can also help in determining the presence and degree of
edema or cotton wool spots. Layers of the retina such as
the RPE and choroid may also be altered.
Age-Related Macular Degeneration
Age related macular degeneration (AMD) is the most
common cause of blindness in patients older than age 65.
In industrialized countries, blindness due to AMD had a
reported 1.47% prevalence and affected 1.75 million people in the United States alone (Eng, et al., 2019).The deposition of yellow, extracellular material underneath the
retinal pigment epithelium that form drusen, indicative of
photoreceptor cells that are degenerating is a key component of AMD (Virgili et al., 2015). The RPE must reuse
materials in order to help revitalize photoreceptors. A
defect in the cycle suggests the poor quality of enzymes
that are responsible for breaking down those materials
(Sarks et al., 1994), leading to degeneration of the RPE
as drusen evolve into geographic atrophy. Extracellular
deposits or atrophy of the RPE near the retina can lead
to significant loss of central vision. As the drusen degenerate, they give a white appearance to the retina with
“irregular margins and foci of calcification before disappearing to leave a focal patch of atrophy” (Sarks et al.,
1994). Most patients complain of blurred or distorted
vision or a scotoma (Cook et al., 2008). Risk factors for
AMD include smoking, hyperlipidemia, and hypertension.
Age-related macular degeneration is also strongly tied to
a genetic predisposition to the point that children and siblings of patients with AMD are automatically considered
suspects for the condition. Many sources rank genetics
as an important contributor to the likelihood of developing age-related macular degeneration. Various studies
show that people of African descent have a reduced risk
for AMD, than does the Caucasian population (Delcourt,
n.d.). Smoking increases the risk of AMD as well.
Although much about AMD and its pathogenesis is still
unknown, studies show “that the largest single genetic
factor contributing to AMD is a variant of codon 402 in
the gene encoding complement…[that] strongly supports
the long-held belief that the immune system is an important contributor to AMD” (Folk & Stone, 2012). In some
observed cases of AMD, inflammatory mediators and
other molecules have been found at the macula, indicating
that there is indeed a connection between the condition
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and inflammation. Furthermore, the release of excess activated macrophages in chronic inflammatory diseases is
linked to cellular damage at the macula. Electron microscopy and immunohistochemistry methods were used to
detect the presence of inflammatory biomarkers at sites
of atrophy and neovascularization in patients with AMD
(Cachulo & Costa, 2017).
Prognosis and Classification of AMD
Age-related macular degeneration is diagnosed with
a dilated retinal examination. Evaluating a case of AMD
requires paying attention to changes at or near the macula. Age-related macular degeneration begins with the
dry form, characterized by the presentation of drusen.
Number, size, and location of drusen are helpful in determining the progression of the condition. Additionally,
drusen with indistinct borders seem to be indicative of
the advancement of AMD (Cachulo & Costa, 2017).
As AMD progresses, the retinal pigment epithelium
layer begins to show signs of atrophy. A case of AMD is
characterized as wet or neovascular once new blood vessels begin to grow over or underneath the RPE (Folk &
Stone, 2012). The generalized term “late AMD” refers to
two specific presentations on the macula with exudates
which can either be geographic atrophy or vascular AMD.
Progression from dry to wet AMD occurs for 15% of
patients complaining of severe loss of central vision and
presenting with geographic atrophy that develops (Eng et
al., 2019). Patients may notice visual distortion of straight
lines. Ten percent of patients with AMD suffer from this
more advanced form. More than 200,000 patients in the
United States alone are diagnosed per year, accounting
for 90% of all severe vision loss (Stewart, 2012). In a large
study done, “the prevalence of large drusen increased
from about 1.5% in Caucasians aged 40-49 years, to more
than 25% in those aged 80 years or more” (Delcourt,
n.d.). This statistic is important to consider because it
indicates that Caucasians appear to be more at risk for
developing AMD than people of other demographics such
as Hispanic American, African American, and Chinese
(Delcourt, n.d.). Of course, as the name of the condition
suggests, the likelihood of developing AMD increases exponentially with age.
VEGF in Ophthalmology
Angiogenesis is a process that can be both lifesaving
and necessary, yet in some cases can be detrimental.
Throughout the body, the natural process for generating
new blood vessels is crucial for maintenance related to
growth (embryonic or otherwise) and repair. Yet in circumstances of hypoxia and inflammation, it allows the

growth of tumors and is linked to the destruction of tissue (Stewart, 2012). Angiogenesis is also important when
neovascularization is required such as after myocardial
infarction. However, in ophthalmic cases, the generation
of new blood vessels can lead to hyperpermeability that
can harm vision by leading to retinal detachments and
edema between the retinal layers. The primary molecule
that is associated with angiogenesis is vascular endothelial
growth factor. “Within the posterior segment of the eye,
VEGF is produced by retinal pigment epithelial cells, neurons, glial cells, endothelial cells, ganglion cells, Muller cells,
and smooth muscle cells” (Stewart, 2012). The primary
cells of interest leading to the harms from AMD and DMR
however, are vascular endothelial cells. Generally, the synthesis of VEGF is triggered by tissue hypoxia that can either be caused by “primary vascular occlusive disease or
anaerobic tumor metabolism” (Stewart, 2012).The mechanism leading to the proliferation of vessels is complex
but it results in mitosis and swelling of the endothelial
cells, as well as vasodilation, helping new blood vessels
develop. Specifically, VEGF works to encourage growth
along the endothelial cells and dissolve the spaces between them, leading to the breakdown of the blood-retinal barrier that makes capillaries leak and new, potentially
detrimental, blood vessels form (Stewart, 2012). VEGF-A,
a subfactor of this molecule, is linked to growth and
permeability of newly-developing blood vessels. VEGF
inhibitors block the receptors that natural VEGF would
bind to, preventing angiogenesis. “Long-term blockade of
VEGF-A [receptor] causes shrinkage and maturing of the
vessels so that they no longer leak. The accumulation of
fluid within and beneath the retina dissolves, and the photoreceptors reattach to the underlying retinal pigment
epithelium” (Folk & Stone, 2012). By using a medication
that reduces the permeability of the retinal vessels and
stopping their growth, leakage is also reduced, preventing
swelling in order to bring the patient’s visual acuity back
to baseline (Folk & Stone, 2012). It is interesting to note
that these drugs are capable of resolving findings associated with two very different conditions in that one is
systemic and can target multiple parts of the body, while
the other is localized in the eye.
VEGF Inhibitors: A Comparison
Although all VEGF inhibitors prevent neovascularization,
there are several subclasses of this drug. Their generic
names aflibercept, bevacizumab, and ranibizumab will be
used throughout this paper (Folk & Stone, 2012). The efficacy of the medications as they compare to each other
is still being studied.
Bevacizumab received approval from the Food and
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Drug Administration for the treatment of colon cancer.
Bevacizumab also binds to VEGF-A, which led clinicians to
think that the drug may also be effective in treating neovascularization and exudates on the retina.Although there
is no FDA approval for its intravitreal use, bevacizumab is
proving itself effective (Folk & Stone, 2012). When compared to other medications in its class, bevacizumab has
a longer half-life. One dose of the drug can reduce levels
of natural VEGF in the blood by 117 times in just one day
and when measured after one month, still maintained a
four-fold reduction (Stewart, 2012). Furthermore, many
clinicians recommend this drug because of its vast difference in cost compared to others. Being prepared in
larger doses than is necessary for the eye means that the
medication can be divided for multiple doses (1.25 mg.
on average), reducing the cost even further. Whereas a
dose of ranibizumab costs $2000, bevacizumab, although
regarded as off label therapy, costs $75 per treatment
(Folk & Stone, 2012).
Ranibizumab was developed specifically for use in the
eye by fragmenting the bevacizumab molecule for higher
affinity by five to twenty times more than bevacizumab
(Stewart, 2012). A study looking at regular monthly treatment with ranibizumab shows that the first five years of
treatment produce the best results in terms of visual acuity, but then results seem to approach baseline levels over
time thereafter (Nishikawa et al., 2019). For treatment with
ranibizumab, the MARINA study attempted to determine
effective dosage of the medication. At random, 716 patients with neovascular AMD were treated with monthly
0.3mg or 0.5mg injections of the drug, or sham treatment
for 24 months. Results showed that 92% of patients that
were treated with 0.3mg of ranibizumab and 90% treated
with 0.5mg lost less than 15 letters when being tested for
changes in visual acuity. Furthermore, 26.1% of patients
that were treated with 0.3mg and 33.3% with 0.5mg treatment had a 15-letter improvement or greater.
When aflibercept is compared to the other drugs, its
increased binding affinity to VEGF-A receptors combined
with its larger molecular size allows for a higher efficacy
and hence, less frequent treatment. When used on a twomonth basis after three monthly consecutive loading doses,
results compared to monthly treatment with ranibizumab
(Stewart, 2012). Patients with neovascular AMD who were
treated with aflibercept intraocular injections were able to
sustain improved vision for four years. Even though after
one year some regression was present, 94.5% of patients
still had improved vision. “Thus, visual gain [of aflibercept]
in the first year is generally favorable, but long-term outcome is not as promising” (Nishikawa et al., 2019).
Conclusively, visual acuity was shown to improve with all
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three classes of treatment, but specific data was shown by
a study conducted by DRCR.net in which 600 Americans
with diabetic edema participated. The average age was 61
and most people had diabetes for over 15 years. Visual
acuity before the study was 20/32 or worse and patients
were administered either of the three drugs at random
and monitored on a monthly basis in the first year of the
study. When comparing the visual acuity of patients after
treatment, those on aflibercept for two years were able
to read 3.5 more lines compared to ranibizumab patients
who read 3, and bevacizumab patients read 2.5 (Wells,
2016). Aflibercept showed better efficacy after the oneand two-year mark. “By two years, 41 percent of participants in the aflibercept group received laser treatment
to treat their macular edema, compared with 64 percent
of participants in the bevacizumab group and 52 percent
in the ranibizumab group.” Ultimately, with treatment involving any of the three drugs, visual acuity was improved
to 20/32 and 20/40. There were even studies showing the
efficacy of bevacizumab in improving patients’ visual acuity from 20/235 to 20/172.The results of the study suggest
that there is a slight difference between the frequencies
at which the drug must be readministered depending on
the specific type of medication chosen. According to the
DRCR study done, there was no significance to using one
medication over another for treatment of mild macular
edema when visual acuity is 20/40 or better. However,
in cases of 20/50 or worse vision it has been shown that
Eylea (aflibercept) performed better than ranibizumab
and bevacizumab (Wells, 2016).
Risks
Although this modality of treatment is usually the first
line of defense against further damage to the retina, existing risks should be considered. Firstly, for all the subclasses of intravitreal injections used for treating chorioretinal
disorders, the risk for eye infection and inflammation is
the same. These are consequences of the administration
and not the drug itself (Wells, 2016). Injection into the
vitreous chamber also raises the risk for endophthalmitis, retinal tear or detachment at the area of injection,
and vitreous hemorrhage because of penetrative trauma
(Pershing et al., 2013). These risks must be kept in mind
when developing a treatment plan for a patient suffering
with other kinds of ocular disease as well. Furthermore,
because additional fluid is added to the vitreous cavity
when the medication is given, an elevation in intraocular
pressure from increased volume in the eye can result.
A study was done spanning academic centers Stanford
University Hospital & Clinics and Mayo Clinic. Patients
who received anti-VEGF injections between January 1,
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2006 and December 31, 2010 participated in order to
determine the relationship between administration of
the drug and intraocular pressure elevation taking place
within 60 days of the injection. Intraocular pressure
asymmetry between the eyes by a value of more than
3mm Hg was also considered. Those with a history of
glaucoma or elevated IOP in the past did not qualify to
participate. “A total of 11,828 bevacizumab injections and
10,354 ranibizumab injections were administered during
the study period at the two clinical sites. In this series, 21
eyes of 18 patients developed elevated IOP of 24mm Hg
of higher within 60 days of previous injection” (Pershing
et al., 2013). Most patients were Caucasian females who
received treatment for wet AMD and presented other
pathology related to elevated IOP, such as narrow anterior chamber angles on gonioscopy. Most of the 21 eyes
needed treatment for elevated pressure, 76% required
prolonged treatment, and 19% resolved with no treatment. It was found that a risk of increase in IOP persisted
even later in treatment after multiple injections to the
eye. This risk was reported regardless of the subclass of
anti-VEGF used, however a higher chance of IOP elevation in ranibizumab treatment was reported (Pershing et
al., 2013). This risk is especially important to consider if
the patient in question has glaucoma or is a glaucoma
suspect, as a subtle rise in intraocular pressure may be
detrimental. In such a case, the drug should be administered and the patient carefully monitored for changes in
IOP that may lead to an acute attack of glaucoma.
Additionally, receiving anti-VEGF drugs alongside having
coexisting cardiovascular conditions may lead to adverse
effects. The SUSTAIN trial showed that although there is
no link to myocardial infarction, a 10% incidence of stroke
was found in patients with previous cerebrovascular disease that were also being treated with VEGF inhibiting
medications (Stewart, 2012). In patients receiving regular
treatment with ranibizumab, there was a higher incidence
of heart attack, stroke, or death from cardiovascular or
unknown conditions (Wells, 2016).
Finally, the nature of this treatment option for AMD/
DMR is that frequent, monthly follow up visits are required to monitor and readminister the drug, rendering compliance of treatment more difficult to upkeep.
Inherent drawbacks to the use of VEGF inhibiting agents
are its cost and frequency of treatment as it relates to
burden on the patient. Perhaps lowering the overall cost
of the treatment (medication and visit) while creating a
medication with a longer half-life or efficacy will allow
more patients to undergo long term treatment, preventing blindness (Baek et al., 2019). In some cases, the use
of a laser to clear drusen and prevent the furthering of

neovascularization may be more appropriate, as will now
be discussed.
Use of Pan Retinal Photocoagulation
Although traditional cases of diabetic retinopathy and
macular degeneration now indicate treatment with intravitreal injections, this has not been the case for long.
In the past, the first line of defense was treatment with
blue-green Argon laser in order to create lesions around
the area of retinal neovascularization and promote the
regression of abnormal blood vessels and drusen. This
option to help DMR and AMD is called pan retinal photocoagulation. In this technique, a beam of light from the
laser is focused onto the retina using a special lens. The
strength of the laser now used is usually weaker, with
studies trying to determine the efficacy of subthreshold
laser treatment to avoid applying more energy than necessary. Up to 300 lesion spots may be delivered, with each
one between 100µm and 200µm in size. “Subthreshold
photocoagulation delivers light energy with very short
impulses that are absorbed by the RPE only, aiming to
spare the neurosensory retina”. Adjusting the strength,
pulse duration, and frequency of the laser makes the
treatment effective yet more gentle on the choroid in
an attempt to reduce potential photoreceptor loss.
Although the mechanism of treatment is not fully known,
some ideas explain its efficiency.
Firstly, the laser may help in clearing remnants left by
phagocytic cells and macrophages along the choroid. It is
hypothesized that the accumulation of these cells leads
to the development of drusen. Another train of thought
is that the laser may precipitate the RPE layer to release
cytokines and growth factors that are able to “modify the
biochemical processes underlying the clinical manifestations of the retinal disorder, rather than simply destroying
drusen, and may also act on the drusen remote from the
site of laser energy application” (Virgili et al., 2015). Also,
the laser energy is capable of causing the temperature of
the retina to rise slightly, leading to the release of heat
shock proteins.They “act as chaperones for refolding misfolded proteins in aging cells, thereby rejuvenating retinal
pigment epithelium (RPE) cells and restoring their cellular
function” (Eng et al., 2019).
A study included patients with extrafoveal neovascular
presentation with drusen. Patients were 50 years of age
or older and visual acuity either was 20/100 or worse
(Silva, 2011). The laser used was a conventional bluegreen Argon laser. Energy was set to be powerful enough
to create the necessary lesions or controlled burns on
neovascular areas. In this study, attention was not paid
to maintaining sub-threshold energy. By using pan retinal
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photocoagulation, the likelihood to stabilize the visual
acuity of a patient doubled for those eyes, showing a 58%
reduction in the risk to have severe vision loss.
Highlights from the Macular Photocoagulation Study
Group (Silva, 2011) are shown here:
A. Five years after treatment, average visual acuity
was 20/125 in the group treated compared to
20/200 in patients not treated with PRP.
B. Within the five-year span of treatment, 54% of
patients had signs of recurring severe vision loss,
with the majority of cases taking place within two
years of treatment.
C. Smoking after PRP treatment was linked to accelerated recurrence of severe vision loss, as 85% of
patients smoked more than 10 cigarettes per day
compared to 51% in the non-smoking population.
An additional analysis of 12 studies of 2,481 eyes that
were treated with subthreshold pan retinal photocoagulation showed similar results. This study included treatments done with 514nm and 810nm lasers. Conclusions
of the review showed that pan retinal photocoagulation
treatment is effective in reducing drusen count and
thereby improving visual acuity in patients with dry AMD
with the 810nm laser being consistently more effective.
However, the study mentions that in order to obtain a
significant improvement in visual acuity, the treatment
must clear a substantial amount of drusen. Additionally,
the study found that among the eyes that were treated,
there was “no significant change in the risk of developing choroidal neovascularization or geographic atrophy”
(Eng et al., 2019) and that more research would need
to be done to conclusively confirm the efficacy of the
810nm infrared diode laser compared to the 514nm laser.
Comparing the treated patients with the observed
patients in the study, the following data was obtained in
regard to the relationship of diminishing drusen and treatment with pan retinal photocoagulation (Eng et al., 2019):
1. In five out of the 12 studies in which visual acuity
was measured, it was determined that there was
no difference in visual acuity in the groups who
had and had not received treatment. Yet, the remaining studies showed a correlation between
receiving treatment and improved visual acuity.
This indicates that although pan retinal photocoagulation may be effective in clearing drusen from
the retina, perhaps more research is necessary to
conclude the effectiveness of the laser in improving the visual outcome for the patient.
2. In regard to the development of choroidal neovascularization (CNV), three of nine studies that
followed up on this mentioned that there was no
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development of CNV. An additional three however noted that eyes treated with subthreshold pan
retinal photocoagulation were slightly more likely
to develop CNV.
3. Geographic atrophy was also monitored in this
series of studies. It was reported that two studies
showed GA in treated eyes, while another study
showed that although the incidence of developing
geographic atrophy in treated eyes was 3.9%, the
likelihood was higher in eyes that were not treated, at 14.0%.
After five years, following up on patients showed 64%
of eyes that were not treated with the laser developed
more severe vision loss compared to 46% of patients that
had treatment with PRP.Yet, the recurrence rate of vision
loss was 54%, with 75% of those recurrences taking place
in the first year (Cook et al., 2008).
Conclusion
Currently, there are a number of available treatment
options to reduce visual complaints and pathological
findings in patients with chorioretinal vascular conditions. Interventions such as subthreshold pan retinal
photocoagulation and vascular endothelial growth factor
inhibiting agents are still undergoing various studies, yet
they do appear to be effective and promising options for
patients battling age related macular degeneration and
diabetic retinopathy. There are reasons why a clinician
may choose one over the other in hopes of achieving
the maximum benefit for the patient, depending on cost,
compliance, and coexisting conditions. Although vascular
endothelial growth factor inhibiting agents have become
the first line of defense against neovascularization and
other such complications of ocular disease, there are still
reasons why they may not be the appropriate treatment
option for a given patient as there are associated risks.
Furthermore, some clinicians believe that using alternatives such as PRP may be a better option altogether. On
the other hand, an advantage of VEGF inhibiting agents
over pan retinal photocoagulation is “prompt regression
of neovascularization and the preservation of peripheral
and night vision” (Buffolino & Park, 2019). Undergoing
treatment with VEGF inhibiting medications for patients
with severe vision loss may not be recommended as the
drug may not be able to restore vision (Baek et al., 2019),
however in most circumstances,VEGF inhibiting drugs can
and perhaps should be implemented to alleviate both the
visual complaints and the pathological dangers associated with chorioretinal vascular conditions. Potential risks
previously discussed such as IOP elevation, inflammation,
visual and pathological damage, and coexisting conditions
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may need to be considered on a case by case basis, necessitating another modality of treatment. Nevertheless,
it should be stressed that without a proper dilated exam,
very little can be observed and treated; imaging methods
can also be used to monitor the stability or progression
of these diseases.
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Abstract
Crohn’s disease and ulcerative colitis are the two most prevalent inflammatory bowel diseases (IBDs) in Jewish and Caucasian populations, affecting as many as one in 250 individuals. Nevertheless, the underlying causes of both disorders are not yet fully understood
and remain unknown. However, current evidence suggests that the exaggerated inflammatory response, more commonly referred
to as IBD, is believed to arise from dysregulation of the gastrointestinal (GI) immune system in genetically predisposed individuals
who are exposed to environmental triggers. Recent advances have identified multiple IBD susceptibility genes; however, only a few
environmental determinants of IBD have been consistently identified. The difficulty in understanding the etiology of IBD is in part
due to the complex interactions between genes and the environment. Additionally, autoimmune mechanisms are believed to play
a role in the development of IBDs, but the target antigens and the underlying pathways have not been sufficiently characterized
and identified. IBD is commonly referred to as an “idiopathic disease;” a disease with an unknown cause (Health &Medicine, 2016;
Sartor, 2006).This paper examines the possible causes of IBD, specifically highlighting Crohn’s disease.
Key Phrase
GI- Gastrointestinal Tract
IBD- Irritable Bowel Disease
CD- Crohn’s Disease
UC- Ulcerative Colitis
Introduction
Crohn’s Disease (CD) is a chronic autoimmune disease
mainly affecting the gastrointestinal (GI) tract extending
from the mouth to the anus; however, it’s most commonly found in the ilium, leading to the alternate name
ileitis (Newman & Siminovitch, 2003). It’s characterized
by thickened areas of the GI wall with inflammation
extending through all four layers including the mucosa,
submucosa, muscularis externa, and serosa (Politics &
Government week, 2017; Ruthruff, 2007). The inflammation is somewhat similar to that of ulcerative colitis,
and commonly leads to abdominal pain, diarrhea, vomiting, weight loss, anemia and fever (Torres et al. 2017).
However, some patients may experience mouth and skin
sores along with joint stiffness and swelling (Creek, 2017).
Unfortunately, patients suffering from CD are at a higher
risk of developing other autoimmune disorders such as
osteoporosis, thyroid disease, as well as colorectal cancer (Baumgart & Sandborn, 2012; O’Sullivan, 2009; Bae
et al. 2014). Symptoms range from mild to severe and
treatment varies depending on the severity of the disease.
Typically, a doctor will perform a series of tests before
confirming CD. These tests may include a physical exam,
lab tests, stool samples, CT scans, MRI, endoscopy and
a colonoscopy (Baumgart & Sandborn, 2012), in which
a small flexible camera is inserted through the rectum
to distinguish abnormalities. Together, these tests detect
abnormalities which may exist throughout the intestinal
track thus indicating IBD.
While there is currently no known cure for CD, treatment options are available (Akobeng, 2008; Michail et al.
2013). It is estimated that roughly ten percent of patients
who undergo surgery will have prolonged clinical remission (Baumgart, 2012; D’Incà & Caccaro, 2014). The goal
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of treatment is to reduce inflammation and to improve
the prognosis by limiting complications (Newman &
Siminovitch, 2003). Noninvasive treatment options include anti-inflammatory medication, antibiotics, and immunosuppressant drugs. Anti-inflammatory medication
controls and suppresses inflammation, thereby decreasing
the frequency of flare ups. With proper treatment over
time, periods of remission can be extended, and flare ups
can be reduced. Alternatively, immunosuppressant medications, such as corticosteroids, aid by suppressing the
immune system, thus allowing the intestinal tissue to heal.
However, in some instances, more invasive treatment
plans are required. Despite significant progress in treatments for CD, it’s estimated that as many as seventy-five
to ninety percent of patients suffering from the disease
will undergo surgery to relieve symptoms at some point
during the patient’s life. (Politics & Government Week,
2017; Liu et al. 2017). At times, CD creates complications
that are deemed a medical emergency, such as a bowel
abscess, a fistula (which may result from an unaddressed
abscess), uncontrolled bleeding, or intestinal blockage, in
which case surgery may be required. As an aside, patients
may also require surgery as a result of previous medications having caused severe side effects, or simply because
the medications have stopped working as effectively as
the body adapts and immunizes itself against the medication (Torres et al. 2017).
There are several types of surgeries that can be performed, the most common one being a bowel resection.
This involves the removal of all parts of the damaged intestine and is performed when parts of the small bowel
are diseased or blocked (Simon et al. 2003). A partial
colectomy is another type of bowel resection in which
the surgeon removes the damaged parts of the colon. It
can be performed openly or laparoscopically. When performed openly, the surgeon manually cuts an extensive
incision; alternatively, the surgeon may prefer to work
laparoscopically, making several small incisions, thereby
allowing him to work outside the body. In some instances, a total colectomy is required in which the surgeon
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removes the entire colon. This is generally required only
in severe cases in which the colon is highly inflamed, and
medication is ineffective (Travis, et al. 2011). A colectomy
often requires further procedures to reattach the disconnected portions of the digestive system, thus permitting
waste to leave the body. For example, in some instances,
an ostomy is performed. This surgery is categorized as
a lifesaving procedure as it is performed when stool is
unable to be eliminated from the body through the rectum (Travis et al. 2011). In this procedure, the colon is
removed, and a stoma is created on the abdomen.Wastes
are then allowed to pass through the surgically created
stoma into an ostomy bag, a prosthetic bag which holds
stool and can be emptied regularly.
Common risk factors of these surgeries include bleeding, bowel obstruction, infection and pulmonary embolism.
Methods
Data was collected using ProQuest and PubMed databases through Touro College’s online library. Among the
key-phrases used were “Crohn’s Disease”,“irritable bowel
disorder”, “epigenetics”, as well as “hygiene hypothesis.”
Genetic Factors
There is a significant amount of evidence suggesting that
genetic factors play a key role in the triggers of IBD. Genetic
mutations lead to the body’s defective defense against microbes in the digestive system, allowing the immune system
to attack the lining of the digestive tract, thereby causing
inflammation indicating IBD.The genetic analysis of complex
diseases, such as IBD, is difﬁcult to identify for several reasons. First, the disease isn’t categorized into a single entity,
but rather into groups of heterogeneous disorders, where
environmental and genetic factors play a signiﬁcant role in
disease expression. Additionally, ethnic differences that may
exist between patients suffering with IBD are associated
with different mutations (Bae et al. 2014). Other difficulties
faced include the relatively low frequency of IBD, about .1-.4
percent, amongst populations (Michail et al. 2013); statistics
showing that only about ten percent, ﬁrst-degree relatives
are affected with the same disorder (Sartor, 2006; Pena,
1998); as well as the presence of genes with minor genetic
effects, are some of the difﬁculties faced with when identifying disease susceptibility. Nevertheless, there is an emerging
understanding of the inherited aspects that predispose an
individual to IBD (Newman & Siminovitch, 2003).
The evidence for genetic involvement in IBD comes from
ethnic e.g., Ashkenazic Jews and family-based studies on
blood relatives affected with CD, associations of IBD with
known genetic syndromes, diseases with known genetic
predisposition such as autoimmune diseases, and more

recently through genetic marker studies (Barber GE,Yajnik
V, Khalili H, et al. 2016).Various genetic markers have shown
different levels of correlation with IBD. Some have failed
to show a consistent association with IBD, including blood
groups, secretor status, a 1-antitrypsin, and immunoglobulin
marker genes. Studies on these markers can be divided into
those in which a genetic element is proven and those in
which a genetic predisposition may be present (Pena,1998).
Several polymorphisms in the genes encoding different cytokines and their receptors have been described and are
potential candidates to be studied scientifically.
There are currently multiple studies being carried out
to help identify the genetic mutations, causes, and susceptibility in developing IBD. In addition, technological progress
in genetic testing and DNA sequencing permitted many
genome-wide association studies (GWAS), which helped
identify new single nucleotide polymorphisms (Loddo
& Romano, 2015). Correspondingly, over the past few
decades, there have been significant advances in the understanding of genetic causes linked to IBD. (Newman &
Siminovitch, 2003). The studies described below are population-based studies in areas that extend over a period of
time, making them most likely to give fair, unbiased results.
These studies have conﬁrmed the increased prevalence
of IBD in family members as compared to those in the
general population. These include studies based on twins,
families, and the Jewish Ashkenazic ethnic group.
The data derived from studies performed on twins powerfully supports the view that IBD is linked to a genetic
component. There is a signiﬁcant increase in the concordance of IBD in monozygotic twins compared to dizygotic
twins, particularly with Crohn’s disease. Twin studies for
CD have shown fifty percent concordance in monozygotic twins compared to less than ten percent in dizygotic
twins (Loddo & Romano, 2015). Environment plays only a
negligible role in predisposition for CD. Indirect evidence
supporting the necessity of predisposing genes for the development of the disease in the presence of a common
environment is the low prevalence in spouses of patients
with IBD. Spouses who both suffer from CD, is deemed as
a highly unusual occurrence, as frequent as can be expected by chance alone (Dudley, 1995)
Family-based studies consist of studying linkage analysis
in sibling pairs and parental transmission in genome-wide
screening using microsatellite markers. Microsatellite
markers, otherwise known as simple sequence repeats
(SSRs), which can be defined as segments of DNA where
the nucleotide sequence repeats. Familial aggregation of
IBD has been well documented in North American and
European studies. It is well established that first degree
relatives, particularly siblings, are at much greater risk in
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developing IBD as compared to those in the general population. For example, if one parent has CD, the child has
a ten percent increased risk in developing CD; and even
if both parents suffer from CD, that likelihood increases
to thirty-five percent (Pena, 1998). It has been shown that
siblings of patients suffering from CD experience a seventeen to thirty-five times greater likelihood of developing
CD (Akobeng, 2008).
Another significant study performed on ethnic populations proved that genetic variants are indeed associated
with CD. People of Ashkenazi Jewish heritage have an increased risk and a higher prevalence in developing CD
as compared to non-Jews (Baumgart & Sandborn, 2012;
Newman & Siminovitch, 2003). Several studies have proven that CD is two-to-four times more prevalent among
individuals of Jewish decent compared to non-Jewish
Europeans living in the same area (NewsRX Health &
Science, 2012). Currently, there are seventy-one genetic variants that have been identified in Ashkenazi Jewish
ancestry that increase an individual’s risk of developing
CD. (Baumgart & Sandborn, 2012). In a study performed
examining over six thousand individuals whose Jewish ancestry was confirmed by a large number of genetic markers, several variants were detected that are associated
with the increased risk of CD. The involvement of twelve
recognized CD risk variants in Ashkenazi Jews was confirmed and identified in novel genetic regions, as opposed
to in non-Jewish European populations (Kenny et al. 2012).
Further studies of these regions may aid in the discovery
of biological pathways affecting susceptibility to CD and
lead to the development of innovative and more effective
treatments. This study not only proves the genetic origin
of CD, but also demonstrates the value of genetic studies
in secluded ethnicities, such as the Ashkenazim. Jewish
heritage is an independent risk factor for developing CD.
Genetic anticipation is the earlier onset of a disease in
the offspring of parents with the disorder; a phenomenon
featured in other genetic diseases, it has now been identified in Crohn’s (Polito et al. 1996).
While genetic studies have been highly successful at
identifying the genetic risk factors for CD, these studies
have proven virtually nothing about why one person will
exhibit only mild symptoms of CD while another patient
may require surgery to treat their condition. However, a
familial link is often noticed in the symptoms of related
patients. Researchers recognize that family members with
CD often tend to have similar progress through treatments (NewRX, 2017). Furthermore, researchers looked
at the genome of two thousand seven hundred patients
who shared similar symptoms and severity of CD. By comparing these patient’s DNA, the researchers discovered
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four genetic variants including FOX10, IGFBP1, MHC, and
XACT that influence the severity of a patient’s condition.
Strikingly, none of these genes have been shown to affect
the risk of developing CD.This fact suggests that it is likely
that genetics not only plays a role in the diagnosis of CD,
but in the patient’s prognosis as well (Obesity, Fitness &
Wellness Week, 2017).
Environmental Factors
Although the precise cause for CD is unknown, it’s believed that environmental factors also play a role in
the development of the disease. Several environmental
risk factors, such poor diet, as well as the side effects
of breastfeeding, smoking, stress, and drugs, are believed
to trigger inflammation. Additionally, childhood exposure
towards an overly hygienic environment, seem to allow
CD to manifest in predisposed patients.
Food is believed to promote the maintenance of gut
integrity. Although the direct cause and effect relationship
between the gut microbiota and IBD is unclear, targeting
the intestinal microbiota allows for prevention of disease,
as well as potential research concerning new treatments.
Diet plays a significant role in a patient suffering from
CD, as the body is unable to digest and absorb food appropriately, thereby causing malnourishment in patients
with CD (O’Sullivan, 2009). Furthermore, many patients
with CD are anemic, as well as deficient in vitamin D, folic
acid and vitamin B12 (Torres et al. 2017; Creek, 2017).
Patients are recommended to avoid certain foods such as
raw fruits and vegetables, dairy, fatty, greasy, spicy, and high
fiber foods, as these foods are more difficult for the body
to digest and absorb, and commonly irritate the bowel
(Livie et al. 2006). While it has not been proven that a
poor diet is a direct cause of CD, research has shown a
common thread, that a proper diet is helpful in several
ways by reducing one’s predisposition to developing CD.
Moreover, diet has also been used as a treatment option
for CD (Akobeng, 2012). Similar research has proven that
maintaining a healthy diet is equally as effective in putting
a patient in remission as corticosteroid treatments, particularly in the case of children (BMJ, 1997). Nutritional
repletion is effective both by affecting the gut mucosa
as well as by decreasing intestinal permeability. There is
some evidence that the enteral diet has a direct effect on
the gut mucosa by reducing cytokine production and the
accompanying inflammation, thus leading to decreased
intestinal permeability (Hanaway, 2006).
Breastfeeding promotes colonization with microbiota
such as Bifidobacteria by providing them with the HMOs
(human milk oligosaccharides) they require to thrive.
According to one study, when specific HMOs, GOSs
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(short-chain galactooligosaccharides) and FOSs (long-chain
fructooligosaccharides), were fed to infants in the first six
months of life, they later had fewer incidences of autoimmune reactions linked to gut microbiota, including recurrent wheezing, and allergic urticaria. Accordingly, Crohn’s
which is an autoimmune disease, may be affected similarly
by breastfeeding (Torres, et al. 2017). Maternal secretory
IgA, a component of breast milk has been proven to affect the composition of intestinal microbiota and the expression of genes associated with intestinal inflammation.
Additionally, a negative correlation has been found between
infants’ exposure to breast milk and the development of
early onset IBD, suggesting breastfeeding has a preventative
effect on IBD development (Stiemsma et al. 2015).
While cigarette smoking is notorious for initiating
health risks such as lung cancer and heart disease, it is
believed to play a role in the development of IBD as well.
Although the pathogenesis for IBD is unclear, cigarette
smoking is associated with IBD outcomes as it exacerbates the condition. Analysis of multiple studies has confirmed that active smokers are at increased risk for acquiring CD (Newman & Siminovitch, 2003). Furthermore,
smoking has repeatedly been proven to worsen the prognosis of CD as it promotes a fistulizing phenotype, aggravates disease course, and produces a decreased response
to medical treatment. (Ole et al. 2009). Interestingly, while
smoking has negative ramifications for Crohn’s sufferers,
it may have a protective effect on those with a genetic
disposition towards UC. Active smokers were proven to
be at a lower risk for developing UC in comparison to
those who never smoked and those who quit smoking.
This phenomenon may be linked to nicotinic acetylcholine receptors, which are present in mucosal epithelial
cells of the bowel, as well as on T cells. However, clinical
trials of nicotine replacement in IBD have only yielded a
modest benefit at best; thus, nicotine alone may not be
the driving factor (Ole et al. 2009).
Despite the significant consequences of smoking associated with patients suffering from IBD pathogenesis, the
highest incidence of CD occurs in countries with a low
prevalence of smoking such as United States and Canada
(Rook, 2012). Furthermore, the majority of patients with
CD are not current smokers and the majority of smokers
do not develop CD, proving that smoking or lack thereof
likely plays a role in the pathogenesis of only a subset of
IBD patients (Torres et al. 2017). These studies display little
correlation between smoking and IBD. Nonetheless, all IBD
patients should be encouraged to quit smoking due to the
deleterious negative health effects associated with smoking.
The role of psychological distress and personality as
predisposing factors for the development of CD remains

controversial. The debate concerning this matter has
been ongoing for over eighty years without reaching a
common ground, as attempts to investigate the role of
psychological factors have unveiled conflicting results.
However, over the past several years, it has become evident that psychological stress is at least associated with
CD. However, that stress may be the result rather than
the cause of chronic and longstanding CD. Unpredictable
flare-ups and changes in body image can also lead to additional stress. This stress may precipitate an exacerbation
of the disorder, thus continuing a vicious cycle of flare ups.
Multiple theories have been presented suggesting explanations on the unknown environmental exposures
that may interact with the immune system and result in
abnormal inflammatory intestinal response. However, the
most predominant theory is the hygiene hypothesis, which
explains the link between exposure to specific microbial allergies and the prevention of certain diseases. This
hypothesis theorizes that when one’s childhood has had
excess hygiene and a lack of exposure to enteric pathogens; the child may not develop sufficient immunity towards pollution and environmental contamination. Thus,
it will inevitably impair microbial competence of the GI
immune system and its ability to recognize new antigens,
thereby predisposing children to immunologic disorders
further on in life (Sabe et al. 2017). While the effect of
lack of exposure is believed to be most profound during
early childhood, the ideal timing and degree of exposure
required remains unclear. The hygiene hypothesis also
theorizes that multiple childhood infections and poor hygiene protects and prevents an individual from developing
Crohn’s disease by allowing the host to develop tolerance
or immunity to agents that may trigger Crohn’s disease
later on in life (Stiemsma et sl. 2015). Additionally, it is
entirely probable that the impact of various exposures
are not mutually exclusive; such that disease development
depends on the dose-response interactions between exposures, and this reflects how strongly one’s exposure
may protect or increase the risk conferred by CD susceptibility mutations) (Sabe et al. 2017).
Interestingly, the ﬁrst Crohn’s disease gene identiﬁed,
CARD 15(caspase-activation recruitment) also referred
to as the NOD2 (nucleotide oligomerization domain
gene), found within IBD1 locus is involved with the innate immune system and the response of monocytes
upon perceiving a bacterial encounter. The abnormal
and unconstrained inﬂammatory response that may
occur in individuals with NOD2/CARD15 mutations is
likely to be involved with the pathogenesis of Crohn’s
disease. Polymorphisms in the CARD15/NOD2/IBD1
locus have been associated with the highest risk for CD
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development. Recent evidence shows that polymorphisms
cause reduced functionality of the immune system and
exacerbated phenotype (Newman & Siminovitch, 2003).
Counterintuitively, countries with poor sanitary conditions such as Africa and the Middle East reportedly have
a relatively low frequency of Crohn’s disease (Torres et
al. 2017), while more developed countries such as Canada
and the United States have the highest rates of CD. It is
believed that endemic parasitic infections may favorably
affect the immune system as to prevent disease by stimulating T-helper type2 (Th-2) cells, which in turn downregulate Th-1 cells and prevent the exaggerated Th-1 response associated with Crohn’s disease. Building on this
theory, the ova of Trichuris suis (eggs of a pig whipworm),
have been successfully used to treat Crohn’s disease
patients, as the intake of these parasites elicit Th-2 cells
thereby suppressing Th-1 cells from activating (Guarneret
et al. 2006; Summers, et al. 2005).
Many physicians treating patients with IBD do not believe that stress or diet are direct causes of IBD. Yet, due
to the lack of understanding of the etiology of IBD, no
known direct cause and cure exist for the disease. The
Crohn’s and Colitis Foundation and medical researchers
suggest that foreign substances found in the environment
or external agents such as bacteria may interact with a
weak immune system, thereby producing an immune response of inflammation which the body is unable to stop
(McGovern, Gardet, Törkvist, et al. 2007).
Epigenetics
It has become apparent that epigenetics plays a significant
role contributing to the development of CD. Epigenetics
can be defined as mitotically heritable changes in gene
expression without shifting the DNA. Gene expression
can be altered by changes to the structure and function of
chromatin. Different cells in the body are characterized by
different functions and different levels of gene expression
despite each sharing the same genetic code.This variation
in gene activity from cell to cell is achieved by mechanisms and processes that are collectively termed epigenetics. The main epigenetic mechanisms include DNA
methylation, histone modification, RNA interference, and
the positioning of nucleosomes. These epigenetic mechanisms, in particular DNA, allow the onset and reactivation
of disease that’s triggered by environmental factors that
rapidly break the mucosal barrier, thus stimulating an immune response or altering the balance between beneficial
and pathogenic enteric bacteria. Different genetic abnormalities can lead to similar disease phenotypes; these
genetic changes can be broadly characterized as causing
defects in mucosal barrier function, immunoregulation
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or bacterial clearance. These new insights will help develop better diagnostic approaches that identify clinically
important subsets of patients for whom the natural history of disease and response to treatment are predictable. Methylation appears to be of great importance in
the interaction between genome and the environment.
Variation in DNA methylation is a well-recognized cause
of human disease and is likely to play a pivotal role in the
cause of complex disorders such as CD.
Discussion and Conclusion
Inflammatory bowel disease is sectioned into two divisions,
CD and UC. Both are complex multifactorial disorders
characterized by chronic relapsing intestinal inflammation.
However, the etiology of both diseases remains largely
unknown as it is characterized as an idiopathic disease
(Sartor, 2006). Understanding the causes and molecular
mechanisms of CD and UC is a leading challenge in gastroenterology research, due in part to the relatively low
frequency of these disorders. Although significant effort
has been made to help identify genetic and environmental
factors that may increase the risk of IBD, little is known
about IBD-specific factors. Recent research has suggested
that IBD is caused by a complex interplay between genetic
predispositions of various genes, combined with an abnormal interaction with environmental factors as a result of
a perceived threat. Epidemiological evidence for a genetic
contribution is made apparent by twin and family studies
of CD patients. Genetic variants that stimulate IBD have
a substantial effect on gene function. These variants are
so rare in allele frequency, that the genetic signals aren’t
detected in genome-wide association studies of patients
with IBD. With recent advances in sequencing techniques,
roughly fifty genetic disorders have been identified and
associated with IBD such as osteoporosis as well as thyroid disease. Monogenic defects have been found to alter
intestinal immune homeostasis through many mechanisms.
Candidate gene resequencing should be carried out in early-onset patients in clinical practice.
The evidence that genetic factors are the prime contributors to disease pathogenesis confirms the insignificant
role of microbial and environmental factors. Epigenetic
factors can mediate interactions between environment
and genome. Epigenetic mechanisms could affect development and progression of IBD. Epigenomics is an emerging
field, and future studies could provide further insight into
the pathogenesis of IBD.
References
Akobeng AK. Crohn’s disease: Current treatment
options. Arch Dis Child. 2008;93(9):787. https://search.

Causes and Mechanisms of Crohn’s Disease

proquest.com/docview/1828278440?accountid=14375.
doi: http://dx.doi.org/10.1136/adc.2007.128751.
BAE J, PARK J,YANG KM, KIM T,YI JM. Detection of
DNA hypermethylation in sera of patients with Crohn’s
disease. Molecular Medicine Reports. 2014;9(2):725.
https://search.proquest.com/docview/1933276210?accountid=14375. doi: http://dx.doi.org/10.3892/
mmr.2013.1840.
Barber GE,Yajnik V, Khalili H, et al. Genetic markers
predict primary non-response and durable response
to anti-TNF biologic therapies in crohn’s disease. Am J
Gastroenterol. 2016;111(12):1816-1822. https://search.
proquest.com/docview/1846297739?accountid=14375.
doi: http://dx.doi.org/10.1038/ajg.2016.408.
Baumgart DC, Sandborn WJ. Crohn’s disease. The
Lancet. 2012;380(9853):1590-605. https://search.proquest.com/docview/1139218039?accountid=14375. doi:
http://dx.doi.org/10.1016/S0140-6736(12)60026-9.
Creek Johns. Crohn disease. Smart Engage.Diseases
& Conditions. 2017. https://search.proquest.com/
docview/2084987354?accountid=14375.
Crohn’s disease; researchers discover 5 genetic variations associated with crohn’s disease in ashkenazi
jews. NewsRx Health & Science. Apr 01 2012:3206.
Available from: https://search.proquest.com/
docview/929827099?accountid=14375.
Dietary treatment of active crohn’s disease. BMJ : British
Medical Journal. 1997;314(7097):1827. https://search.
proquest.com/docview/1777563070?accountid=14375.
doi: http://dx.doi.org/10.1136/bmj.314.7097.1827a.
Digestive system diseases and conditions - crohn’s disease; crohn’s disease risk and prognosis determined by
different genes, study finds. Obesity, Fitness & Wellness
Week. Jan 28 2017:1733. Available from: https://search.
proquest.com/docview/1859820888?accountid=14375.
Digestive system diseases and conditions - crohn’s
disease; patent application titled “diagnostic markers for crohn’S disease” published online (USPTO
20170349930). Politics & Government Week. Dec 28
2017:3201. Available from: https://search.proquest.com/
docview/1978949385?accountid=14375.
Digestive system diseases and conditions - crohn’s
disease; researchers from mayo clinic report findings
in crohn’s disease (crohn’s disease diagnosis, treatment
approach, and management paradigm: What the radiologist needs to know). Gastroenterology Week. May 08
2017:278. Available from: https://search.proquest.com/
docview/1895256668?accountid=14375.

Digestive system diseases and conditions - crohn’s
disease; researchers from university of paris detail
findings in crohn’s disease (crohn’s disease mistaken for
long-standing idiopathic mesenteric panniculitis: A case
report and management algorithm). Health & Medicine
Week. Nov 18 2016:1308. Available from: https://search.
proquest.com/docview/1837763373?accountid=14375.
D’Incà R, Caccaro R. Measuring disease activity in
crohn’s disease: What is currently available to the
clinician. Clinical and Experimental Gastroenterology.
2014;7:151-161. https://search.proquest.com/
docview/2224570671?accountid=14375. doi: http://dx.
doi.org/10.2147/CEG.S41413.
Dudley SL. Correlates of uncertainty in inflammatory
bowel disease. [Order No. 9604387]. University of
Maryland, Baltimore; 1995.
Guarner F, Bourdet-sicard R, Brandtzaeg P, et al.
Mechanisms of disease: The hygiene hypothesis revisited. Nature Clinical Practice Gastroenterology &
Hepatology. 2006;3(5):275-284. https://search.proquest.
com/docview/1788525249?accountid=14375. doi: http://
dx.doi.org/10.1038/ncpgasthep0471.
Hanaway P. BALANCE OF FLORA, GALT, AND
MUCOSAL INTEGRITY. Altern Ther Health Med.
2006;12(5):52-60; quiz 61-2. https://search.proquest.
com/docview/204834112?accountid=14375. http://www.
fadidiab.com/site/images/ibd2.jpg. Accessed on October
17, 2019
Kenny EE, Karban A, Ozelius L, et al. A genome-wide
scan of ashkenazi jewish crohn’s disease suggests novel
susceptibility loci. PLoS Genetics. 2012;8(3). https://
search.proquest.com/docview/1313531118?accountid=14375. doi: http://dx.doi.org/10.1371/journal.
pgen.1002559.
Liu S, Miao J, Wang G, et al. Risk factors for postoperative surgical site infections in patients with Crohn’s
disease receiving definitive bowel resection. Scientific
Reports (Nature Publisher Group). 2017;7:1-6. https://
search.proquest.com/docview/1957861512?accountid=14375. doi: http://dx.doi.org/10.1038/
s41598-017-10603-8.
Livie J, Walsh S, Ziyaie D, et al. PWE-047 bowel resections for inflammatory bowel disease in nhs tayside,
scotland: A retrospective study. Gut. 2015;64. https://
search.proquest.com/docview/2043392110?accountid=14375. doi: http://dx.doi.org/10.1136/
gutjnl-2015-309861.496.
Loddo I, Romano C. Inflammatory Bowel Disease:

63

Chana Weis

Genetics, Epigenetics, and Pathogenesis. Front Immunol.
2015;6:551. Published 2015 Nov 2. doi:10.3389/
fimmu.2015.00551
Michail S, Bultron G, DePaolo RW. Genetic variants
associated with crohn’s disease. The Application of
Clinical Genetics. 2013;6:25-32. https://search.proquest.
com/docview/2222905329?accountid=14375. doi: http://
dx.doi.org/10.2147/TACG.S33966.
Newman B, Siminovitch K. Inflammatory bowel disease: Crohn’s disease and the success of NODern
genetics. Clinical and Investigative Medicine.
2003;26(6):303-14. https://search.proquest.com/
docview/196429421?accountid=14375.
Ole HN, Jacob TB, Csillag C, Nielsen FC, Olsen J.
Influence of smoking on colonic gene expression profile
in crohn’s disease. PLoS One. 2009;4(7). https://search.
proquest.com/docview/1291066543?accountid=14375.
doi: http://dx.doi.org/10.1371/journal.pone.0006210.
O’Sullivan M. Session 3: Joint nutrition society and irish
nutrition and dietetic institute symposium on ‘nutrition
and autoimmune disease’ nutrition in crohn’s disease.
Proc Nutr Soc. 2009;68(2):127-34. https://search.proquest.com/docview/227373319?accountid=14375. doi:
http://dx.doi.org/10.1017/S0029665109001025.
Peña AS, Crusius JB. Genetics of inflammatory bowel
disease: Implications for the future. World J Surg.
1998;22(4):390-3. https://search.proquest.com/
docview/995514051?accountid=14375. doi: http://dx.doi.
org/10.1007/s002689900402.
Polito,Joseph M.,,II, Rees RC, Childs B, Mendeloff AI,
al e. Preliminary evidence for genetic anticipation in
crohn’s disease. The Lancet. 1996;347(9004):798-800.
https://search.proquest.com/docview/199038802?accountid=14375. doi: http://dx.doi.org/10.1016/
S0140-6736(96)90870-3.
Rook GA, W. Hygiene hypothesis and autoimmune
diseases. Clin Rev Allergy Immunol. 2012;42(1):5-15.
https://search.proquest.com/docview/914486202?accountid=14375. doi: http://dx.doi.org/10.1007/
s12016-011-8285-8.
Ruthruff, Brenda, MSN,A.P.R.N.-B.C., C.W.O.C.N.
Clinical review of crohn’s disease. J Am Acad Nurse
Pract. 2007;19(8):392-7. https://search.proquest.com/
docview/212890019?accountid=14375.
Sabe VT, Basson AR, Jordaan E, Mazinu M. The association
between environmental exposures during childhood and
the subsequent development of Crohn’s disease: A score
analysis approach. PLoS One. 2017;12(2). https://search.

64

proquest.com/docview/1865761315?accountid=14375.
doi: http://dx.doi.org/10.1371/journal.pone.0171742.
Sartor RB. Mechanisms of disease: Pathogenesis
of crohn’s disease and ulcerative colitis. Nature
Clinical Practice Gastroenterology & Hepatology.
2006;3(7):390-407. https://search.proquest.com/
docview/1788526489?accountid=14375. doi: http://dx.
doi.org/10.1038/ncpgasthep0528.
Simon T, Orangio G, Ambroze W, Schertzer M,
Armstrong D. Laparoscopic-assisted bowel resection
in Pediatric/Adolescent inflammatory bowel disease:
Laparoscopic bowel resection in children. Diseases of
the Colon & Rectum. 2003;46(10):1325-31. https://
search.proquest.com/docview/214068890?accountid=14375. doi: http://dx.doi.org/10.1007/
s10350-004-6742-7.
Stiemsma LT, Reynolds LA, Turvey SE, Finlay BB. The
hygiene hypothesis: Current perspectives and future
therapies. ImmunoTargets and Therapy. 2015;4:143-157.
https://search.proquest.com/docview/2229347032?accountid=14375. doi: http://dx.doi.org/10.2147/ITT.
S61528.
Summers RW, Elliott DE, Urban JF, Thompson R,
Weinstock JV. Trichuris suis therapy in crohn’s disease.
Gut. 2005;54(1):87. https://search.proquest.com/
docview/1779331942?accountid=14375. doi: http://dx.
doi.org/10.1136/gut.2004.041749.
Torres J, Mehandru S, Jean-Frédéric Colombel,
Peyrin-Biroulet L. Crohn’s disease. The Lancet.
2017;389(10080):1741-1755. https://search.proquest.
com/docview/1892784316?accountid=14375. doi: http://
dx.doi.org/10.1016/S0140-6736(16)31711-1.

Is Hyperbaric Oxygen Therapy Effective For Treating Autism?
Malky Meyer
Malky Meyer graduated in January 2020 with a Bachelor of Science degree in Biology. She will attend Touro
Bayshore Physician Assistant program.

Abstract
Autism spectrum disorder (ASD) is characterized as a developmental disability caused by abnormalities in brain function. Studies
link ASD with various physiological abnormalities, such as cerebral hypoperfusion, oxidative stress, inflammation, and mitochondrial dysfunction. Studies show that diminished blood flow to the brain demonstrates a connection between several core autistic
behaviors, and the hypoperfusion generally worsen with age, growing more prevalent in older children. Although hyperbaric oxygen
therapy (“HBOT”) is not yet approved by the United States Food and Drug Administration ) (“FDA”), several studies performed
internationally have proven its efficacy in treating people with autism. Even so, the FDA does approve of its use for other medical
conditions such as decompression sickness (the bends) experienced by divers, treatment of air or gas embolism, carbon monoxide
poisoning , and thermal burns. Hyperbaric oxygen therapy chambers expose the patient to 100% oxygen (unlike the 21% oxygen
found in the air we breathe) by increasing the air pressure in the chamber up to three times higher than normal air pressure of
1 atm. This allows the lungs to take in more than the expected amount of oxygen and thus be distributed throughout the body
to the cells that are deprived of oxygen. This paper examines the effectiveness of HBOT in children with ASD, by reviewing the
available research.
Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by “persistent deficits in social
communication and social interaction across multiple
contexts and restricted repetitive patterns of behavior,
interests, or activities,” (APA, 2013). ASD includes autistic
disorder, pervasive developmental disorder, and Asperger
syndrome. Approximately 1 out of 110 people in the
United States are currently affected by ASD (Rice, 2006).
The cause of ASD is unclear. Although several genetic
syndromes, such as Fragile X and Rett syndromes, have
been linked with ASD, the majority of ASD cases are not
due to a simple single gene or chromosomal disorder;
studies have estimated that genetic syndromes only account for 6-15% of ASD cases (Schaefer & Mendelsohn,
2008). Recently, research and clinical studies in ASD have
linked physiological abnormalities, such as cerebral hypoperfusion, inflammation, oxidative stress, mitochondrial
dysfunction and immune dysregulation (Rossignol & Frye,
2012). With this perspective, ASD may consist of physiological irregularities rather than merely a CNS disorder
(Herbert, 2005). Treating ASD is not a simple matter;
there are a limited number of treatments. The behavioral
aspects of ASD are manageable with the help of behavioral therapies. Applied behavioral analysis (ABA), specifically,
has been proven to lead to advances in certain children
with ASD. In two years, ABA brought about remarkable
improvements in the IQ and behavioral issues of several
children with ASD (Lovaas, 1987). After four years, ABA
researchers at the Wisconsin Early Autism project found
analogous results of improved IQ and behavior (Sallows
& Graupner, 2005). Conversely, researchers in Norway
found that eclectic therapy (a form of psychotherapy)
was successful in the treatment of children with ASD
who were observed for only one year.The results proved
to supersede the effective outcomes of ABA (Eikeseth,
et al., 2002). When it comes to cognitive and behavioral

transformations in children with ASD, behavioral therapies are not an ideal approach, as they are quite time demanding. Additional treatments for ASD that aim to treat
physiological irregularities have been conveyed, yet, a
majority of these forms of treatments have not been critically assessed. However, many studies were performed
to test the effects of HBOT to treat the physiological abnormalities possessed by people with ASD, many of which
have shown promising results.
Methods
The research incorporated in this paper was retrieved
from original research papers and scholarly articles obtained through Touro College’s library of databases, such
as ProQuest and EBSCO. Google scholar, and PubMed
were also used to acquire data. The articles chosen were
critically assessed, compared, and analyzed to evaluate if
hyperbaric oxygen therapy is effective for treating autism
History of Hyperbaric Chambers
Hyperbaric air or “air under pressure” is a medical treatment that dates back over 150 years. In 1662, a British
physician created a sealed chamber in which the air was
compressed and decompressed using valves and oxygen.
This was extraordinary;it preceded the discovery of
oxygen and was utilized as a treatment for respiratory
diseases (Clarke, 2008). The idea of employing pressurized environments developed further in 1879, when the
French surgeon, Fontaine, built a pressurized mobile operating room. He observed that inhaled nitrous oxide
had greater efficacy when used under pressure. Patients
treated in an increased pressure environment were
not as cyanotic as those treated in standard conditions.
Additionally, his patients experienced improved oxygenation (Fontaine, 1879). In the early 1900’s, Dr. Orville
Cunningham, a professor of anesthesia, found a greater
improvement in heart disease victims when they resided
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closer to sea level than when they were living at higher
altitudes. Later, hyperbaric chambers were utilized by the
military, in the 1940’s, to treat deep-sea divers who experienced decompression sickness. In the 1950’s, physicians
first used HBOT during lung and heart surgery, which
steered to its use for carbon monoxide poisoning in the
1960’s. Since then, over 10,000 clinical trials and case
studies have been achieved for several other health-related purposes, with the great majority reporting successful
outcomes (Ohnishi, et al. 2000).
Hyperbaric oxygen therapy (HBOT)
Hyperbaric oxygen therapy (HBOT) is the medical use
of oxygen in a pressurized environment, and involves
breathing 100% oxygen while inside a hyperbaric chamber that exhibits pressures greater than sea level (1 atmosphere). The increased pressure permits oxygen to
dissolve and saturate the blood plasma (autonomous of
hemoglobin), which yields an extensive array of valuable
physiological and cellular outcomes. This noninvasive
therapy is the most reliable way to provide ample oxygen
to all organs of the body. The standard treatment lasts
for 60-90 minutes, during which the patient lies down
and breathes regularly (Feldmeier, 2003). The use of hyperbaric oxygen treatment (HBOT) was implemented
as a treatment method for numerous clinical disorders.
It has been proven in several clinical studies to enhance
the body’s inherent ability to regenerate and repair. It is
used as a therapy to facilitate the healing process in both
chronic and acute disorders. Decompression sickness,
stroke victims, arterial gas embolism, healing of wounds,
severe carbon monoxide poisoning and smoke inhalation
are only some of the common uses of HBOT. However,
in 2005, researchers began to consider using HBOT to
improve behavioral and physiological abnormalities found
in individuals with ASD (Leach, et al. 1998). This paper will
evaluate the current data on treating ASD with HBOT.
First, the effects of HBOT on physiological irregularities
in children with ASD will be evaluated. Then, the effects
on autistic behaviors will be examined. Finally, the apparent contrary effects of HBOT in ASD and restrictions of
studies will be assessed.
Cerebral Hypoperfusion in ASD and the Effects
of HBOT
Cerebral hypoperfusion is characterized as insufficient
blood flow in the brain and is one of the common physiological abnormalities possessed by individuals with ASD.
Positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) were used in
studies to discern hypoperfusion exhibited in the brains of
66

people with ASD versus normal healthy brains (Bjørklund,
et al. 2018). Both PET and SPECT scans are types of nuclear imaging tests that utilize radioactive tracers to create three-dimensional images. However, they differ in the
radiotracers used. Studies have proven these scans to be
a reliable measure of cerebral blood flow in observing
what areas of the brain are receiving more blood flow.
(Amen, et al. 2011; NIH CC, 2002). Common autistic
behaviors such as need for consistency (Ohnishi, et al.
2000), habitual behaviors (Starkstein, et al. 2000), disability
in processing emotions and facial expressions (Critchley,
et al. 2000), and delayed language development (Wilcox,
et al. 2002), are linked to hypoperfusion. Moreover, hypoperfusion is related with increasing age in children with
ASD (Wilcox, et al. 2002). It is possible that HBOT could
improve cerebral hypoperfusion in ASD. Numerous studies were completed that evaluated the effects of HBOT
to treat various neurological disorders, such as chronic
brain injury and traumatic brain injury. The results of the
SPECT scans were evaluated before and after the delivery of HBOT at low pressures (1.3 to 1.5 atm). These
studies showed significant results (Harch, et al. 2012),
(Golden, et al. 2002). Histograms correlated to the pre
and post SPECT scans were analyzed with a widely used
medical images software called Osirix DICOM. Results
from both scans showed significant pattern differences
beneath the cerebral cortex in the central area of white
matter, known as the centrum ovale. The pre-HBOT images displayed a larger array of counts in the histograms
than in the post-HBOT. The narrower range of counts in
the post-HBOT corresponded to the increase of perfusion to the lacking areas. The effectiveness was studied
through many areas in addition to SPECT: physical exam,
symptoms, and psychological measurement (Harch, et al.
2012). Moreover, numerous case studies have reported
enhancements in cerebral perfusion after HBOT treatment. One study involved a child with ASD who received
one hour of HBOT at 1.3 atm and 24% oxygen per day for
ten days (Heuser, et al. 2002). The SPECT scans revealed
increased perfusion. However, the effects of ten treatments only lasts several months. For longer lasting effects
(6-18 months) more treatments are necessary (20-60
treatments). Behavioral improvements were detected in
this child including cognitive and memory functions. The
child became sympathetic, started to point and articulate,
and interact with others. Another child with ASD, who
received 40 treatments of HBOT at 1.3 atm and 24%
oxygen, also presented behavioral improvements, such
as, improvements in speech and communication and fine
motor skills (Rossignol, 2008).
Another study involved 108 children with ASD who
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experienced decreased perfusion in their temporal lobes
as measured by SPECT scans (Kinaci, et al. 1970). They
received HBOT at 1.5 atm with 100% oxygen for an hour
a day for 50 days. After their treatments, SPECT scans
revealed that 82.40% showed improvements in their
temporal lobes, 85.26% in their frontal lobes, and 75.75%
in other areas. Furthermore, clinicians did an Autism
Treatment Evaluation Checklist (ATEC) on 54 of the individuals and significant improvements were noted: 85.5%
in Sociability, 79% in Speech/Language/Communication,
75.2% in Health/Physical/Behavior, and 87% in Sensory/
Cognitive Awareness. This study revealed major improvements in the physical, behavioral and cerebral perfusion of
children with ASD after HBOT (Kinaci, et al. 1970). This
study is reliable due to the large sample size, unbiased
SPECT imaging, and therapist assessments.
Oxidative Stress in ASD and the Effects of HBOT
Oxidative stress is defined as an imbalance between the
production of reactive oxygen species (free radicals) and
antioxidant defenses. Some children with ASD experience
oxidative stress. Some researchers believe that HBOT indirectly causes an increase in oxidative stress due to the
amplified production of reactive oxygen species (“ROS”)
from the elevated oxygen levels (Alleva, et al. 2005).
Therefore, they are reluctant to use HBOT on children
with ASD, since some of them already have elevated oxidative stress levels (Rossignol, et al. 2007). A contributing
factor to their increased oxidative stress levels might be
due to the excessive amounts of oxygen supply to their
cell’s mitochondria, which can escalate the production of
ROS. In contrast, HBOT has proven to upregulate antioxidant enzyme production that can aid with detoxification
issues found in children with ASD such as glutathione
peroxidase, superoxide dismutase (Gulec, et al. 2004),
and catalase (Nie, et al. 2006). The antioxidant enzyme
level increase can protect against harm initiated by ROS
(Rossignol, 2007). Additionally, minor elevations in ROS
created by HBOT can be advantageous, as they increase
mitochondrial biogenesis (Gutsaeva, et al. 2006).
Two studies have observed the influences of HBOT
on oxidative stress in children with autism (Audhya,
2007; Rossignol, et al. 2007). The first study included administering HBOT at 1.3 atm daily to 48 children with
autism. Catalase, glutathione peroxidase and superoxide
dismutase (SOD) levels were screened before beginning
HBOT and again after day 1 and day 32 of HBOT (Audhya,
2007). Results demonstrated a 1.9-fold increase of the
original catalase levels after the first day and a 90% improvement after 32 days. Glutathione peroxidase showed
a 1.4-fold increase after 1 day and a 1.2-fold increase after

32 days from the initial HBOT. Finally, a 4.5-fold increase
of SOD was observed after 1 day and a 4.7-fold increase
after 32 days of starting HBOT. The results of HBOT on
antioxidant enzymes can be considered conditioning.
The second study involved 18 autistic children from
ages 3-16. This open label, prospective study included administering 40 treatments of HBOT, with 24% oxygen, at
1.3 atm, to 12 children, and 100% oxygen at 1.5 atm to 6
children. Blood markers were taken before and after 40
treatments (Rossignol, et al. 2007). Researchers noticed
dramatic improvements in speech, socialization, GI function, and strength. The effects persisted months after the
study was completed. Furthermore, insignificant changes were seen in plasma-oxidized glutathione levels. This
proves that oxidative stress markers did not worsen because oxidized glutathione is transported from within the
cells when intracellular levels surpass the redox capacity
(Dickinson and Forman, 2002). However, the intracellular oxidative stress levels in the children with ASD did
not diminish with the lower HBOT pressures (Rossignol,
et al. 2007). The open-label nature of this study and the
two diverse treatment groups (one group who received
24% oxygen at 1.3 atm versus the other group who received 100% oxygen at 1.5 arm), as well as the absence
of a control group, are some of the limitations of this
study. Nonetheless, the prospective nature of this study
strengthens it.
Inflammation in ASD and the Effects of HBOT
Some individuals with ASD experience inflammation, such
as neuroinflammation, gastrointestinal inflammation and
immune dysregulation as supported by recent studies.
Numerous studies have conveyed atypical inflammatory
indicators in children with ASD. For instance, increases
in Tumor Necrosis Factor-alpha (TNF-alpha) (Chez, et al.
2007), and neopterin (cellular immune system activation
marker) (Messahel, et al. 1998), were related in studies
of children with ASD. Additionally, studies showed that
children with ASD, who reported having gastrointestinal
inflammation, have analogous symptoms to one suffering
from inflammatory bowel disease (IBD) (Ashwood, et
al. 2003). Anti-inflammatory results were reported after
treatment with HBOT. A decrease in pro-inflammatory
cytokines (including TNF-alpha, IL-1 and IL-6) (Weisz, et
al. 1997), and an increase in counter-inflammatory IL-10
levels were reported after HBOT (Buras, et al. 2006).
Moreover, improvements in IBD were reported in a
systematic review that used HBOT (Rossignol 2012).
A study reported a decrease in production of interferon-gamma by lymphocytes with HBOT at 2.0 atm/10.5%
oxygen, but an increase in interferon-gamma with 100%
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oxygen administered at 1.0 atm (Granowitz, et al. 2002).
Therefore, it is concluded that the result of HBOT on
reducing inflammation is facilitated through the pressure-related component and not particularly on the delivery of oxygen.
Unfortunately, a series of recurring events can cause
amplified inflammation which can lead to escalated cerebral hypoperfusion. This may cause hypoxia, which leads
to production of HIF-1a (hypoxia-inducible factor-1alpha)
which induces inflammation (Nathan, 2003). HIF-1a is
fundamental in the innate immune system, as it triggers
inflammation by myeloid cells (Cramer, et al. 2003).
The effects of HBOT on biomarkers of inflammation
in children with ASD were inspected in two prospective
studies. The first study included 12 children who were
given 40 treatments of HBOT at 1.3 atm/24% oxygen
and 6 children who were given HBOT at 1.5 atm/100%
oxygen. Biomarkers were measured before and after the
treatments by testing the participants’ blood specimens
taken before and after the treatments (Rossignol, et al.
2007). Improvements were seen in C-reactive proteins
(non-specific inflammation markers), as their levels decreased in the total study population (p=0.021).The most
significant decrease was seen in children with the highest
levels of C-reactive proteins prior to the study. These
children also showed behavioral improvements. SRS
(Social Responsiveness Scale), ABC-C (Aberrant Behavior
Checklist – Community), and ATEC (Autism Treatment
Evaluation Checklist) were filled out by the parents and
were used to calculate the scores for each child before
and after their treatments.
The second study measured plasma cytokine levels, including some related to inflammation prior to and after
HBOT.Ten children with ASD participated in this 20 week
study with 80 sessions of HBOT given to them at 1.5
atm/100% oxygen (Bent, et al. 2012). Although the study
reported behavioral improvements, negligible modifications were observed in cytokines. Yet, the authors mentioned that none of the children actually had irregular
cytokine levels prior to the study, so notable variations
could not be seen.
In another study, a child with ASD who suffered from
eczema and bowel inflammation, with a distended abdomen, displayed significant improvements after 40 treatments of HBOT at 1.5 atm and 100% oxygen over the
course of a month (Rossignol 2008).
Mitochondrial Dysfunction in ASD and the
Effects of HBOT
Mitochondrial dysfunction is observed in some people
with ASD (Rossignol & Frye, 2011; Frye & Rossignol, 2011).
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HBOT is considered a possible treatment for mitochondrial dysfunction, although treatments for this condition
are minimal (Rossignol & Frye, 2011). The outcomes of
HBOT on mitochondrial dysfunction were measured in
various studies.
In a controlled study HBOT at 1.5 atm and 100%
oxygen was administered to 69 patients who obtained
severe traumatic brain injury (TBI), within 24 hours of injury. Significant increases in brain oxygen concentrations
were seen, as well as increases in cerebral blood flow
and reduced CSF lactate levels (elevated CSF lactate is
an indicator of mitochondrial dysfunction). Results also
showed improvements in mitochondrial function and
brain metabolism after contrasting both room air treatment of 21% oxygen and 100% oxygen given at normal
pressure (1 atm) (Rockswold, et al. 2010).
HBOT can make more electron transport chains in
mitochondria. In 2008, a study was conducted on healthy
rat tissue (Kurt, et al. 2008). HBOT was done on the rat
and the tissues were looked at before and after the treatment. Results showed that the mitochondria were working more efficiently. Mitochondria work more efficiently
through physical exercise. During exercise, the cells are
stressed and mitochondria are making more electron
transport chains. Similarly, with HBOT, the cells are slightly stressed and they make more electron transport chains
thereby working more efficiently and experiencing less
oxidative stress.
Furthermore, a study was conducted in 2006, which
showed it is possible to increase the number of mitochondria in the brain cells of rats. This phenomenon is
called mitochondrial biogenesis (Gutsaeva et al. 2006).
This was not demonstrated in humans, because it would
require risky brain biopsies to be performed on patients.
This can be one possible mechanism as to why HBOT is
working. Although these results seem promising, no clinical studies were performed to test the effects of HBOT
on mitochondrial dysfunction in children with ASD.
Behavioral Measurements in ASD and the Effects
of HBOT
Most of the studies performed using HBOT for children with ASD have inquired behavioral rather than
physiological factors. In a current systematic review,
two double-blind, arbitrary, controlled trials were reviewed regarding the use of HBOT in children with ASD
(Ghanizadeh, 2012).The first study examined the outcome
of giving 33 children with ASD, 40 treatments of HBOT
with 24% oxygen at 1.3 atm, which included 2 treatments
each day for 5 days a week, over the course of 4 weeks.
This study was performed in comparison to 29 control
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children with ASD who were given room air that was
slightly pressurized (1.03 atm/21% oxygen) (Rossignol, et
al. 2009). Noteworthy improvements were detected in
the treated children on the ATEC scales (questionnaire
that measures changes in severity of ASD in response to
treatment) by the caregiver, as well as on the CGI scales
(Clinical Global Impression rating scales: measures the
severity of symptoms, treatment response and the effectiveness of treatments) by the clinicians and parents. The
results showed improvements in language, eye contact,
cognitive attentiveness and overall functioning. Strengths
of this study comprise of the involvement of 6 medical
centers (which limited possible biases correlated to a
specific site study), assessments by blinded parents and
clinicians and the use of a control group.
The second study examined the outcome of giving 18
children with ASD, 80 treatments of HBOT with 24% oxygen at 1.3 atm, within a 15 week duration. These results
were compared to 16 children who were treated with a
placebo, involving air flowing through a chamber at normal
pressure. Subsequently, ABA therapy was given to both
groups, yet insignificant changes were observed using various behavioral scales (Granpeesheh, et al. 2010). These
undesirable results can be attributed to the fact that rigorous ABA therapy was given during the administration
of HBOT which did not seem successful (Ghanizadeh,
2012). On the other hand, this study is reliable because of
the blinded evaluators as well as the control group. The
contrasting results can be ascribed to the discrepancies
among the two controlled trials (Ghanizadeh, 2012). For
example, the age and quantity differences of the participants, as well as the magnitude of treatments. One study
delivered 10 hours of HBOT per week (Rossignol, et al.
2009). While the other study provided 5 hours per week
(Granpeesheh, et al. 2010). There were also probable distinctions in ASD severity.
Antagonistic Properties of HBOT in ASD
Among the many studies performed, minimal unfavorable
outcomes were reported of HBOT usage for people with
autism. One study stated that “HBOT was safely administered to autistic children and all participants were able
to finish 40 HBOT sessions without any major adverse
events” (Rossignol, et al. 2007). A different study informed
minor antagonistic effects, including 4 kids with earaches,
2 kids with otitis media and other individuals who were
autonomously affected with insomnia, seizures, lethargy,
amplified vocal sensitivity and hyperactivity (Bent, et al.
2012). In a controlled study, one of the participants experienced frequent urination and a skin rash which the
doctor attributed to yeast as the causing factor. Other

participants withdrew from the study, specifically one
child who experienced regressing symptoms of asthma after several HBOT treatments. The physicians did
not think the two were related, but removed the child
as a safeguard. Another child withdrew from the study
before completing it due to anxiety. One participant in
the control group experienced diarrhea and abdominal
swelling, yet still completed the experiment. In addition,
another control group participant experienced worsening of pre-existing eczema. Seizures or barotrauma,
however, were not detected in neither the treatment nor
control groups (Rossignol, et al. 2007). In a study performed on the effects of HBOT in Thai autistic children,
it was reported in the data analysis that “there was no
serious adverse effect in any case and tinnitus was a mild
side effect in one case and it went away in one week”
(Chungpaibulpatana, et al. 2008).
According to the FDA, “patients receiving HBOT are
at risk of suffering an injury that can be mild (such as
sinus pain, ear pressure, painful joints) or serious (such
as paralysis, or air embolism). Since hyperbaric chambers
are oxygen rich environments, there is also a risk of fire”
(FDA commissioner, 2013) .
Restrictions of the Studies Performed
Most of the studies performed contain restraints that
contribute to the erratic results among them, including
the retrospective approaches, the absence of control
participants and the minimal amount of participants.
Moreover, the open trials increase bias, as both the participants and the researchers are aware which treatment
is being given. However, two of the controlled studies did
not contain these restraints. Furthermore, other studies
utilized observational methods which are not efficient
when analyzing modifications in memory and attentiveness (Jepson, et al. 2011). Unfortunately, the long-term
effects of HBOT are unknown because once the study
was complete researchers did not follow up on the
long-lasting effects. Additionally, a majority of the studies
focused on behavioral modifications rather than physiological modifications. Earlier studies proved that ABA
therapy in individuals with autism is only effective when
done over a substantial period of time. For example, ABA
therapy studies displayed significant behavioral changes
over a one to four year duration (Lovaas, 1987; Sallows &
Graupner, 2005).
It is common for the physiological modifications seen
in autistic children treated with HBOT to be observed
before intellectual and developmental enhancements due
to the intricacies of brain maturation. Studies have found
significant physiological improvements after a short time
69

Malky Meyer

in participants who were treated with HBOT, specifically
modifications with cerebral hypoperfusion. While most
of the studies noted behavioral enhancements in several children with autism, the studies only persisted for a
few months. This short duration of time is not enough
to determine the influence HBOT has on development.
Further studies are necessary to investigate the long lasting results of HBOT in people with autism.
Many studies noted behavioral and physiological advances when treating autistic children using HBOT. Yet,
noteworthy developments were not found when researchers from a common group performed two studies
(Granpeesheh, et al. 2010; Jepson, et al. 2011), and insignificant results were noticed in a different minor study
(Lerman, et al. 2009). The inconsistent outcomes among
the studies may be attributed to the autistic children’s
opposing responses to HBOT (Jepson, et al. 2011). To
illustrate, children who possess certain physiological abnormalities such as mitochondrial dysfunction, cerebral
hypoperfusion and inflammation might be more prone to
display improvements. Nevertheless, most of the studies
performed to test behavioral aspects did not analyze the
chemical aspects such as levels of oxidative stress or inflammatory markers. However, one behavioral study did
analyze alterations in the levels of cytokine, but insignificant modifications in cytokines were seen because all the
participants already had regular cytokine levels prior to
their HBOT treatment (Bent, et al. 2011).
Further investigation is required including participants
with ASD who possess specific physiological abnormalities and which analyze variations in these physiological
issues such as cerebral hypoperfusion and inflammation.
Noteworthy improvements were related in studies which
administered HBOT sessions more frequently. This also
seemed true in studies that used HBOT to treat patients
with traumatic brain injuries, (Harch, et al. 2012). More
studies, however, are needed to analyze several HBOT
factors, such as the ideal oxygen and pressure limits required to treat patients with ASD.
HBOT in Thailand
In 2008, the first study in Thailand was performed to determine the effects of HBOT to treat autistic children and
whether it is safe or not (Chungpaibulpatana, et al. 2008).
The study included 7 Thai autistic children who received
10 sessions of HBOT once a week at 1.3 atm. Before and
after the treatments, five areas were evaluated: “1. Social
development 2. Fine motor and Eye-hand coordination 3.
Language development 4. Gross motor development 5.
Self - help skills” (Chungpaibulpatana, et al. 2008). Results
showed advances within these five domains with 75% of
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children who displayed progress while 25% showed no
reaction to the treatment.
FDA Approval
Although HBOT is currently being used as a treatment
method to treat various disorders in Thailand such as
autism, it has not been clinically verified or cleared by
the FDA to cure or be successful in the treatment of autism, cancer, or diabetes (FDA, 2013). However, the FDA
did approve the use of HBOT for several other conditions. These include “treatment of air or gas embolism
(dangerous ‘bubbles’ in the bloodstream that obstruct
circulation), carbon monoxide poisoning, decompression
sickness (‘the bends’), and thermal burns (caused by heat
or fire),” (FDA, 2013).
Disadvantages
Dr. Paul Claus, medical director of Mayo Clinic’s
Hyperbaric and Altitude Medicine Program, relates risk
factors of HBOT. The increased oxygen of the chamber
supports combustion which poses a risk for fires in the
facility. Therefore, necessary precautions are taken. The
patients are required to remove their street clothes since
polyester is fuel for fire. The patients are provided with
cotton blend clothing instead.Additionally, the treatments
are quite expensive; they are approximately $1,500 an
hour in most hospital settings (Claus, 2017). However,
if more studies are done documenting improvements of
HBOT, then hopefully the cost will be covered by the
healthcare system or insurance companies to further
benefit those with autism. .
Conclusion
“There is no one-answer for many questions but there
are many answers for one question. Multiple factors are
the possible causes of autism.The curative factors may be
from multidisciplinary approaches,” (Chungpaibulpatana,
et al. 2008). Numerous studies have demonstrated that
HBOT is an effective treatment for children with autism.
The pressures utilized during treatment with HBOT (1.5
atm/100% oxygen maximum) are proven to improve the
common physiological abnormalities in individuals with
ASD; such as, cerebral hypoperfusion, oxidative stress, inflammation and mitochondrial dysfunction. Furthermore,
studies that targeted the behavioral measurements in
ASD also showed positive results even though most of
those studies did not use control groups.The two studies
that did utilize control groups however related opposing
outcomes. However, multiple crucial variations between
the trials were noted. Taken together, the studies imply
that the use of HBOT in children with autism correlates
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with marginal antagonistic effects and is handled well. In
conclusion, HBOT is a harmless and possibly beneficial
treatment for kids with autism. However, additional studies are necessary before it can become an internationally
accepted treatment method. Future studies should be
more specific and directed towards the specific physiological abnormalities within the various ASD subdivisions
and should use control groups as well to promote efficiency and determine which people can gain from HBOT
treatment. Furthermore, why don’t the hospitals in
Thailand publish anything regarding their routine HBOT
usage? They value intellectual property not academic
publications. If it were not more clinically effective than
the use of HBOT would not be used regularly and its
ineffectiveness would spread like wildfire. Based on the
studies performed, overall, the use of hyperbaric oxygen
therapy appears to be a promising treatment for children
with ASD.
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Abstract
With obesity on the rise, and subsequently numerous diseases, many people are looking for newer ways to counter the effects of the
influx of fatty, high sugar and unhealthy foods they are consuming. The most common and widely used method is a diet plan. The
key to both a healthy and effective diet is knowing what the diet does to the body. There are short term diets which have adverse
effects if kept for too long and long-term diets which are aimed for a healthy lifestyle. Every diet is based on the increased and
decreased consumption of different macronutrients and therefore, each affects the body differently. The Ketogenic Diet is a high fat
consumption diet that is gaining credence from its success rate. However, due to it being a relatively new diet fad, there are not too
many who understand the long-term adverse effects of a high fat diet.
Introduction
We live in a world of instant gratification. Smart phones,
smart cars and smart homes are the new social norm.
Another idea of the now world we live in is takeout food.
Instead of preparing meals, one can be picked up or even
delivered to your home at minimal charge. This would
seem to be useful for person who is too busy to cook but
is leading to a major problem in western culture – obesity. With obesity on the rise, many people are looking for
newer ways to counter the effects of the influx of fatty,
high sugar and unhealthy foods they are consuming. The
most common and widely used method is a diet plan.
The word diet is simply the amount of food or drink
a person consumes. When people speak about a diet
though, they are referring to a special course of controlled or restricted intake of food and or drink for a
particular purpose. Magazines, websites, and health moguls are promoting new diets and fads almost daily. It has
reached a point where weight loss has become a societal pressure leading people to come up with numerous
‘quick fix’ diets to lose the ‘excess’ weight so as not to
deviate from society.
Aside from body image concerns, there are many
chronic illnesses that are related to obesity. To name a
few, hypertension, diabetes, joint pain, and cardiovascular
diseases, such as an acute myocardial infarction, are all
largely products of unhealthy chosen lifestyles and poor
dietary habits.While there are certain diets that are great
in preventing, or at least not promoting, various diseases
they are mistakenly used by healthy individuals who are
possibly harming themselves as they are unaware of the
side effects.
The aesthetics of being leaner and thinner have become
the idol of, and completely overtaken, the views of almost
every individual today. It has become such an obsession
that new diet plans are arising daily. Some plans are more
beneficial than others and some are just fads, but they are
all developed on the same basis of energy expenditure.
To start with, the two biggest fat loss myths must be
disproven. First, calorie counting does not work. For
those who want nothing more than to hear that they can
get lean and fit by only paying attention to what they eat
and not how much, this idea is what they thrive on. This
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is total fools play since how much you eat is significantly
more important than what you eat. For example, John
Cisna, a science teacher, lost 60 pounds in six months
eating food bought solely from McDonalds every day. He
wanted to burst the lie that people believe about food
intake. While his diet plan may not have been too nutritious, it proved that you can lose weight by eating whatever junk food you would like as long as you are minimizing
your calorie intake (Peterson, 2015). This kind of plan
will give the wanted weight loss; however, such an eating
regimen will slowly affect his visceral health if it is kept
up. These types of fast foods are high in fat without many
vitamins which can cause, amongst many other issues,
high cholesterol levels and high blood pressure due to the
buildup of plaque and therefore narrowing of the arteries.
The proper way to diet is to have a plan that is both balanced as well as nutritious. A balanced plan is consuming
the proper percentage of both macro and micronutrients.
Nutritious foods are ones that are rich in those nutrients
that are needed daily for an organism to uphold its proper functions. Food is the material we take into our bodies
to nourish it with the (hopefully) proper nutrients and
other substances it needs for energy, health, and growth.
Macronutrients are the substances our bodies require in
large amounts. Namely protein, carbohydrates, and fats.
There are also some minerals needed in relatively large
quantities, but this paper will focus on fats, carbohydrates
and protein as most diets pertain to altering the consumption of one of such food groups.
Secondly, it is important to understand the one most
important thing about weight loss. It comes down to
energy balance which is the correlation between energy
intake and energy expenditure (Lean, Astrup, & Roberts,
2018). Put in more than you take out and you will have
an excess amount of energy meaning you will gain weight.
Eat about as much as you burn daily, and your weight
will stay the same. Take in less energy than you use and
there will be a deficit and you will lose weight. This is
not some wild un-based theory either. According to the
first law of thermodynamics, energy cannot be destroyed
nor created, but can only change its form within a system.
Our bodies absorb the food we eat and transform the
stored energy into energy we can use. Muscles convert
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the stored energy for mechanical energy, digestive system
for body fat (chemical energy) and our organs convert
energy into thermal energy. This is evidence how energy
is never lost, but rather converted to the form each part
of our body needs based on demand.
The process of our body transforming the food we intake to usable energy is one of the purposes of energy
expenditure. Energy expenditure (EE) is the amount of
energy that a body needs to carry out its physical and
physiological functions and is measured in calories. It is
the combination of a basal metabolic rate (BMR) or standard metabolic rate (SMR) and their activity level. Basal
metabolic rate represents the minimum energy expenditure for a resting and fasting animal at thermoneutrality
(Nilsson & Nilsson, 2016). This means BMR is the lowest sustainable energetic (caloric) cost required to keep
one’s body functioning at rest. Activity level is movement
that requires additional energy aside from one’s BMR.
Activity level is not only pumping iron five days a week
at the gym, it is also taking the stairs rather than the elevator during the day, mowing the lawn, changing a tire,
or pushing a shopping cart. The more physical activity a
person is involved in, also adds to a greater amount of
energy a person expends and therefore the more s/he
needs to consume.
Aside from physical activity there are other factors that
play a role in determining a person’s BMR - gender, body
mass index, age and yes, even genetics. Due to these various factors, nutritional requirements differ from person to
person and are therefore evaluated based on kilogram of
body weight and every person will alter the amount based
on their energy exertion during both health and disease.
It should come as no surprise then that consuming less
energy than your body requires for a couple weeks or
months would account for less energy in the body and
therefore a leaner and leaner body type. Since energy
balance has been proven to be the basic regulation for
weight loss and weight gain it is found at the baseline of
every proper diet plan.
In addition to dieting, it is both scientifically proven
as well as seen in people’s success that exercise in synchrony with a healthy diet plan is the most advantageous.
Individuals who exercise along with being careful with
what they eat will lose weight. They expend more calories than they take in daily and the deficit results in a loss
of body weight. The Cleveland Clinic agrees and explains
why exercising without a diet plan is not too effective for
weight loss (Team, W., 2018). They state that in order
to lose weight one of two options must be done; either
one must burn more calories by working out than s/he
consumes in one day or take in fewer calories alone than

one’s body uses daily. To summarize, putting one’s body
into an energy deficit will cause weight loss and this is the
basis for the majority of diet plans.
The two main types of diets are long-term plans and
short-term plans. Long term diets aim to benefit a person’s healthy well-being for the long haul. The results
may not be instantaneous, yet the programs are easier to
follow. These diets do not restrict a certain food group
completely which prevents the process from becoming
too arduous for someone who thinks that diets are restraining. The overall objective is a healthy lifestyle.
Alternatively, short term diets are the quick fixes.
These diet plans usually see results within a week of following them. Diets that fall under this category are ones
where quick weight loss is desired for aesthetic looks or
necessary in preventing larger health issues, like cardiovascular disease or diabetes. These usually entail many
restrictions which aside from making the dieter unwilling
to stick with the plan, it makes them unhappy to comply
with the rules.
One severe version of a short-term diet is known as
crash dieting. These diets are severely low total calorie plans and are sustainable for a couple weeks at most.
They are mostly used by bodybuilders and other professions before a performance where by eating very minimally, they can accentuate the appearance of their muscle
hypertrophy. The problem begins the week after the diet
is over. Many people find motivation to continue such
a restricted diet in the promise of the prize. The logic
behind knowing the situation is temporary gives way to
individuals being able to have greater self-control which
is a staple in crash diets. Additionally, in such a case not
having an end goal also makes such diets extremely difficult and not very long lasting in general.
While these diets may help people lose much more
weight than they would on a gradual diet plan, they are
worse for the person in the long run. As an individual
loses weight rapidly, their metabolism slows down. The
metabolism lowers because the body tries to preserve
its energy stores. This helps the short-term diet process
by decreasing the ‘hunger’ a person would feel due to the
body’s adaptation to the caloric decrease. However, after
such a severe low-calorie diet is over and an individual
loses thirty or more pounds, their metabolism does not
rise back up right away. At this point, the body requires
fewer calories due to the decrease of energy metabolized. Adding much more calories to a metabolism that
is designed to burn fewer amounts per day will result in
increased weight and will likely leave the person worse
off than where s/he started.
A large example is shown in the weight loss program
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The Biggest Loser, which is a 30-week weight loss television program for bariatric adults. In 2016 a study was
done on six men and eight women who participated in
the show to see if the weight they lost while on the show
stayed. Part of the ‘Biggest Loser Study’ found that the
majority of the show’s contestants regained a significant
amount of the weight they had lost within six years after
exiting the show. A few even ended up heavier than they
had been before they started the competition (Fothergill
et al. 2016). It was as if their bodies were intensifying
their effort to pull the contestants back to their original
weight (Oshin, 2020).
This phenomenon can happen to anyone, not just those
on low-calories diets. For every kilogram of weight loss
a person experiences, their metabolism slows down
around twenty to thirty calories. But while it is burning
less, the body also wants to eat more – the appetite of
someone losing weight increases, making the person want
to consume about one hundred calories more than they
were having before. The process, known as adaptive thermogenesis, serves the purpose of regulating an organism’s
energy balance after changes in diet.
The body has a certain amount of fat – a “set point” –
that it is comfortable with from a survival standpoint and
wants to maintain. When a person begins vigorous training combined with a restrictive diet, the body responds
by thinking it is under threat. The training may increase
the body’s muscle mass, but when the diet becomes too
restrictive – which varies from person to person – leptin,
the satiety hormone, begins to drop, somewhat like a
starvation alarm. Leptin manifests itself as hunger and
you either don’t get as full from your meals, or you can’t
go as long between meals without getting hungry.
Nowadays, there are various lauded fad diets. One
of which is called the Ketogenic diet, more commonly
known as the keto diet. This diet is a short term diet
based on two main goals. The primary goal is to greatly
reduce the number of carbohydrates consumed. Without
the intake of carbohydrates, the body cannot synthesize
glucose, it’s main energy source, and therefore, will need
to resort to an alternate fuel. Secondly, fat consumption
needs to be increased in order to become the new primary source of energy.
To reduce the intake of glucose one must consume
fewer carbohydrates. Carbohydrates are the primary
source of energy production in the body. When the
body is deprived of carbohydrates due to reducing intake (to about less than 50g per day), insulin secretion
is significantly reduced and the body enters a catabolic
state. Glycogen storage depletes which forces the body
to go through certain metabolic changes. Two metabolic
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processes that come into action when there is low carbohydrate availability in body tissues are gluconeogenesis
and ketogenesis.
Gluconeogenesis is when the body produces its own
glucose. This is primarily done in the liver using lactic acid,
glycerol, and certain amino acids (alanine and glutamine).
When glucose availability drops further, gluconeogenesis
is not enough to keep up with the needs of the body and
ketogenesis begins and provides the body with ketone
bodies as an alternate source of energy in the form of
ketone bodies. Ketone bodies synthesized in the body can
be easily utilized for energy production by heart, muscle
tissue, and the kidneys. Even though the brain normally
uses a large percent of the carbohydrate intake to sustain
its function, it can learn to use ketone bodies as they are
able to pass the blood brain barrier as well.
The ketogenic diet consists of seventy percent fat,
twenty five percent protein and five percent carbohydrates. The mechanism by which the Ketogenic diet induces weight loss is by minimizing carbohydrate intake,
which reduces insulin production, and thereby decreases
the amount of glucose stored as fat in cells. Digested
fat does not convert to glucose and thus does not activate insulin secretion. The Keto diet emphasizes high fat
consumption based on the physiological metabolism of
fat, where it is lysed to energy instead of being stored in
adipocytes. Fat calories consumed are not stored. For
the body to replace the energy it lacks from glucose, due
to low carbohydrate intake, the body turns to its current
reservoir of fat storage, in addition to the fatty foods,
which in turn facilitates weight loss.
The basic ketone bodies that accumulate in the body
during ketogenic diet, namely beta-hydroxybutyrate and
acetone, are formed from the oxidation of fatty acids into
acetoacetate. This metabolic state is referred to as “nutritional ketosis” and as long as the body is deprived of
glucose, this ketotic state will remain.
Since ketone bodies are released only in small concentrations and don’t alter the blood’s pH, nutritional ketosis
is quite safe. The issue arises when ketones build up in
the body mainly due to diabetes, especially if combined
with a disease or severe starvation. Accumulation of ketone bodies dramatically lowers the pH (increase acidity)
of the blood which leads to ketoacidosis and if left untreated can eventually cause severe dehydration, coma or
death.
Why are ketone bodies used as an efficient energy
source in the body? Ketone bodies produce more adenosine triphosphate (ATP) in comparison to glucose,
and are therefore used as an efficient energy source to
the body. One hundred grams of acetoacetate generates
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9400 grams of ATP, and 100 g of beta-hydroxybutyrate
yields 10,500 grams of ATP; whereas, 100 grams of glucose produces only 8,700 grams of ATP. This allows the
body to maintain efficient fuel production even during a
caloric deficit (Masood, et. al, 2020).
An increased fat presence in the gastrointestinal tract
increases satiety by stimulating the secretion of orexigenic hormones, an appetite stimulant, like GLP-1 and CCK.
These hormones delay gastric emptying and decrease
motility which allows food to pass through the system at
a slower rate. This causes an individual to feel satiated for
a longer period. This may also be the reason why many
people on the ketogenic diet lose weight. Individuals on
such a diet consume large amounts of fat which keeps
them full in between meals. Therefore, it prevents them
from snacking throughout the day and eating excessive
amounts of unnecessary calories.
Over the past decade, nutrition science has produced
robust evidence that high-carbohydrate diets contribute
to obesity and chronic disease, and that very low-carbohydrate, ketogenic diets provide a healthy alternative.
Since then, another study concluded that low-carbohydrate diets should be avoided just as much as high carb
diets because they are both associated with higher overall mortality and shorter average lifespans (Bellemare &
Finaret, 2018).
Both high and low percentages of carbohydrate diets
were associated with increased mortality, with minimal
risk observed at fifty to fifty five percent carbohydrate
intake. Low carbohydrate dietary patterns favoring animal-derived protein and fat sources, from sources such as
lamb, beef, pork, and chicken, were associated with higher
mortality, whereas those that favored plant-derived protein and fat intake, from sources such as vegetables, nuts,
peanut butter, and whole-grain breads, were associated
with lower mortality, suggesting that the source of food
notably modifies the association between carbohydrate
intake and mortality.
The ketogenic diet was originally developed to help
children with epilepsy. According to Greene,et al.(2003)
“…ketones, unlike glucose, may be unable to deliver the
immediate and large amount of energy necessary to initiate or sustain seizure activity”. In this way, seizures can be
decreased as the glucose necessary to sustain such high
brain activity is not available. Furthermore, seizures would
subside or become less severe in times of fasting. Fasting
prevented seizure spikes. Researchers further thought
of what would happen if they were to find a diet with
similar effects as if one fasted - ketone bodies. Epileptics
would be able to control their seizures somewhat possibly and thereby some part of their life for longer periods

of time. This led to the high fat, low carb ketogenic diet
and it worked because like fasting, ketone bodies were
produced and not taking in excess sugar which also peaks
the strength of seizures. For certain people with epilepsy,
the ketogenic diet should be followed, according to the
guidelines of a certified professional, as the benefits may
outweigh the disadvantages for individuals. The diet regimen may have a higher mortality rate but for them, they
would rather be in better control of their lives.
In addition to preventing seizures, the ketogenic diet is
believed to be related to other long-term effects as well.
Since it is a relatively new concept, there hasn’t been that
much long-term time for research but an excess of fat in
the body has many effects. Although this is the case the
diet seems to be effective. A study on eighty three obese
patients, with a body mass index greater than thirty five,
who took part in a twenty four week ketogenic diet; reported a significant decrease in the body weight, increase
in high density lipoproteins, and decease of low density
lipoproteins (Dashti et al.(2004)
People have become very interested in this diet due
to its ability to reduce weight. However, people are not
aware of the long-term effects this may have on their
overall health. An evidence-based case study reported
that the ketogenic diet can increase the risk for cardiovascular disease by twenty six percent each year. This
statement is backed up by the evidence they found about
this diet in particular. The ketogenic diet increases LDL,
low density lipoprotein, levels because of the increased
intake of saturated fat ( Dashti, et al. 2004).
LDL is a lipoprotein mainly made from cholesterol,
which transports lipids from the liver to peripheral tissue
for it to be stored or utilized as energy. Cells in the body
have receptors that bind to LDL and engulf it via endocytosis. The cholesterol esters in the LDL can be stored
or hydrolyzed into cholesterol and fatty acids to be used
for hormones, bile, or the cell membrane. LDL is known
as the unwanted cholesterol in the blood because of its
function. It is undesirable to have stored cholesterol (a
form of fat) in the organs, tissues, and cells throughout
the body.
The more fat you eat - and a ketogenic diet requires
a lot of fat - the more low density lipoproteins are produced, but when receiving cells are saturated by cholesterol (lipids) the residual low density lipoproteins remain
in the bloodstream. This is dangerous as it can cause atherosclerosis - plaque buildup in the arteries which can
lead to various cardiovascular emergencies.
Another negative side effect of high fat diets is Biliary
Disease. Biliary disease is a condition that affects the bile
duct whose purpose is to pass bile to the small intestine.
77

Esther Abady

For example, Cholecystitis, the production of gallstones
in the gallbladder, which can occur from an overconsumption of fat or increased blood cholesterol. Gallstones can
block the bile duct thereby prohibiting the passage of bile.
This will prevent fat from being broken down, digested,
and absorbed. In theory this may sound great because if
fat is not absorbed it will pass through our digestive tract
without increasing the calorie intake.This is true although
it will cause fatty stool and anal leakage.
An additional overwhelming issue that will be caused by
Cholelithiasis (gallstones) is pancreatitis (inflammation of
the pancreas). The reason why these two issues are connected is because the bile duct from the gallbladder and
the pancreatic duct merge before entering the intestine.
Bile from the liver and enzymes from the pancreas both
pass through this common duct. When gallstones are
lodged in this area, the pancreas cannot release enzymes
such as proteases, lipases and amylase into the intestine.
When this happens, a process known as auto digestion
begins to occur where proteases like trypsin and chymotrypsin begin to digest pancreatic tissue instead of being
released to break down proteins taken in by the body.
Other negative side effects of the keto diet include
edema, swelling catalyzed by fluid buildup, fat necrosis, a
lump of dead or damaged tissue and pancreatic hemorrhage, bleeding in the pancreas. Another issue that can
arise from the keto diet is fatty liver, an increased buildup of fat in the liver. Non-alcoholic fatty liver disease
(NAFLD) is asymptomatic and therefore, an individual will
be unaware of this disease until the condition worsens.
People on the keto diet consume such large quantities of
fat that their livers overload. This is especially dangerous
if sustained, because their energy stores stem from fat
consumed being lysed to ketones. If the liver minimizes
its bile secretion, less fat will be utilized for ketone bodies
and thereby, drain the body’s energy stores. This leads to
fatigue, dizziness, lack of energy and motivation which in
turn leads to the people being lax in their health and exercise - countering the reason they started the diet in the
first place. Only once a fatty liver further manifests into
hepatitis will these symptoms become prominent will the
dieter seek medical attention.
A positive side effect of the ketogenic diet also primes
us to burn the excess fat that so many of us are carrying
around our waists. Our glucose levels return to normal,
we become less insulin resistant, we shed fat, and significantly reduce our risk of developing chronic disease.
Another significant benefit is the production of ketone
bodies, now the subject of intense scientific investigation
due to their many health-promoting properties including
protection of the brain and nervous system, reduction of
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systemic inflammation, the root cause of cardiovascular
disease, and anti-cancer effects.
Low carbohydrate diets, which restrict carbohydrate in
favor of increased protein or fat intake, or both, are a popular weight-loss strategy. However, the long-term effect of
carbohydrate restriction on mortality is controversial and
could depend on whether dietary carbohydrate is replaced
by plant-based or animal-based fat and protein. One widely followed long-term diet that has been proven to be very
beneficial and effective is the Whole Food and Plant Based
diet more commonly known as the vegan diet.
In another study 15,428 adults aged forty five to sixty
four were evaluated periodically through interviews
where they filled out semi quantitative food frequency
questionnaires. Typical portion sizes were provided as
reference so that they could estimate their intake of each
food item consumed. The results were adjusted for age,
sex, race, total energy consumption, diabetes, cigarette
smoking, physical activity, income level, and education.
In conclusion, the low carbohydrate diets that substituted the carbohydrates for animal derived fat and protein sources, such as from lamb, pork, beef, and chicken
were accompanied by higher mortality. In comparison,
the low carbohydrate diets that replaced carbohydrates
with fat and protein from a plant base such as from vegetables, nuts and whole grain were associated with mortality. This finding suggests that the source of protein and fat
in one’s diet can change mortality showing that these two
things are related. The optimal quantity of carbohydrates
consumed in a diet should be between fifty to fifty five
percent of total intake. For this reason, less than fifty
percent or more than fifty percent of carbohydrates consumed seems to be ineffective (Seidelmann et al 2018).
Long-term effects of a low carbohydrate diet with typically low plant and increased animal protein and fat consumption have been hypothesized to stimulate inflammatory pathways, biological ageing, and oxidative stress. On
the other end of the spectrum, high carbohydrate diets,
which are common in Asian and less economically advantaged nations, tend to be high in refined carbohydrates,
such as white rice. These types of diets might reflect poor
food quality and confer a chronically high glycemic load
that can lead to negative metabolic consequences.
One diet plan based on this philosophy is the vegan
diet. A study was aimed clarifying the association between vegetarian, vegan diets, risk factors for chronic
diseases, risk of all-cause mortality, incidence, and mortality from cardio-cerebrovascular diseases, total cancer
and specific type of cancer (colorectal, breast, prostate
and lung), through meta-analysis. This comprehensive
meta-analysis reported a significant protective effect of
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a vegetarian diet versus the incidence and/or mortality
from ischemic heart disease (-25%) and incidence from
total cancer (-8%). A vegan diet conferred a significant
reduced risk (-15%) of incidence from total cancer (Dinu,
et. al., 2017).
In conclusion, finding a diet that suits an individual is
not so simple. According to the International Society of
Sports Nutrition (ISSN), there are two main positions
in regard to diets. The nature of the diet and the way it
influences the body composition. Each diet type has its
own various sub classifications that fall under the main
eating style. Therefore, while diets are a good way to lose
weight, there is a point where they can do more harm
than good. The keto diet is a great plan to stick with for
a short while; however, consuming mostly fat every day,
takes a toll on the body. Although the ketogenic diet is
popular there are many long term diets that are undoubtedly safer and healthier for the body.
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